Radiolabeled O +
m B-Chemical +
- I-Chemical +
iodobenzylguanidine I-Chemical +
( O +
MIBG B-Chemical +
) O +
is O +
a O +
tumor O +
- O +
seeking O +
radioactive O +
drug O +
used O +
in O +
the O +
diagnosis O +
and O +
treatment O +
of O +
pheochromocytomas O +
and O +
neuroblastomas O +
. O +

It O +
is O +
transported O +
into O +
the O +
tumor O +
cells O +
by O +
the O +
neuronal O +
norepinephrine B-Chemical +
( O +
NE B-Chemical +
) O +
transporter O +
( O +
NET O +
) O +
which O +
is O +
expressed O +
in O +
almost O +
all O +
neuroblastoma O +
cells O +
. O +

Here O +
, O +
we O +
describe O +
the O +
synthesis O +
and O +
some O +
pharmacological O +
properties O +
of O +
a O +
series O +
of O +
fluorescent O +
compounds O +
structurally O +
related O +
to O +
the O +
NET O +
substrate O +
, O +
MIBG B-Chemical +
, O +
or O +
to O +
the O +
NET O +
inhibitors O +
, O +
( B-Chemical +
- I-Chemical +
) I-Chemical +
- I-Chemical +
( I-Chemical +
2R I-Chemical +
, I-Chemical +
3S I-Chemical +
) I-Chemical +
- I-Chemical +
cocaine I-Chemical +
and O +
nisoxetine B-Chemical +
. O +

Three O +
of O +
synthesized O +
fluorescent O +
compounds O +
, O +
1 B-Chemical +
- I-Chemical +
( I-Chemical +
1 I-Chemical +
- I-Chemical +
naphthylmethyl I-Chemical +
) I-Chemical +
guanidinium I-Chemical +
sulfate I-Chemical +
( O +
1 O +
) O +
, O +
1 B-Chemical +
- I-Chemical +
[ I-Chemical +
2 I-Chemical +
- I-Chemical +
( I-Chemical +
dibenz I-Chemical +
[ I-Chemical +
b I-Chemical +
, I-Chemical +
f I-Chemical +
] I-Chemical +
azepin I-Chemical +
- I-Chemical +
5 I-Chemical +
- I-Chemical +
yl I-Chemical +
) I-Chemical +
ethyl I-Chemical +
] I-Chemical +
guanidinium I-Chemical +
sulfate I-Chemical +
( O +
2 O +
) O +
, O +
and O +
( B-Chemical +
2R I-Chemical +
, I-Chemical +
3S I-Chemical +
) I-Chemical +
- I-Chemical +
2beta I-Chemical +
- I-Chemical +
ethoxycarbonyl I-Chemical +
- I-Chemical +
3beta I-Chemical +
- I-Chemical +
tropanyl I-Chemical +
5 I-Chemical +
- I-Chemical +
( I-Chemical +
dimethylamino I-Chemical +
) I-Chemical +
naphthalene I-Chemical +
- I-Chemical +
1 I-Chemical +
- I-Chemical +
sulfonate I-Chemical +
( O +
6 O +
) O +
, O +
exhibited O +
high O +
affinity O +
( O +
IC O +
( O +
) O +
about O +
nM O +
) O +
for O +
the O +
NET O +
. O +

The O +
nisoxetine B-Chemical +
derivatives B-Chemical +
8 O +
( O +
rac B-Chemical +
- I-Chemical +
N I-Chemical +
- I-Chemical +
[ I-Chemical +
( I-Chemical +
3 I-Chemical +
- I-Chemical +
methylamino I-Chemical +
- I-Chemical +
1 I-Chemical +
- I-Chemical +
phenyl I-Chemical +
) I-Chemical +
propyl I-Chemical +
] I-Chemical +
- I-Chemical +
5 I-Chemical +
- I-Chemical +
( I-Chemical +
dimethylamino I-Chemical +
) I-Chemical +
- I-Chemical +
1 I-Chemical +
- I-Chemical +
naphthale I-Chemical +
nesulfonamide I-Chemical +
) O +
and O +
9 O +
( O +
rac B-Chemical +
- I-Chemical +
4 I-Chemical +
- I-Chemical +
[ I-Chemical +
( I-Chemical +
3 I-Chemical +
- I-Chemical +
methylamino I-Chemical +
- I-Chemical +
1 I-Chemical +
- I-Chemical +
phenyl I-Chemical +
) I-Chemical +
propyl I-Chemical +
] I-Chemical +
amino I-Chemical +
- I-Chemical +
7 I-Chemical +
- I-Chemical +
nitro I-Chemical +
- I-Chemical +
2,1 I-Chemical +
, I-Chemical +
3 I-Chemical +
- I-Chemical +
benzoxadiazole I-Chemical +
) O +
and O +
especially O +
the O +
guanidine B-Chemical +
derivative B-Chemical +
4 O +
( O +
1 B-Chemical +
- I-Chemical +
[ I-Chemical +
4 I-Chemical +
- I-Chemical +
( I-Chemical +
4 I-Chemical +
- I-Chemical +
phenyl I-Chemical +
- I-Chemical +
1,3 I-Chemical +
- I-Chemical +
butadienyl I-Chemical +
) I-Chemical +
benzyl I-Chemical +
] I-Chemical +
guanidinium I-Chemical +
sulfate I-Chemical +
) O +
which O +
are O +
characterized O +
by O +
intermediate O +
affinity O +
for O +
the O +
NET O +
( O +
IC O +
( O +
) O +
nM O +
) O +
caused O +
significant O +
and O +
nisoxetine B-Chemical +
- O +
sensitive O +
cell O +
fluorescence O +
. O +

At O +
least O +
the O +
guanidine B-Chemical +
derivative B-Chemical +
4 O +
might O +
represent O +
a O +
potentially O +
useful O +
agent O +
for O +
imaging O +
of O +
neuroblastoma O +
cells O +
. O +

A O +
series O +
of O +
2 B-Chemical +
- I-Chemical +
( I-Chemical +
diethylamino I-Chemical +
) I-Chemical +
thieno1 I-Chemical +
, I-Chemical +
3 I-Chemical +
? I-Chemical +
xazin I-Chemical +
- I-Chemical +
4 I-Chemical +
- I-Chemical +
ones I-Chemical +
was O +
synthesized O +
and O +
evaluated O +
in O +
vitro O +
for O +
inhibitory O +
activity O +
toward O +
human O +
leukocyte O +
elastase O +
( O +
HLE O +
) O +
. O +

The O +
Gewald O +
thiophene B-Chemical +
synthesis O +
was O +
utilized O +
to O +
obtain O +
several O +
ethyl B-Chemical +
2 I-Chemical +
- I-Chemical +
aminothiophene I-Chemical +
- I-Chemical +
3 I-Chemical +
- I-Chemical +
carboxylates I-Chemical +
. O +

These O +
precursors O +
were O +
subjected O +
to O +
a O +
five O +
- O +
step O +
route O +
to O +
obtain O +
thieno2 B-Chemical +
, I-Chemical +
3 I-Chemical +
- I-Chemical +
d1 I-Chemical +
, I-Chemical +
3 I-Chemical +
? I-Chemical +
xazin I-Chemical +
- I-Chemical +
4 I-Chemical +
- I-Chemical +
ones I-Chemical +
bearing O +
various O +
substituents O +
at O +
positions O +
5 O +
and O +
6 O +
. O +

Both O +
thieno2 B-Chemical +
, I-Chemical +
3 I-Chemical +
- I-Chemical +
d I-Chemical +
and O +
thieno3 B-Chemical +
, I-Chemical +
2 I-Chemical +
- I-Chemical +
d I-Chemical +
fused O +
oxazin B-Chemical +
- I-Chemical +
4 I-Chemical +
- I-Chemical +
ones I-Chemical +
possess O +
extraordinary O +
chemical O +
stability O +
, O +
which O +
was O +
expressed O +
as O +
rate O +
constants O +
of O +
the O +
alkaline O +
hydrolysis O +
. O +

The O +
kinetic O +
parameters O +
of O +
the O +
HLE O +
inhibition O +
were O +
determined O +
. O +

The O +
most O +
potent O +
compound O +
, O +
2 B-Chemical +
- I-Chemical +
( I-Chemical +
diethylamino I-Chemical +
) I-Chemical +
- I-Chemical +
4H I-Chemical +
- I-Chemical +
1benzothieno2 I-Chemical +
, I-Chemical +
3 I-Chemical +
- I-Chemical +
d1 I-Chemical +
, I-Chemical +
3 I-Chemical +
? I-Chemical +
xazin I-Chemical +
- I-Chemical +
4 I-Chemical +
- I-Chemical +
one I-Chemical +
, O +
exhibited O +
a O +
K O +
( O +
i O +
) O +
value O +
of O +
5.8 O +
nM O +
. O +

2 B-Chemical +
- I-Chemical +
( I-Chemical +
Diethylamino I-Chemical +
) I-Chemical +
thieno1 I-Chemical +
, I-Chemical +
3 I-Chemical +
? I-Chemical +
xazin I-Chemical +
- I-Chemical +
4 I-Chemical +
- I-Chemical +
ones I-Chemical +
act O +
as O +
acyl O +
- O +
enzyme O +
inhibitors O +
of O +
HLE O +
, O +
similar O +
to O +
the O +
inhibition O +
of O +
serine O +
proteases O +
by O +
4H B-Chemical +
- I-Chemical +
3,1 I-Chemical +
- I-Chemical +
benzoxazin I-Chemical +
- I-Chemical +
4 I-Chemical +
- I-Chemical +
ones I-Chemical +
. O +

The O +
isosteric O +
benzene B-Chemical +
- I-Chemical +
thiophene I-Chemical +
replacement O +
accounts O +
for O +
an O +
enhanced O +
stability O +
of O +
the O +
acyl O +
- O +
enzyme O +
intermediates O +
. O +

Enalapril B-Chemical +
in O +
subantihypertensive O +
dosage O +
attenuates O +
kidney O +
proliferation O +
and O +
functional O +
recovery O +
in O +
normotensive O +
ablation O +
nephropathy O +
of O +
the O +
rat O +
. O +

Most O +
studies O +
on O +
the O +
antiproliferative O +
action O +
of O +
angiotensin O +
converting O +
enzyme O +
inhibitors O +
( O +
ACEI O +
) O +
were O +
performed O +
in O +
a O +
rat O +
hypertensive O +
remnant O +
kidney O +
model O +
with O +
5 O -
/ O -
6 O +
kidney O +
ablation O +
which O +
raised O +
objections O +
about O +
the O +
antihypertensive O +
effect O +
of O +
ACEI O +
and O +
the O +
influence O +
of O +
other O +
antihypertensive O +
drugs O +
administered O +
to O +
remnant O +
kidney O +
control O +
rats O +
. O +

To O +
prevent O +
these O +
objections O +
, O +
a O +
normotensive O +
4 O -
/ O -
6 O +
remnant O +
kidney O +
model O +
was O +
elaborated O +
and O +
a O +
subantihypertensive O +
dosage O +
of O +
enalapril B-Chemical +
was O +
used O +
to O +
evaluate O +
its O +
antiproliferative O +
action O +
. O +

Subtotally O +
nephrectomized O +
rats O +
( O +
Nx O +
) O +
markedly O +
increased O +
the O +
remnant O +
kidney O +
weight O +
during O +
a O +
4 O +
- O +
week O +
period O +
and O +
this O +
rise O +
was O +
prevented O +
by O +
the O +
treatment O +
with O +
enalapril B-Chemical +
( O +
NxE O +
) O +
( O +
Nx O +
+ O +
297 O +
+ O +
/ O +
- O +
35 O +
mg O +
vs. O +
sham O +
- O +
operated O +
+ O +
145 O +
+ O +
/ O +
- O +
32 O +
mg O +
, O +
p O +
< O +
0.001 O +
; O +
NxE O +
+ O +
154 O +
+ O +
/ O +
- O +
35 O +
mg O +
vs. O +
Nx O +
p O +
< O +
0.001 O +
) O +
. O +

While O +
collagen O +
concentration O +
in O +
the O +
kidney O +
cortex O +
was O +
not O +
increased O +
in O +
sham O +
- O +
operated O +
rats O +
( O +
Sham O +
) O +
in O +
comparison O +
with O +
the O +
control O +
group O +
( O +
Ctrl O +
) O +
at O +
the O +
beginning O +
of O +
the O +
study O +
, O +
the O +
subsequent O +
increase O +
was O +
significant O +
in O +
the O +
Nx O +
group O +
and O +
enalapril B-Chemical +
did O +
not O +
attenuate O +
this O +
increase O +
( O +
Sham O +
148 O +
+ O +
/ O +
- O +
5 O +
mg O +
/ O +
g O +
w O +
. O +

w O +
. O +
vs. O +
Nx O +
164 O +
+ O +
/ O +
- O +
2 O +
mg O +
/ O +
g O +
w O +
. O +

w O +
. O +
, O +
p O +
< O +
0.01 O +
; O +
NxE O +
161 O +
+ O +
/ O +
- O +
4 O +
mg O +
/ O +
g O +
w O +
. O +

w O +
. O +
vs. O +
Sham O +
p O +
< O +
0.05 O +
) O +
. O +

The O +
tubular O +
protein O +
/ O +
DNA O +
ratio O +
increase O +
, O +
which O +
was O +
significant O +
in O +
the O +
Nx O +
group O +
, O +
was O +
inhibited O +
by O +
enalapril B-Chemical +
( O +
Nx O +
26.2 O +
+ O +
/ O +
- O +
vs. O +
NxE O +
15.3 O +
+ O +
/ O +
- O +
2.6 O +
, O +
p O +
< O +
0.05 O +
) O +
. O +

The O +
protein O +
/ O +
DNA O +
ratio O +
was O +
much O +
lower O +
in O +
glomeruli O +
, O +
with O +
no O +
significant O +
changes O +
in O +
either O +
the O +
Nx O +
or O +
NxE O +
groups O +
. O +

Serum O +
urea B-Chemical +
concentrations O +
were O +
slightly O +
higher O +
in O +
the O +
Nx O +
group O +
than O +
in O +
the O +
sham O +
- O +
operated O +
group O +
, O +
but O +
markedly O +
elevated O +
in O +
the O +
NxE O +
group O +
( O +
Nx O +
+ O +
/ O +
- O +
0.76 O +
mmol O +
/ O +
l O +
vs. O +
Sham O +
6.10 O +
+ O +
/ O +
- O +
0.33 O +
mmol O +
/ O +
l O +
, O +
p O +
< O +
0.001 O +
; O +
NxE O +
28.9 O +
+ O +
/ O +
- O +
2.6 O +
mmol O +
/ O +
l O +
vs. O +
Sham O +
p O +
< O +
0.001 O +
) O +
. O +

Creatinine B-Chemical +
concentrations O +
in O +
the O +
Nx O +
group O +
were O +
increased O +
in O +
comparison O +
with O +
the O +
sham O +
- O +
operated O +
group O +
and O +
markedly O +
increased O +
in O +
the O +
NxE O +
group O +
( O +
Nx O +
63.7 O +
+ O +
/ O +
- O +
3.56 O +
micromol O +
/ O +
l O +
vs. O +
Sham O +
37.2 O +
+ O +
/ O +
- O +
2.84 O +
micromol O +
/ O +
l O +
, O +
p O +
< O +
0.001 O +
; O +
NxE O +
+ O +
/ O +
- O +
5.2 O +
micromol O +
/ O +
l O +
vs. O +
Sham O +
p O +
< O +
0.001 O +
) O +
. O +

The O +
clearance O +
of O +
creatinine B-Chemical +
was O +
lower O +
in O +
the O +
Nx O +
group O +
than O +
in O +
the O +
sham O +
- O +
operated O +
group O +
and O +
was O +
markedly O +
reduced O +
in O +
the O +
NxE O +
group O +
( O +
Nx O +
0.89 O +
+ O +
/ O +
- O +
0.06 O +
ml O +
/ O +
min O +
. O +

g O +
kidney O +
wt O +
. O +
vs. O +
Sham O +
1.05 O +
+ O +
/ O +
- O +
0.16 O +
ml O +
/ O +
min O +
x O +
g O +
kidney O +
wt O +
. O +
, O +
p O +
< O +
0.01 O +
; O +
NxE O +
0.58 O +
+ O +
/ O +
- O +
0.029 O +
ml O +
/ O +
min O +
x O +
g O +
kidney O +
wt O +
. O +
vs. O +
Sham O +
, O +
p O +
< O +
0.001 O +
) O +
. O +

Enalapril B-Chemical +
improved O +
proteinuria O +
in O +
comparison O +
with O +
the O +
Nx O +
group O +
( O +
NxE O +
5.6 O +
+ O +
/ O +
- O +
0.6 O +
mg O +
/ O +
24 O +
h O +
vs. O +
Nx O +
16.1 O +
+ O +
/ O +
- O +
3.4 O +
mg O +
/ O +
24 O +
h O +
, O +
p O +
< O +
0.05 O +
) O +
. O +

Thus O +
remnant O +
kidney O +
proliferation O +
is O +
substantial O +
even O +
in O +
normotensive O +
rats O +
. O +

It O +
includes O +
both O +
proliferation O +
and O +
collagen O +
accumulation O +
with O +
partial O +
recovery O +
of O +
kidney O +
weight O +
and O +
function O +
, O +
but O +
is O +
accompanied O +
by O +
enhanced O +
proteinuria O +
. O +

Enalapril B-Chemical +
attenuates O +
the O +
proliferation O +
and O +
decreases O +
proteinuria O +
but O +
prolongs O +
kidney O +
function O +
recovery O +
. O +

Antiestrogens O +
reduce O +
plasma O +
levels O +
of O +
endothelin O +
- O +
1 O +
without O +
affecting O +
nitrate B-Chemical +
levels O +
in O +
breast O +
cancer O +
patients O +
. O +

Tamoxifen B-Chemical +
protects O +
against O +
myocardial O +
infarction O +
through O +
mechanisms O +
that O +
are O +
poorly O +
understood O +
. O +

We O +
studied O +
the O +
effects O +
of O +
tamoxifen B-Chemical +
and O +
another O +
antiestrogen O +
, O +
toremifene B-Chemical +
, O +
on O +
the O +
production O +
of O +
vasoconstrictive O +
endothelin O +
- O +
1 O +
and O +
of O +
vasodilatory O +
nitric B-Chemical +
oxide I-Chemical +
in O +
44 O +
postmenopausal O +
patients O +
with O +
breast O +
cancer O +
. O +

These O +
started O +
treatment O +
, O +
in O +
randomized O +
order O +
, O +
with O +
either O +
tamoxifen B-Chemical +
( O +
mg O +
/ O +
day O +
; O +
n O +
= O +
25 O +
) O +
or O +
toremifene O +
( O +
mg O +
/ O +
day O +
; O +
n O +
= O +
19 O +
) O +
. O +

Plasma O +
samples O +
collected O +
before O +
treatment O +
and O +
after O +
6 O +
and O +
12 O +
months O +
of O +
both O +
regimens O +
were O +
assayed O +
for O +
endothelin O +
- O +
1 O +
with O +
a O +
specific O +
radioimmunoassay O +
and O +
for O +
nitrite B-Chemical +
/ O +
nitrate B-Chemical +
with O +
a O +
method O +
based O +
on O +
the O +
Griess O +
reaction O +
. O +

The O +
antiestrogen O +
group O +
as O +
a O +
whole O +
showed O +
a O +
fall O +
in O +
endothelin O +
- O +
1 O +
at O +
6 O +
months O +
( O +
5.9 O +
+ O +
/ O +
- O +
3.3 O -
% O +
; O +
p O +
= O +
0.06 O +
) O +
( O +
mean O +
+ O +
/ O +
- O +
SE O +
) O +
and O +
at O +
12 O +
months O +
( O +
7.1 O +
+ O +
/ O +
- O +
5.5 O -
% O +
; O +
p O +
= O +
0.03 O +
) O +
. O +

This O +
fall O +
was O +
solely O +
due O +
to O +
toremifene B-Chemical +
, O +
the O +
use O +
of O +
which O +
was O +
associated O +
with O +
falls O +
in O +
endothelin O +
- O +
1 O +
at O +
6 O +
months O +
( O +
12.9 O +
+ O +
/ O +
- O +
4.7 O -
% O +
; O +
p O +
= O +
0.01 O +
) O +
and O +
12 O +
months O +
( O +
9.2 O +
+ O +
/ O +
- O +
6.2 O -
% O +
; O +
p O +
= O +
0.06 O +
) O +
. O +

The O +
antiestrogen O +
regimen O +
failed O +
to O +
affect O +
plasma O +
nitric B-Chemical +
oxide I-Chemical +
significantly O +
but O +
nevertheless O +
the O +
ratio O +
between O +
nitric B-Chemical +
oxide I-Chemical +
and O +
endothelin O +
- O +
1 O +
rose O +
by O +
31.6 O +
+ O +
/ O +
- O +
13.3 O -
% O +
at O +
6 O +
months O +
and O +
by O +
35.6 O +
+ O +
/ O +
- O +
15.3 O -
% O +
at O +
12 O +
months O +
in O +
the O +
antiestrogen O +
users O +
, O +
an O +
effect O +
similar O +
in O +
the O +
tamoxifen B-Chemical +
and O +
toremifene B-Chemical +
groups O +
. O +

We O +
conclude O +
that O +
antiestrogens O +
may O +
protect O +
against O +
myocardial O +
infarction O +
by O +
preventing O +
the O +
release O +
of O +
endothelin O +
- O +
1 O +
and O +
by O +
shifting O +
the O +
balance O +
between O +
nitric B-Chemical +
oxide I-Chemical +
and O +
endothelin O +
- O +
1 O +
to O +
the O +
dominance O +
of O +
the O +
former O +
. O +

Our O +
data O +
predict O +
that O +
toremifene B-Chemical +
and O +
tamoxifen B-Chemical +
at O +
the O +
doses O +
studied O +
here O +
will O +
provide O +
similar O +
cardiovascular O +
protection O +
. O +

Allopurinol B-Chemical +
induces O +
renal O +
toxicity O +
by O +
impairing O +
pyrimidine B-Chemical +
metabolism O +
in O +
mice O +
. O +

We O +
investigated O +
the O +
relationship O +
between O +
the O +
toxic O +
effect O +
of O +
allopurinol B-Chemical +
and O +
pyrimidine B-Chemical +
metabolism O +
in O +
mice O +
. O +

Allopurinol B-Chemical +
- O +
induced O +
increases O +
in O +
plasma O +
transaminase O +
levels O +
in O +
dinitrofluorobenzene B-Chemical +
( O +
DNFB B-Chemical +
) O +
- O +
sensitized O +
mice O +
were O +
not O +
affected O +
by O +
uridine B-Chemical +
. O +

In O +
contrast O +
, O +
plasma O +
creatinine B-Chemical +
and O +
BUN O +
tended O +
to O +
decrease O +
18 O +
hr O +
after O +
the O +
last O +
injection O +
of O +
uridine B-Chemical +
. O +

Both O +
plasma O +
and O +
urinary O +
orotidine B-Chemical +
( O +
OD B-Chemical +
) O +
were O +
detected O +
in O +
DNFB O +
- O +
sensitized O +
mice O +
after O +
administration O +
of O +
a O +
single O +
dose O +
of O +
allopurinol B-Chemical +
. O +

In O +
contrast O +
, O +
TEI B-Chemical +
- I-Chemical +
, O +
a O +
newly O +
synthesized O +
xanthine O +
oxidase O +
/ O +
xanthine O +
dehydrogenase O +
inhibitor O +
, O +
caused O +
neither O +
pyrimidine B-Chemical +
metabolism O +
abnormality O +
nor O +
renal O +
impairment O +
in O +
DNFB B-Chemical +
- O +
sensitized O +
mice O +
. O +

Also O +
, O +
normal O +
mice O +
administered O +
high O +
doses O +
of O +
allopurinol B-Chemical +
showed O +
abnormal O +
pyrimidine B-Chemical +
metabolism O +
together O +
with O +
renal O +
toxicity O +
which O +
could O +
be O +
ameliorated O +
by O +
uridine B-Chemical +
, O +
indicating O +
that O +
allopurinol B-Chemical +
essentially O +
causes O +
pyrimidine B-Chemical +
metabolism O +
abnormality O +
leading O +
to O +
renal O +
impairment O +
. O +

In O +
DNFB O +
- O +
sensitized O +
mice O +
, O +
allopurinol B-Chemical +
increased O +
urinary O +
OD B-Chemical +
excretion O +
to O +
an O +
extent O +
similar O +
to O +
that O +
in O +
normal O +
mice O +
administered O +
the O +
same O +
dose O +
of O +
allopurinol B-Chemical +
. O +

However O +
, O +
renal O +
impairment O +
by O +
allopurinol B-Chemical +
was O +
more O +
striking O +
in O +
DNFB O +
- O +
sensitized O +
mice O +
than O +
in O +
normal O +
mice O +
. O +

Histopathological O +
observations O +
showed O +
that O +
allopurinol B-Chemical +
induced O +
calculus O +
formation O +
in O +
the O +
collecting O +
tubules O +
and O +
papillary O +
duct O +
. O +

Calculus O +
formation O +
was O +
increased O +
by O +
DNFB B-Chemical +
and O +
decreased O +
by O +
uridine B-Chemical +
. O +

These O +
observations O +
indicate O +
that O +
the O +
enhancement O +
of O +
the O +
renal O +
toxicity O +
of O +
allopurinol B-Chemical +
by O +
DNFB O +
- O +
sensitization O +
may O +
be O +
due O +
to O +
some O +
biological O +
interactions O +
between O +
DNFB B-Chemical +
and O +
allopurinol B-Chemical +
. O +

In O +
humans O +
, O +
it O +
is O +
possible O +
that O +
there O +
are O +
some O +
biological O +
interactions O +
which O +
serve O +
to O +
enhance O +
the O +
toxicity O +
of O +
allopurinol B-Chemical +
, O +
resulting O +
in O +
the O +
development O +
of O +
allopurinol B-Chemical +
hypersensitivity O +
syndrome O +
( O +
AHS O +
) O +
. O +

In O +
contrast O +
, O +
TEI B-Chemical +
- I-Chemical +
, O +
had O +
no O +
effect O +
on O +
pyrimidine B-Chemical +
metabolism O +
and O +
showed O +
no O +
toxic O +
effect O +
. O +

11597479 O +
Synthesis O +
of O +
pyridino B-Chemical +
[ I-Chemical +
2,3 I-Chemical +
- I-Chemical +
f I-Chemical +
] I-Chemical +
indole I-Chemical +
- I-Chemical +
4,9 I-Chemical +
- I-Chemical +
dione I-Chemical +
and O +
6,7 B-Chemical +
- I-Chemical +
disubstituted I-Chemical +
quinoline I-Chemical +
- I-Chemical +
5,8 I-Chemical +
- I-Chemical +
dione I-Chemical +
derivatives B-Chemical +
and O +
evaluation O +
on O +
their O +
cytotoxic O +
activity O +
. O +

We O +
report O +
upon O +
the O +
synthesis O +
of O +
the O +
following O +
derivatives O +
: O +
N B-Chemical +
- I-Chemical +
substituted I-Chemical +
- I-Chemical +
pyridino I-Chemical +
[ I-Chemical +
2,3 I-Chemical +
- I-Chemical +
f I-Chemical +
] I-Chemical +
indole I-Chemical +
- I-Chemical +
4,9 I-Chemical +
- I-Chemical +
dione I-Chemical +
, O +
and O +
6 B-Chemical +
- I-Chemical +
( I-Chemical +
alpha I-Chemical +
- I-Chemical +
diethoxycarbonyl I-Chemical +
- I-Chemical +
methyl I-Chemical +
) I-Chemical +
- I-Chemical +
7 I-Chemical +
- I-Chemical +
substituted I-Chemical +
- I-Chemical +
amino I-Chemical +
- I-Chemical +
quinoline I-Chemical +
- I-Chemical +
5,8 I-Chemical +
- I-Chemical +
dione I-Chemical +
, O +
which O +
contain O +
the O +
active O +
quinoline B-Chemical +
- I-Chemical +
5,8 I-Chemical +
- I-Chemical +
dione I-Chemical +
( O +
VII O +
) O +
moiety B-Chemical +
. O +

The O +
cytotoxic O +
activities O +
of O +
these O +
compounds O +
have O +
been O +
tested O +
in O +
SRB O +
( O +
SulfoRhodamine O +
B O +
) O +
assays O +
against O +
the O +
cancer O +
cell O +
lines O +
of O +
A O +
- O +
549 O +
( O +
human O +
lung O +
cancer O +
) O +
, O +
SK O +
- O +
MEL O +
- O +
2 O +
( O +
human O +
melanoma O +
cancer O +
) O +
, O +
SK O +
- O +
OV O +
- O +
3 O +
( O +
human O +
ovarian O +
cancer O +
) O +
, O +
XF O +
- O +
498 O +
( O +
human O +
brain O +
cancer O +
) O +
and O +
HCT O +
15 O +
( O +
human O +
colon O +
cancer O +
) O +
. O +

The O +
compound O +
, O +
N B-Chemical +
- I-Chemical +
benzyl I-Chemical +
- I-Chemical +
3 I-Chemical +
- I-Chemical +
ethoxycarbonyl I-Chemical +
- I-Chemical +
2 I-Chemical +
- I-Chemical +
hydroxy I-Chemical +
- I-Chemical +
pyridino I-Chemical +
[ I-Chemical +
2,3 I-Chemical +
- I-Chemical +
f I-Chemical +
] I-Chemical +
indole I-Chemical +
- I-Chemical +
4,9 I-Chemical +
- I-Chemical +
dione I-Chemical +
( O +
A O +
- O +
9 O +
) O +
, O +
also O +
showed O +
higher O +
activity O +
than O +
cis B-Chemical +
- I-Chemical +
platin I-Chemical +
. O +

The O +
highest O +
level O +
of O +
cytotoxic O +
activity O +
in O +
these O +
human O +
tumor O +
cell O +
lines O +
was O +
observed O +
in O +
the O +
compound O +
6 B-Chemical +
- I-Chemical +
( I-Chemical +
alpha I-Chemical +
- I-Chemical +
diethoxycarbonyl I-Chemical +
- I-Chemical +
methyl I-Chemical +
) I-Chemical +
- I-Chemical +
7 I-Chemical +
- I-Chemical +
( I-Chemical +
2 I-Chemical +
- I-Chemical +
methyl I-Chemical +
- I-Chemical +
phenylamino I-Chemical +
) I-Chemical +
- I-Chemical +
quinoline I-Chemical +
- I-Chemical +
5,8 I-Chemical +
- I-Chemical +
dione I-Chemical +
( O +
B O +
- O +
3 O +
) O +
. O +

Maitotoxin B-Chemical +
- O +
induced O +
calcium O +
entry O +
in O +
human O +
lymphocytes O +
: O +
modulation O +
by O +
yessotoxin B-Chemical +
, O +
Ca B-Chemical +
( I-Chemical +
2 I-Chemical -
+ I-Chemical +
) I-Chemical +
channel O +
blockers O +
and O +
kinases O +
. O +

We O +
have O +
studied O +
the O +
effect O +
of O +
the O +
ciguatera O +
- O +
related O +
toxin O +
maitotoxin B-Chemical +
( O +
MTX B-Chemical +
) O +
on O +
the O +
cytosolic O +
free O +
calcium B-Chemical +
concentration O +
( O +
[ O +
Ca B-Chemical +
( I-Chemical +
2 I-Chemical -
+ I-Chemical +
) I-Chemical +
] O +
i O +
) O +
of O +
human O +
peripheral O +
blood O +
lymphocytes O +
loaded O +
with O +
the O +
fluorescent O +
probe O +
Fura2 O +
and O +
the O +
regulation O +
of O +
MTX B-Chemical +
action O +
by O +
different O +
drugs O +
known O +
to O +
interfere O +
in O +
cellular O +
Ca B-Chemical +
( I-Chemical +
2 I-Chemical -
+ I-Chemical +
) I-Chemical +
signalling O +
mechanisms O +
and O +
by O +
the O +
marine O +
phycotoxin O +
yessotoxin B-Chemical +
( O +
YTX B-Chemical +
) O +
. O +

MTX B-Chemical +
produced O +
a O +
concentration O +
- O +
dependent O +
elevation O +
of O +
[ O +
Ca B-Chemical +
( I-Chemical +
2 I-Chemical -
+ I-Chemical +
) I-Chemical +
] O +

i O +
in O +
a O +
Ca B-Chemical +
( I-Chemical +
2 I-Chemical -
+ I-Chemical +
) I-Chemical +
- O +
containing O +
medium O +
. O +

This O +
effect O +
was O +
stimulated O +
by O +
pretreatment O +
with O +
YTX B-Chemical +
1 O +
microM O +
and O +
NiCl B-Chemical +
( I-Chemical +
2 I-Chemical +
) I-Chemical +
15 O +
microM O +
. O +

The O +
voltage O +
- O +
independent O +
Ca B-Chemical +
( I-Chemical +
2 I-Chemical -
+ I-Chemical +
) I-Chemical +
channel O +
antagonist O +
1 B-Chemical +
- I-Chemical +
[ I-Chemical +
beta I-Chemical +
- I-Chemical +
[ I-Chemical +
3 I-Chemical +
- I-Chemical +
( I-Chemical +
4 I-Chemical +
- I-Chemical +
methoxyphenyl I-Chemical +
) I-Chemical +
propoxyl I-Chemical +
] I-Chemical +
- I-Chemical +
4 I-Chemical +
- I-Chemical +
methoxyphenyl I-Chemical +
] I-Chemical +
- I-Chemical +
1H I-Chemical +
- I-Chemical +
imidazole I-Chemical +
hydrochloride I-Chemical +
( O +
SKF96365 B-Chemical +
) O +
blocked O +
the O +
MTX B-Chemical +
- O +
induced O +
[ O +
Ca B-Chemical +
( I-Chemical +
2 I-Chemical -
+ I-Chemical +
) I-Chemical +
] O +
i O +
elevation O +
, O +
while O +
the O +
L O +
- O +
type O +
channel O +
blocker O +
nifedipine B-Chemical +
had O +
no O +
effect O +
. O +

Pretreatment O +
with O +
NiCl B-Chemical +
( I-Chemical +
2 I-Chemical +
) I-Chemical +
or O +
nifedipine B-Chemical +
did O +
not O +
modify O +
YTX B-Chemical +
- O +
induced O +
potentiation O +
of O +
MTX B-Chemical +
effect O +
, O +
and O +
SKF96365 B-Chemical +
- O +
induced O +
inhibition O +
was O +
reduced O +
in O +
the O +
presence O +
of O +
YTX B-Chemical +
, O +
which O +
suggest O +
different O +
pathways O +
to O +
act O +
on O +
[ O +
Ca B-Chemical +
( I-Chemical +
2 I-Chemical -
+ I-Chemical +
) I-Chemical +
] O +
i O +
. O +

Preincubation O +
with O +
N B-Chemical +
- I-Chemical +
[ I-Chemical +
2 I-Chemical +
- I-Chemical +
( I-Chemical +
p I-Chemical +
- I-Chemical +
bromocinnamylamino I-Chemical +
) I-Chemical +
ethyl I-Chemical +
] I-Chemical +
- I-Chemical +
5 I-Chemical +
- I-Chemical +
isoquinolinesulfonamide I-Chemical +
. O +

2HCl B-Chemical +
( O +
H B-Chemical +
- I-Chemical +
89 I-Chemical +
) O +
or O +
genistein B-Chemical +
( O +
microM O +
) O +
also O +
had O +
no O +
effect O +
on O +
the O +
MTX B-Chemical +
- O +
induced O +
[ O +
Ca B-Chemical +
( I-Chemical +
2 I-Chemical -
+ I-Chemical +
) I-Chemical +
] O +
i O +
increment O +
. O +

In O +
contrast O +
, O +
the O +
PKC O +
inhibitor O +
bisindolilmaleimide B-Chemical +
I I-Chemical +
( O +
GF109203X B-Chemical +
1 O +
microM O +
) O +
potentiated O +
the O +
MTX B-Chemical +
effect O +
, O +
whereas O +
phosphatidylinositol O +
( O +
PI O +
) O +
3 O +
- O +
kinase O +
inhibition O +
with O +
wortmannin B-Chemical +
( O +
nM O +
) O +
reduced O +
the O +
MTX B-Chemical +
- O +
elicited O +
Ca B-Chemical +
( I-Chemical +
2 I-Chemical -
+ I-Chemical +
) I-Chemical +
entry O +
. O +

In O +
summary O +
, O +
MTX B-Chemical +
produced O +
Ca B-Chemical +
( I-Chemical +
2 I-Chemical -
+ I-Chemical +
) I-Chemical +
influx O +
into O +
human O +
lymphocytes O +
through O +
a O +
SKF96365 B-Chemical +
- O +
sensitive O +
, O +
nifedipine B-Chemical +
- O +
insensitive O +
pathway O +
. O +

The O +
MTX B-Chemical +
- O +
induced O +
[ O +
Ca B-Chemical +
( I-Chemical +
2 I-Chemical -
+ I-Chemical +
) I-Chemical +
] O +
i O +
elevation O +
was O +
stimulated O +
by O +
the O +
marine O +
toxin O +
YTX B-Chemical +
through O +
a O +
mechanism O +
insensitive O +
to O +
SKF96365 B-Chemical +
, O +
nifedipine B-Chemical +
or O +
NiCl B-Chemical +
( I-Chemical +
2 I-Chemical +
) I-Chemical +
. O +

It O +
was O +
also O +
stimulated O +
by O +
the O +
divalent O +
cation O +
Ni B-Chemical +
( I-Chemical +
2 I-Chemical -
+ I-Chemical +
) I-Chemical +
and O +
PKC O +
inhibition O +
and O +
was O +
partially O +
inhibited O +
by O +
PI O +
3 O +
- O +
kinase O +
inhibition O +
. O +

A O +
number O +
of O +
derivatives O +
structurally O +
related O +
to O +
cirazoline B-Chemical +
( O +
1 O +
) O +
were O +
synthesized O +
and O +
studied O +
with O +
the O +
purpose O +
of O +
modulating O +
alpha2 O +
- O +
adrenoreceptors O +
selectivity O +
versus O +
both O +
alpha1 O +
- O +
adrenoreceptors O +
and O +
I2 O +
imidazoline B-Chemical +
binding O +
sites O +
. O +

The O +
most O +
potent O +
alpha2 O +
- O +
agonist O +
was O +
2 B-Chemical +
- I-Chemical +
[ I-Chemical +
1 I-Chemical +
- I-Chemical +
( I-Chemical +
biphenyl I-Chemical +
- I-Chemical +
2 I-Chemical +
- I-Chemical +
yloxy I-Chemical +
) I-Chemical +
ethyl I-Chemical +
] I-Chemical +
- I-Chemical +
4,5 I-Chemical +
- I-Chemical +
dihydro I-Chemical +
- I-Chemical +
1H I-Chemical +
- I-Chemical +
imidazole I-Chemical +
( O +
7 O +
) O +
, O +
whose O +
key O +
pharmacophoric O +
features O +
closely O +
matched O +
those O +
found O +
in O +
the O +
alpha2 O +
- O +
agonist O +
2 B-Chemical +
- I-Chemical +
( I-Chemical +
3 I-Chemical +
- I-Chemical +
exo I-Chemical +
- I-Chemical +
( I-Chemical +
3 I-Chemical +
- I-Chemical +
phenylprop I-Chemical +
- I-Chemical +
1 I-Chemical +
- I-Chemical +
yl I-Chemical +
) I-Chemical +
- I-Chemical +
2 I-Chemical +
- I-Chemical +
exo I-Chemical +
- I-Chemical +
norbornyl I-Chemical +
) I-Chemical +
amino I-Chemical +
- I-Chemical +
2 I-Chemical +
- I-Chemical +
oxazoline I-Chemical +
( O +
15 O +
) O +
. O +

( O +
S O +
) O +
- O +
( O +
- O +
) O +
- O +
7 O +
was O +
the O +
most O +
potent O +
of O +
the O +
two O +
enantiomers O +
, O +
confirming O +
the O +
stereospecificity O +
of O +
the O +
interaction O +
with O +
alpha2 O +
- O +
adrenoreceptors O +
. O +

This O +
eutomer O +
was O +
tested O +
on O +
two O +
algesiometric O +
paradigms O +
and O +
, O +
because O +
of O +
the O +
interaction O +
with O +
alpha2 O +
- O +
adrenoreceptors O +
, O +
showed O +
a O +
potent O +
and O +
long O +
- O +
lasting O +
antinociceptive O +
activity O +
, O +
since O +
it O +
was O +
abolished O +
by O +
the O +
selective O +
alpha2 O +
- O +
antagonist O +
RX821002 B-Chemical +
. O +

In O +
an O +
attempt O +
to O +
increase O +
the O +
combined O +
toxicity O +
of O +
the O +
metabolic O +
end O +
- O +
products O +
[ O +
acrolein B-Chemical +
( O +
4 O +
) O +
and O +
phosphoramide O +
mustard O +
( O +
3 O +
) O +
] O +
from O +
cyclophosphamide B-Chemical +
( O +
1 O +
) O +
, O +
the O +
analog B-Chemical +
2 B-Chemical +
- I-Chemical +
[ I-Chemical +
bis I-Chemical +
( I-Chemical +
2 I-Chemical +
- I-Chemical +
chloroethyl I-Chemical +
) I-Chemical +
amino I-Chemical +
] I-Chemical +
tetrahydro I-Chemical +
- I-Chemical +
6 I-Chemical +
- I-Chemical +
trifluoromethyl I-Chemical +
- I-Chemical +
2H I-Chemical +
- I-Chemical +
1,3,2 I-Chemical +
- I-Chemical +
oxazaphosphorine I-Chemical +
2 I-Chemical +
- I-Chemical +
oxide I-Chemical +
( O +
2 B-Chemical +
, I-Chemical +
6 I-Chemical +
- I-Chemical +
trifluoromethylcyclophosphamide I-Chemical +
) O +
was O +
synthesized O +
and O +
its O +
metabolism O +
and O +
antitumor O +
activity O +
studied O +
. O +

Following O +
metabolism O +
of O +
2 O +
by O +
rat O +
liver O +
microsomes O +
the O +
predicted O +
formation O +
of O +
4,4,4 B-Chemical +
- I-Chemical +
trifluorocrotonaldehyde I-Chemical +
( O +
5 O +
) O +
was O +
confirmed O +
by O +
isolation O +
and O +
identification O +
, O +
by O +
mass O +
spectrometry O +
, O +
of O +
its O +
dinitrophenylhydrazone B-Chemical +
. O +

The O +
therapeutic O +
indices O +
( O +
LD50 O +
- O +
/ O +
ID90 O +
) O +
for O +
2 O +
against O +
the O +
ADJ O +
/ O +
PC6 O +
mouse O +
tumor O +
and O +
the O +
Walker O +
256 O +
tumor O +
in O +
the O +
rat O +
were O +
28.6 O +
and O +
7.7 O +
, O +
respectively O +
, O +
and O +
were O +
lower O +
than O +
the O +
corresponding O +
values O +
for O +
1 O +
( O +
91.8 O +
and O +
33.2 O +
, O +
respectively O +
) O +
although O +
the O +
toxicities O +
toward O +
Walker O +
cells O +
in O +
a O +
bioassay O +
system O +
of O +
1 O +
and O +
2 O +
following O +
microsomal O +
metabolism O +
were O +
similar O +
. O +

In O +
order O +
to O +
study O +
the O +
toxicities O +
of O +
4 O +
and O +
5 O +
released O +
under O +
drug O +
metabolizing O +
conditions O +
independently O +
of O +
the O +
production O +
of O +
a O +
toxic O +
mustard B-Chemical +
the O +
analogs B-Chemical +
18 O +
[ O +
2 B-Chemical +
- I-Chemical +
( I-Chemical +
diethylamino I-Chemical +
) I-Chemical +
tetrahydro I-Chemical +
- I-Chemical +
2H I-Chemical +
- I-Chemical +
1,3,2 I-Chemical +
- I-Chemical +
oxazaphosphorine I-Chemical +
2 I-Chemical +
- I-Chemical +
oxide I-Chemical +
] O +
and O +
6 O +
[ O +
2 B-Chemical +
- I-Chemical +
( I-Chemical +
diethylamino I-Chemical +
) I-Chemical +
tetrahydro I-Chemical +
- I-Chemical +
6 I-Chemical +
- I-Chemical +
trifluoromethyl I-Chemical +
- I-Chemical +
2H I-Chemical +
- I-Chemical +
1,3,2 I-Chemical +
- I-Chemical +
oxazaphosphorine I-Chemical +
2 I-Chemical +
- I-Chemical +
oxide I-Chemical +
] O +
were O +
also O +
synthesized O +
. O +

The O +
release O +
of O +
5 O +
from O +
6 O +
following O +
metabolism O +
was O +
confirmed O +
and O +
shown O +
by O +
use O +
of O +
the O +
bioassay O +
system O +
to O +
be O +
an O +
event O +
of O +
similar O +
toxicity O +
to O +
release O +
of O +
4 O +
from O +
18 O +
; O +
in O +
vivo O +
, O +
however O +
, O +
6 O +
( O +
LD50 O +
mg O +
/ O +
kg O +
) O +
was O +
more O +
toxic O +
to O +
mice O +
than O +
18 O +
( O +
LD50 O +
greater O +
than O +
mg O +
/ O +
kg O +
) O +
. O +

A O +
novel O +
class O +
of O +
5 B-Chemical +
- I-Chemical +
substituted I-Chemical +
acyclic I-Chemical +
pyrimidine I-Chemical +
nucleosides I-Chemical +
, O +
1 B-Chemical +
- I-Chemical +
[ I-Chemical +
( I-Chemical +
2 I-Chemical +
- I-Chemical +
hydroxyethoxy I-Chemical +
) I-Chemical +
methyl I-Chemical +
] I-Chemical +
- I-Chemical +
5 I-Chemical +
- I-Chemical +
( I-Chemical +
1 I-Chemical +
- I-Chemical +
azidovinyl I-Chemical +
) I-Chemical +
uracil I-Chemical +
( O +
9a O +
) O +
, O +
1 B-Chemical +
- I-Chemical +
[ I-Chemical +
( I-Chemical +
2 I-Chemical +
- I-Chemical +
hydroxy I-Chemical +
- I-Chemical +
1 I-Chemical +
- I-Chemical +
( I-Chemical +
hydroxymethyl I-Chemical +
) I-Chemical +
ethoxy I-Chemical +
) I-Chemical +
methyl I-Chemical +
] I-Chemical +
- I-Chemical +
5 I-Chemical +
- I-Chemical +
( I-Chemical +
1 I-Chemical +
- I-Chemical +
azidovinyl I-Chemical +
) I-Chemical +
uracil I-Chemical +
( O +
9b O +
) O +
, O +
and O +
1 B-Chemical +
- I-Chemical +
[ I-Chemical +
4 I-Chemical +
- I-Chemical +
hydroxy I-Chemical +
- I-Chemical +
3 I-Chemical +
- I-Chemical +
( I-Chemical +
hydroxymethyl I-Chemical +
) I-Chemical +
- I-Chemical +
1 I-Chemical +
- I-Chemical +
butyl I-Chemical +
] I-Chemical +
- I-Chemical +
5 I-Chemical +
- I-Chemical +
( I-Chemical +
1 I-Chemical +
- I-Chemical +
azidovinyl I-Chemical +
) I-Chemical +
uracil I-Chemical +
( O +
9c O +
) O +
, O +
were O +
synthesized O +
by O +
regiospecific O +
addition O +
of O +
bromine B-Chemical +
azide I-Chemical +
to O +
the O +
5 B-Chemical +
- I-Chemical +
vinyl I-Chemical +
substituent B-Chemical +
of O +
the O +
respective O +
5 B-Chemical +
- I-Chemical +
vinyluracils I-Chemical +
( O +
2a O +
- O +
c O +
) O +
followed O +
by O +
treatment O +
of O +
the O +
obtained O +
5 B-Chemical +
- I-Chemical +
( I-Chemical +
1 I-Chemical +
- I-Chemical +
azido I-Chemical +
- I-Chemical +
2 I-Chemical +
- I-Chemical +
bromoethyl I-Chemical +
) I-Chemical +
compounds B-Chemical +
( O +
3a O +
- O +
c O +
) O +
with O +
t B-Chemical +
- I-Chemical +
BuOK I-Chemical +
, O +
to O +
affect O +
the O +
base O +
- O +
catalyzed O +
elimination O +
of O +
HBr B-Chemical +
. O +

Thermal O +
decomposition O +
of O +
9b O +
and O +
9c O +
at O +
degrees O +
C O +
in O +
dioxane B-Chemical +
yielded O +
corresponding O +
5 B-Chemical +
- I-Chemical +
[ I-Chemical +
2 I-Chemical +
- I-Chemical +
( I-Chemical +
1 I-Chemical +
- I-Chemical +
azirinyl I-Chemical +
) I-Chemical +
] I-Chemical +
uracil I-Chemical +
analogues B-Chemical +
( O +
, O +
c O +
) O +
. O +

The O +
5 B-Chemical +
- I-Chemical +
( I-Chemical +
1 I-Chemical +
- I-Chemical +
azidovinyl I-Chemical +
) I-Chemical +
uracil I-Chemical +
derivatives B-Chemical +
9a O +
- O +
c O +
were O +
found O +
to O +
exhibit O +
potent O +
and O +
selective O +
in O +
vitro O +
anti O +
- O +
HBV O +
activity O +
against O +
duck O +
hepatitis O +
B O +
virus O +
( O +
DHBV O +
) O +
infected O +
primary O +
duck O +
hepatocytes O +
at O +
low O +
concentrations O +
( O +
EC O +
( O +
) O +
= O +
0.01 O -
- O -
0.1 O +
microg O +
/ O +
mL O +
range O +
) O +
. O +

The O +
most O +
active O +
anti O +
- O +
DHBV O +
agent O +
( O +
9c O +
) O +
, O +
possessing O +
a O +
[ B-Chemical +
4 I-Chemical +
- I-Chemical +
hydroxy I-Chemical +
- I-Chemical +
3 I-Chemical +
- I-Chemical +
( I-Chemical +
hydroxymethyl I-Chemical +
) I-Chemical +
- I-Chemical +
1 I-Chemical +
- I-Chemical +
butyl I-Chemical +
] I-Chemical +
substituent B-Chemical +
at O +
N O +
- O +
1 O +
, O +
exhibited O +
an O +
activity O +
( O +
EC O +
( O +
) O +
of O +
0.01 O -
- O -
0.05 O +
microg O +
/ O +
mL O +
) O +
comparable O +
to O +
that O +
of O +
reference O +
compound O +
( B-Chemical +
- I-Chemical +
) I-Chemical +
- I-Chemical +
beta I-Chemical +
- I-Chemical +
L I-Chemical +
- I-Chemical +
2 I-Chemical -
' I-Chemical +
, I-Chemical +
3 I-Chemical -
' I-Chemical +
- I-Chemical +
dideoxy I-Chemical +
- I-Chemical +
3 I-Chemical -
' I-Chemical +
- I-Chemical +
thiacytidine I-Chemical +
( O +
3 O +
- O +
TC O +
) O +
( O +
EC O +
( O +
) O +
= O +
0.01 O -
- O -
0.05 O +
microg O +
/ O +
mL O +
) O +
. O +

In O +
contrast O +
, O +
related O +
5 B-Chemical +
- I-Chemical +
[ I-Chemical +
2 I-Chemical +
- I-Chemical +
( I-Chemical +
1 I-Chemical +
- I-Chemical +
azirinyl I-Chemical +
) I-Chemical +
] I-Chemical +
uracil I-Chemical +
analogues B-Chemical +
( O +
, O +
c O +
) O +
were O +
devoid O +
of O +
anti O +
- O +
DHBV O +
activity O +
, O +
indicating O +
that O +
an O +
acyclic O +
side O +
chain O +
at O +
C O +
- O +
5 O +
position O +
of O +
the O +
pyrimidine B-Chemical +
ring O +
is O +
essential O +
for O +
anti O +
- O +
HBV O +
activity O +
. O +

The O +
pyrimidine B-Chemical +
nucleosides B-Chemical +
( O +
9a O +
- O +
c O +
, O +
, O +
c O +
) O +
exhibited O +
no O +
cytotoxic O +
activity O +
against O +
a O +
panel O +
of O +
human O +
cancer O +
cell O +
lines O +
. O +

All O +
of O +
the O +
compounds O +
investigated O +
did O +
not O +
show O +
any O +
detectable O +
toxicity O +
to O +
several O +
stationary O +
and O +
proliferating O +
host O +
cell O +
lines O +
or O +
to O +
mitogen O +
stimulated O +
proliferating O +
human O +
T O +
lymphocytes O +
, O +
up O +
to O +
the O +
highest O +
concentration O +
tested O +
. O +

We O +
have O +
previously O +
described O +
( B-Chemical +
RS I-Chemical +
) I-Chemical +
- I-Chemical +
2 I-Chemical +
- I-Chemical +
amino I-Chemical +
- I-Chemical +
3 I-Chemical +
- I-Chemical +
( I-Chemical +
3 I-Chemical +
- I-Chemical +
hydroxy I-Chemical +
- I-Chemical +
7,8 I-Chemical +
- I-Chemical +
dihydro I-Chemical +
- I-Chemical +
6H I-Chemical +
- I-Chemical +
cyclohepta I-Chemical +
[ I-Chemical +
d I-Chemical +
] I-Chemical +
isoxazol I-Chemical +
- I-Chemical +
4 I-Chemical +
- I-Chemical +
yl I-Chemical +
) I-Chemical +
propionic I-Chemical +
acid I-Chemical +
( O +
4 B-Chemical +
- I-Chemical +
AHCP I-Chemical +
) O +
as O +
a O +
highly O +
effective O +
agonist O +
at O +
non O +
- O +
N O +
- O +
methyl O +
- O +
d O +
- O +
aspartate O +
( O +
non O +
- O +
NMDA O +
) O +
glutamate O +
( O +
Glu O +
) O +
receptors O +
in O +
vivo O +
, O +
which O +
is O +
more O +
potent O +
than O +
( B-Chemical +
RS I-Chemical +
) I-Chemical +
- I-Chemical +
2 I-Chemical +
- I-Chemical +
amino I-Chemical +
- I-Chemical +
3 I-Chemical +
- I-Chemical +
( I-Chemical +
3 I-Chemical +
- I-Chemical +
hydroxy I-Chemical +
- I-Chemical +
5 I-Chemical +
- I-Chemical +
methylisoxazol I-Chemical +
- I-Chemical +
4 I-Chemical +
- I-Chemical +
yl I-Chemical +
) I-Chemical +
propionic I-Chemical +
acid I-Chemical +
( O +
AMPA B-Chemical +
) O +
but O +
inactive O +
at O +
NMDA O +
receptors O +
. O +

However O +
, O +
4 B-Chemical +
- I-Chemical +
AHCP I-Chemical +
was O +
found O +
to O +
be O +
much O +
weaker O +
than O +
AMPA B-Chemical +
as O +
an O +
inhibitor O +
of O +
[ B-Chemical +
( I-Chemical +
3 I-Chemical +
) I-Chemical +
H I-Chemical +
] I-Chemical +
AMPA I-Chemical +
binding O +
and O +
to O +
have O +
limited O +
effect O +
in O +
a O +
[ B-Chemical +
( I-Chemical +
3 I-Chemical +
) I-Chemical +
H I-Chemical +
] I-Chemical +
kainic I-Chemical +
acid I-Chemical +
binding O +
assay O +
using O +
rat O +
cortical O +
membranes O +
. O +

To O +
shed O +
light O +
on O +
the O +
mechanism O +
( O +
s O +
) O +
underlying O +
this O +
quite O +
enigmatic O +
pharmacological O +
profile O +
of O +
4 B-Chemical +
- I-Chemical +
AHCP I-Chemical +
, O +
we O +
have O +
now O +
developed O +
a O +
synthesis O +
of O +
( B-Chemical +
S I-Chemical +
) I-Chemical +
- I-Chemical +
4 I-Chemical +
- I-Chemical +
AHCP I-Chemical +
( O +
6 O +
) O +
and O +
( B-Chemical +
R I-Chemical +
) I-Chemical +
- I-Chemical +
4 I-Chemical +
- I-Chemical +
AHCP I-Chemical +
( O +
7 O +
) O +
. O +

At O +
cloned O +
metabotropic O +
Glu O +
receptors O +
mGluR1alpha O +
( O +
group O +
I O +
) O +
, O +
mGluR2 O +
( O +
group O +
II O +
) O +
, O +
and O +
mGluR4a O +
( O +
group O +
III O +
) O +
, O +
neither O +
6 O +
nor O +
7 O +
showed O +
significant O +
agonist O +
or O +
antagonist O +
effects O +
. O +

The O +
stereoisomer O +
6 O +
, O +
but O +
not O +
7 O +
, O +
activated O +
cloned O +
AMPA O +
receptor O +
subunits O +
GluR1o O +
, O +
GluR3o O +
, O +
and O +
GluR4o O +
with O +
EC O +
( O +
) O +
values O +
in O +
the O +
range O +
4.5 O -
- O -
15 O +
microM O +
and O +
the O +
coexpressed O +
kainate B-Chemical +
- O +
preferring O +
subunits O +
GluR6 O +
+ O +
KA2 O +
( O +
EC O +
( O +
) O +
= O +
6.4 O +
microM O +
) O +
. O +

Compound O +
6 O +
, O +
but O +
not O +
7 O +
, O +
proved O +
to O +
be O +
a O +
very O +
potent O +
agonist O +
( O +
EC O +
( O +
) O +
= O +
0.13 O +
microM O +
) O +
at O +
the O +
kainate B-Chemical +
- O +
preferring O +
GluR5 O +
subunit O +
, O +
equipotent O +
with O +
( B-Chemical +
S I-Chemical +
) I-Chemical +
- I-Chemical +
2 I-Chemical +
- I-Chemical +
amino I-Chemical +
- I-Chemical +
3 I-Chemical +
- I-Chemical +
( I-Chemical +
5 I-Chemical +
- I-Chemical +
tert I-Chemical +
- I-Chemical +
butyl I-Chemical +
- I-Chemical +
3 I-Chemical +
- I-Chemical +
hydroxyisothiazol I-Chemical +
- I-Chemical +
4 I-Chemical +
- I-Chemical +
yl I-Chemical +
) I-Chemical +
propionic I-Chemical +
acid I-Chemical +
[ O +
( B-Chemical +
S I-Chemical +
) I-Chemical +
- I-Chemical +
Thio I-Chemical +
- I-Chemical +
ATPA I-Chemical +
, O +
4 O +
] O +
and O +
almost O +
4 O +
times O +
more O +
potent O +
than O +
( B-Chemical +
S I-Chemical +
) I-Chemical +
- I-Chemical +
2 I-Chemical +
- I-Chemical +
amino I-Chemical +
- I-Chemical +
3 I-Chemical +
- I-Chemical +
( I-Chemical +
5 I-Chemical +
- I-Chemical +
tert I-Chemical +
- I-Chemical +
butyl I-Chemical +
- I-Chemical +
3 I-Chemical +
- I-Chemical +
hydroxyisoxazol I-Chemical +
- I-Chemical +
4 I-Chemical +
- I-Chemical +
yl I-Chemical +
) I-Chemical +
propionic I-Chemical +
acid I-Chemical +
[ O +
( B-Chemical +
S I-Chemical +
) I-Chemical +
- I-Chemical +
ATPA I-Chemical +
, O +
3 O +
] O +
. O +

Compound O +
6 O +
thus O +
represents O +
a O +
new O +
structural O +
class O +
of O +
GluR5 O +
agonists O +
. O +

Molecular O +
modeling O +
and O +
docking O +
to O +
a O +
crystal O +
structure O +
of O +
the O +
extracellular O +
binding O +
domain O +
of O +
the O +
AMPA B-Chemical +
subunit O +
GluR2 O +
has O +
enabled O +
identification O +
of O +
the O +
probable O +
active O +
conformation O +
and O +
binding O +
mode O +
of O +
6 O +
. O +

We O +
are O +
able O +
to O +
rationalize O +
the O +
observed O +
selectivities O +
by O +
comparing O +
the O +
docking O +
of O +
4 O +
and O +
6 O +
to O +
subtype O +
constructs O +
, O +
i.e. O +
, O +
a O +
crystal O +
structure O +
of O +
the O +
extracellular O +
binding O +
domain O +
of O +
GluR2 O +
and O +
a O +
homology O +
model O +
of O +
GluR5 O +
. O +

12742193 O +
Attenuation O +
of O +
cerebral O +
vasospasm O +
in O +
rabbits O +
using O +
clonidine B-Chemical +
hydrochloride I-Chemical +
, O +
a O +
central O +
adrenergic O +
agonist O +
. O +

The O +
aim O +
of O +
this O +
study O +
was O +
to O +
assess O +
, O +
firstly O +
, O +
if O +
exclusion O +
of O +
central O +
noradrenergic O +
areas O +
in O +
the O +
hypothalamus O +
and O +
brain O +
stem O +
with O +
the O +
central O +
sympathetic O +
blocker O +
clonidine B-Chemical +
hydrochloride I-Chemical +
could O +
prevent O +
the O +
development O +
of O +
chronic O +
vasospasm O +
following O +
experimental O +
subarachnoid O +
haemorrhage O +
in O +
rabbits O +
and O +
, O +
secondly O +
, O +
if O +
, O +
parallel O +
with O +
the O +
effect O +
on O +
cerebral O +
arteries O +
, O +
changes O +
in O +
dopamine O +
beta O +
- O +
hydroxylase O +
concentration O +
in O +
the O +
hypothalamus O +
and O +
brain O +
stem O +
could O +
also O +
be O +
detected O +
. O +

Experimental O +
subarachnoid O +
haemorrhage O +
, O +
in O +
concentrations O +
of O +
1 O +
ml O +
of O +
autologous O +
arterial O +
blood O +
/ O +
1 O +
kg O +
of O +
body O +
weight O +
was O +
carried O +
out O +
on O +
18 O +
New O +
Zealand O +
rabbits O +
. O +

Histological O +
specimens O +
were O +
obtained O +
by O +
the O +
method O +
of O +
perfusion O +
fixation O +
after O +
the O +
rabbits O +
were O +
sacrificed O +
on O +
day O +
8 O +
after O +
subarachnoid O +
haemorrhage O +
. O +

The O +
spastic O +
effect O +
of O +
experimentally O +
induced O +
subarachnoid O +
haemorrhage O +
was O +
determined O +
by O +
assessing O +
the O +
intensity O +
of O +
corrugation O +
of O +
the O +
intima O +
of O +
the O +
rabbit O +
basilar O +
artery O +
by O +
the O +
previously O +
developed O +
method O +
of O +
corrugation O +
coefficient O +
and O +
computer O +
image O +
analysis O +
. O +

The O +
concentration O +
and O +
localization O +
of O +
dopamine O +
beta O +
- O +
hydroxylase O +
in O +
noradrenaline B-Chemical +
- O +
containing O +
neurons O +
was O +
immunohistochemically O +
assessed O +
( O +
semiquantitatively O +
as O +
0 O +
, O +
1 O +
and O +
2 O +
) O +
with O +
anti O +
- O +
dopamine O +
beta O +
- O +
hydroxylase O +
, O +
at O +
precisely O +
defined O +
sites O +
of O +
the O +
hypothalamus O +
and O +
brain O +
stem O +
of O +
the O +
same O +
rabbit O +
. O +

The O +
results O +
revealed O +
less O +
corrugated O +
and O +
smoother O +
intima O +
in O +
the O +
basilar O +
artery O +
and O +
significantly O +
lower O +
dopamine O +
beta O +
- O +
hydroxylase O +
concentration O +
in O +
the O +
control O +
group O +
of O +
rabbits O +
with O +
sham O +
subarachnoid O +
haemorrhage O +
and O +
without O +
any O +
additional O +
interventions O +
( O +
mean O +
corrugation O +
coefficient O +
= O +
1.123 O +
+ O +
/ O +
- O +
0.024 O +
, O +
P O +
= O +
0.35 O +
x O +
( O +
- O +
3 O +
) O +
; O +
mean O +
dopamine O +
beta O +
- O +
hydroxylase O +
= O +
0.350 O +
+ O +
/ O +
- O +
0.071 O +
, O +
P O +
= O +
0.22 O +
x O +
( O +
- O +
3 O +
) O +
) O +
, O +
and O +
smoother O +
intima O +
in O +
the O +
basilar O +
artery O +
with O +
significantly O +
lower O +
concentration O +
of O +
dopamine O +
beta O +
- O +
hydroxylase O +
in O +
the O +
clonidine B-Chemical +
group B-Chemical +
( O +
rabbits O +
with O +
subarachnoid O +
haemorrhage O +
and O +
central O +
alpha O +
( O +
2 O +
) O +
- O +
blocker O +
clonidine B-Chemical +
hydrochloride I-Chemical +
at O +
a O +
daily O +
dose O +
of O +
0.03 O +
mg O +
/ O +
kg O +
of O +
body O +
weight O +
for O +
8 O +
days O +
; O +
mean O +
corrugation O +
coefficient O +
= O +
1.177 O +
+ O +
/ O +
- O +
0.058 O +
, O +
P O +
= O +
1.7 O +
x O +
( O +
- O +
3 O +
) O +
; O +
mean O +
dopamine B-Chemical +
beta O +
- O +
hydroxylase O +
= O +
0.583 O +
+ O +
/ O +
- O +
0.175 O +
, O +
P O +
= O +
1.1 O +
x O +
( O +
- O +
3 O +
) O +
) O +
. O +

In O +
comparison O +
, O +
the O +
haemorrhage O +
only O +
group O +
( O +
rabbits O +
with O +
subarachnoid O +
haemorrhage O +
and O +
without O +
medication O +
; O +
mean O +
corrugation O +
coefficient O +
= O +
1.370 O +
+ O +
/ O +
- O +
0.101 O +
; O +
mean O +
dopamine O +
beta O +
- O +
hydroxylase O +
= O +
1.214 O +
+ O +
/ O +
- O +
0.313 O +
) O +
displayed O +
intensive O +
corrugation O +
of O +
the O +
intima O +
of O +
the O +
basilar O +
artery O +
and O +
a O +
significantly O +
more O +
intensive O +
accumulation O +
of O +
dopamine O +
beta O +
- O +
hydroxylase O +
than O +
did O +
the O +
control O +
group O +
and O +
the O +
clonidine O +
group O +
. O +

The O +
results O +
of O +
this O +
study O +
demonstrated O +
that O +
the O +
central O +
alpha O +
( O +
2 O +
) O +
- O +
blocker O +
clonidine B-Chemical +
hydrochloride I-Chemical +
effectively O +
prevents O +
vasospasm O +
, O +
and O +
diminishes O +
the O +
concentration O +
of O +
cerebral O +
dopamine O +
beta O +
- O +
hydroxylase O +
in O +
the O +
hypothalamus O +
and O +
brain O +
stem O +
after O +
experimental O +
subarachnoid O +
haemorrhage O +
in O +
rabbits O +
. O +

Involvement O +
of O +
phospholipase O +
D2 O +
in O +
lysophosphatidate B-Chemical +
- O +
induced O +
transactivation O +
of O +
platelet O +
- O +
derived O +
growth O +
factor O +
receptor O +
- O +
beta O +
in O +
human O +
bronchial O +
epithelial O +
cells O +
. O +

Lysophosphatidate B-Chemical +
( O +
LPA B-Chemical +
) O +
mediates O +
multiple O +
cellular O +
responses O +
via O +
heterotrimeric O +
G O +
protein O +
coupled O +
LPA O +
- O +
1 O +
, O +
LPA O +
- O +
2 O +
, O +
and O +
LPA O +
- O +
3 O +
receptors O +
. O +

Many O +
G O +
protein O +
- O +
coupled O +
receptors O +
stimulate O +
ERK O +
following O +
tyrosine B-Chemical +
phosphorylation O +
of O +
growth O +
factor O +
receptors O +
; O +
however O +
, O +
the O +
mechanism O +
( O +
s O +
) O +
of O +
transactivation O +
of O +
receptor O +
tyrosine O +
kinases O +
are O +
not O +
well O +
defined O +
. O +

Here O +
, O +
we O +
provide O +
evidence O +
for O +
the O +
involvement O +
of O +
phospholipase O +
D O +
( O +
PLD O +
) O +
in O +
LPA B-Chemical +
- O +
mediated O +
transactivation O +
of O +
platelet O +
- O +
derived O +
growth O +
factor O +
receptor O +
- O +
beta O +
( O +
PDGF O +
- O +
R O +
beta O +
) O +
. O +

In O +
primary O +
cultures O +
of O +
human O +
bronchial O +
epithelial O +
cells O +
( O +
HBEpCs O +
) O +
, O +
LPA B-Chemical +
stimulated O +
tyrosine B-Chemical +
phosphorylation O +
of O +
PDGF O +
- O +
R O +
beta O +
and O +
threonine B-Chemical +
/ O +
tyrosine B-Chemical +
phosphorylation O +
of O +
ERK1 O -
/ O -
2 O +
. O +

The O +
LPA B-Chemical +
- O +
mediated O +
activation O +
of O +
ERK O +
and O +
tyrosine B-Chemical +
phosphorylation O +
of O +
PDGF O +
- O +
R O +
beta O +
was O +
attenuated O +
by O +
tyrphostin B-Chemical +
AG B-Chemical +
1296 I-Chemical +
, O +
an O +
inhibitor O +
of O +
PDGF O +
- O +
R O +
kinase O +
, O +
suggesting O +
transactivation O +
of O +
PDGF O +
- O +
R O +
by O +
LPA B-Chemical +
. O +

Furthermore O +
, O +
LPA B-Chemical +
- O +
, O +
but O +
not O +
PDGF O +
beta O +
- O +
chain O +
homodimer O +
- O +
induced O +
tyrosine O +
phosphorylation O +
of O +
PDGF O +
- O +
R O +
beta O +
was O +
partially O +
blocked O +
by O +
pertussis O +
toxin O +
, O +
indicating O +
coupling O +
of O +
LPA B-Chemical +
- O +
R O +
( O +
s O +
) O +
to O +
Gi O +
. O +

Exposure O +
of O +
HBEpCs O +
to O +
LPA O +
activated O +
PLD O +
. O +

Butan B-Chemical +
- I-Chemical +
1 I-Chemical +
- I-Chemical +
ol I-Chemical +
, O +
which O +
acts O +
as O +
an O +
acceptor O +
of O +
phosphatidate B-Chemical +
generated O +
by O +
the O +
PLD O +
pathway O +
, O +
blocked O +
LPA B-Chemical +
- O +
mediated O +
transactivation O +
of O +
PDGF O +
- O +
R O +
beta O +
. O +

This O +
effect O +
was O +
not O +
seen O +
with O +
butan B-Chemical +
- I-Chemical +
3 I-Chemical +
- I-Chemical +
ol I-Chemical +
, O +
suggesting O +
PLD O +
involvement O +
. O +

The O +
role O +
of O +
PLD1 O +
and O +
PLD2 O +
in O +
the O +
PDGF O +
- O +
R O +
beta O +
transactivation O +
by O +
LPA B-Chemical +
was O +
investigated O +
by O +
infection O +
of O +
cells O +
with O +
adenoviral O +
constructs O +
of O +
wild O +
type O +
and O +
catalytically O +
inactive O +
mutants O +
of O +
PLD O +
. O +

LPA B-Chemical +
activated O +
both O +
PLD1 O +
and O +
PLD2 O +
in O +
HBEpCs O +
; O +
however O +
, O +
infection O +
of O +
cells O +
with O +
cDNA O +
for O +
wild O +
type O +
PLD2 O +
, O +
but O +
not O +
PLD1 O +
, O +
increased O +
the O +
tyrosine O +
phosphorylation O +
of O +
PDGF O +
- O +
R O +
beta O +
in O +
response O +
to O +
LPA B-Chemical +
. O +

Also O +
, O +
the O +
LPA B-Chemical +
- O +
mediated O +
tyrosine B-Chemical +
phosphorylation O +
of O +
PDGF O +
- O +
R O +
beta O +
was O +
attenuated O +
by O +
the O +
catalytically O +
inactive O +
mutant O +
mPLD2 O +
- O +
K758R O +
. O +

Infection O +
of O +
HBEpCs O +
with O +
adenoviral O +
constructs O +
of O +
wild O +
type O +
hPLD1 O +
, O +
mPLD2 O +
, O +
and O +
the O +
inactive O +
mutants O +
of O +
hPLD1 O +
and O +
mPLD2 O +
resulted O +
in O +
association O +
of O +
PLD2 O +
wild O +
type O +
and O +
inactive O +
mutant O +
proteins O +
with O +
the O +
PDGF O +
- O +
R O +
beta O +
compared O +
with O +
PLD1 O +
. O +

These O +
results O +
show O +
for O +
the O +
first O +
time O +
that O +
transactivation O +
of O +
PDGF O +
- O +
R O +
beta O +
by O +
LPA B-Chemical +
in O +
HBEpCs O +
is O +
regulated O +
by O +
PLD2 O +
. O +

Nucleotide B-Chemical +
regulation O +
of O +
heat O +
- O +
stable O +
enterotoxin O +
receptor O +
binding O +
and O +
of O +
guanylate O +
cyclase O +
activation O +
. O +

Certain O +
nucleotides B-Chemical +
were O +
found O +
to O +
regulate O +
the O +
binding O +
of O +
the O +
Escherichia O +
coli O +
heat O +
- O +
stable O +
enterotoxin O +
( O +
STa O +
) O +
to O +
its O +
receptor O +
in O +
pig O +
intestinal O +
brush O +
border O +
membranes O +
. O +

ATP B-Chemical +
and O +
adenine B-Chemical +
nucleotide B-Chemical +
analogues B-Chemical +
inhibited O +
125I O +
- O +
STa O +
binding O +
, O +
while O +
guanine B-Chemical +
nucleotide B-Chemical +
analogues B-Chemical +
stimulated O +
binding O +
, O +
with O +
maximal O +
effects O +
at O +
0.5 O -
- O -
1.0 O +
mM O +
. O +

The O +
strongest O +
inhibitors O +
were O +
adenosine B-Chemical +
5 I-Chemical -
' I-Chemical +
- I-Chemical +
[ I-Chemical +
beta I-Chemical +
gamma I-Chemical +
- I-Chemical +
imido I-Chemical +
] I-Chemical +
triphosphate I-Chemical +
( O +
App B-Chemical +
[ I-Chemical +
NH I-Chemical +
] I-Chemical +
p I-Chemical +
) O +
( O +
36 O -
% O +
) O +
and O +
adenosine B-Chemical +
5 I-Chemical -
' I-Chemical +
- I-Chemical +
[ I-Chemical +
beta I-Chemical +
- I-Chemical +
thio I-Chemical +
] I-Chemical +
diphosphate I-Chemical +
( O +
ADP B-Chemical +
[ I-Chemical +
S I-Chemical +
] I-Chemical +
) O +
( O +
41 O -
% O +
) O +
. O +

Inhibition O +
did O +
not O +
require O +
Mg2 B-Chemical -
+ I-Chemical +
, O +
and O +
was O +
blocked O +
by O +
p B-Chemical +
- I-Chemical +
chloromercuribenzenesulphonate I-Chemical +
( O +
PCMBS B-Chemical +
) O +
. O +

Stimulation O +
of O +
binding O +
required O +
Mg2 B-Chemical -
+ I-Chemical +
, O +
was O +
not O +
prevented O +
by O +
PCMBS B-Chemical +
and O +
was O +
maximal O +
with O +
GDP B-Chemical +
[ I-Chemical +
S I-Chemical +
] I-Chemical +
( O +
41 O -
% O +
) O +
. O +

While O +
App B-Chemical +
[ I-Chemical +
NH I-Chemical +
] I-Chemical +
p I-Chemical +
and O +
MgGDP B-Chemical +
[ I-Chemical +
S I-Chemical +
] I-Chemical +
appeared O +
to O +
be O +
acting O +
at O +
different O +
sites O +
, O +
they O +
also O +
interfered O +
with O +
each O +
other O +
. O +

These O +
nucleotides B-Chemical +
exerted O +
only O +
inhibitory O +
effects O +
on O +
STa O +
- O +
stimulated O +
guanylate O +
cyclase O +
activity O +
, O +
in O +
contrast O +
with O +
the O +
stimulatory O +
effects O +
of O +
adenine B-Chemical +
nucleotides O +
on O +
atrial O +
natriuretic O +
peptide O +
( O +
ANP O +
) O +
- O +
stimulated O +
guanylate O +
cyclase O +
. O +

Inhibition O +
by O +
low O +
concentrations O +
of O +
MgApp B-Chemical +
[ I-Chemical +
NH I-Chemical +
] I-Chemical +
p I-Chemical +
and O +
MgATP B-Chemical +
was O +
weaker O +
above O +
0.1 O +
mM O +
, O +
while O +
MgGDP B-Chemical +
[ I-Chemical +
S I-Chemical +
] I-Chemical +
and O +
magnesium B-Chemical +
guanosine I-Chemical +
5 I-Chemical -
' I-Chemical +
- I-Chemical +
[ I-Chemical +
gamma I-Chemical +
- I-Chemical +
thio I-Chemical +
] I-Chemical +
triphosphate I-Chemical +
( O +
MgGTP B-Chemical +
[ I-Chemical +
S I-Chemical +
] I-Chemical +
) O +
inhibited O +
in O +
a O +
single O +
phase O +
. O +

Inhibition O +
by O +
MgApp B-Chemical +
[ I-Chemical +
NH I-Chemical +
] I-Chemical +
p I-Chemical +
, O +
at O +
all O +
concentrations O +
, O +
was O +
competitive O +
with O +
the O +
substrate O +
( O +
MgGTP B-Chemical +
) O +
, O +
as O +
was O +
that O +
by O +
MgGDP B-Chemical +
[ I-Chemical +
S I-Chemical +
] I-Chemical +
and O +
MgGTP B-Chemical +
[ I-Chemical +
S I-Chemical +
] I-Chemical +
. O +

Whereas O +
membrane O +
guanylate O +
cyclases O +
usually O +
show O +
positively O +
co O +
- O +
operative O +
kinetics O +
with O +
respect O +
to O +
the O +
substrate O +
, O +
STa O +
- O +
stimulated O +
activity O +
exhibited O +
Michaelis O +
- O +
Menten O +
kinetics O +
with O +
respect O +
to O +
MgGTP B-Chemical +
. O +

This O +
changed O +
to O +
positive O +
co O +
- O +
operativity O +
when O +
Lubrol B-Chemical +
PX I-Chemical +
was O +
the O +
activator O +
, O +
or O +
when O +
the O +
substrate O +
was O +
MnGTP B-Chemical +
. O +

These O +
results O +
suggest O +
the O +
presence O +
of O +
both O +
a O +
regulatory O +
and O +
a O +
catalytic O +
nucleotide O +
- O +
binding O +
site O +
, O +
which O +
do O +
not O +
interact O +
co O +
- O +
operatively O +
with O +
STa O +
activation O +
. O +

14591846 O +
Cognitive O +
assessment O +
of O +
geriatric O +
schizophrenic O +
patients O +
with O +
severe O +
impairment O +
. O +

There O +
is O +
evidence O +
that O +
some O +
elderly O +
patients O +
with O +
chronic O +
schizophrenia O +
experience O +
marked O +
impairments O +
in O +
cognitive O +
functioning O +
. O +

Assessment O +
of O +
these O +
patients O +
may O +
be O +
difficult O +
with O +
traditional O +
neuropsychological O +
measures O +
. O +

The O +
purpose O +
of O +
the O +
present O +
study O +
was O +
to O +
determine O +
if O +
cognitive O +
functioning O +
could O +
be O +
validly O +
assessed O +
with O +
the O +
Alzheimer O +
's O +
Disease O +
Assessment O +
Scale O +
- O +
Late O +
Version O +
Cognitive O +
factor O +
score O +
( O +
ADAS O +
- O +
L O +
Cog O +
) O +
in O +
patients O +
whose O +
scores O +
on O +
the O +
Mini O +
- O +
Mental O +
State O +
Examination O +
( O +
MMSE O +
) O +
reflect O +
profound O +
cognitive O +
impairment O +
. O +

Patients O +
with O +
MMSE O +
scores O +
from O +
0 O +
to O +
were O +
selected O +
from O +
a O +
larger O +
database O +
. O +

Neuropsychological O +
instruments O +
designed O +
for O +
the O +
assessment O +
of O +
mild O +
to O +
moderate O +
dementia O +
were O +
found O +
to O +
be O +
inadequate O +
in O +
this O +
profoundly O +
impaired O +
population O +
, O +
due O +
to O +
floor O +
effects O +
. O +

In O +
contrast O +
, O +
there O +
was O +
a O +
significant O +
relationship O +
between O +
ADAS O +
- O +
L O +
scores O +
and O +
several O +
criterion O +
measures O +
, O +
including O +
the O +
MMSE O +
( O +
R O +
= O +
- O +
.71 O +
, O +
P O +
< O +
.001 O +
) O +
, O +
the O +
Social O +
Adaptive O +
Functions O +
Evaluation O +
( O +
SAFE O +
) O +
social O +
functions O +
scale O +
( O +
R O +
= O +
.47 O +
, O +
P O +
< O +
.001 O +
) O +
, O +
and O +
the O +
negative O +
symptom O +
total O +
score O +
of O +
the O +
Positive O +
and O +
Negative O +
Syndrome O +
Scale O +
( O +
PANSS O +
) O +
( O +
R O +
= O +
.412 O +
, O +
P O +
< O +
.001 O +
) O +
. O +

The O +
MMSE O +
was O +
somewhat O +
less O +
strongly O +
correlated O +
with O +
both O +
social O +
functions O +
( O +
R O +
= O +
- O +
.401 O +
, O +
P O +
< O +
.001 O +
) O +
and O +
the O +
negative O +
symptom O +
total O +
score O +
of O +
the O +
PANSS O +
( O +
R O +
= O +
- O +
.366 O +
, O +
P O +
< O +
.001 O +
) O +
. O +

These O +
results O +
suggest O +
that O +
cognition O +
can O +
be O +
reliably O +
and O +
validly O +
assessed O +
with O +
instruments O +
such O +
as O +
the O +
ADAS O +
- O +
L O +
that O +
are O +
designed O +
for O +
the O +
assessment O +
of O +
severely O +
impaired O +
patients O +
. O +

In O +
a O +
continuing O +
effort O +
to O +
design O +
small O +
- O +
molecule O +
inhibitors O +
of O +
dihydrofolate O +
reductase O +
( O +
DHFR O +
) O +
that O +
combine O +
the O +
enzyme O +
- O +
binding O +
selectivity O +
of O +
2,4 B-Chemical +
- I-Chemical +
diamino I-Chemical +
- I-Chemical +
5 I-Chemical +
- I-Chemical +
( I-Chemical +
3 I-Chemical -
' I-Chemical +
, I-Chemical +
4 I-Chemical -
' I-Chemical +
, I-Chemical +
5 I-Chemical -
' I-Chemical +
- I-Chemical +
trimethoxybenzyl I-Chemical +
) I-Chemical +
pyrimidine I-Chemical +
( O +
trimethoprim B-Chemical +
, O +
TMP B-Chemical +
) O +
with O +
the O +
potency O +
of O +
2,4 B-Chemical +
- I-Chemical +
diamino I-Chemical +
- I-Chemical +
5 I-Chemical +
- I-Chemical +
methyl I-Chemical +
- I-Chemical +
6 I-Chemical +
- I-Chemical +
( I-Chemical +
2 I-Chemical -
' I-Chemical +
, I-Chemical +
5 I-Chemical -
' I-Chemical +
- I-Chemical +
dimethoxybenzyl I-Chemical +
) I-Chemical +
pyrido I-Chemical +
[ I-Chemical +
2,3 I-Chemical +
- I-Chemical +
d I-Chemical +
] I-Chemical +
pyrimidine I-Chemical +
( O +
piritrexim B-Chemical +
, O +
PTX B-Chemical +
) O +
, O +
seven O +
previously O +
undescribed O +
2,4 B-Chemical +
- I-Chemical +
diamino I-Chemical +
- I-Chemical +
5 I-Chemical +
- I-Chemical +
[ I-Chemical +
2 I-Chemical -
' I-Chemical +
- I-Chemical +
methoxy I-Chemical +
- I-Chemical +
5 I-Chemical -
' I-Chemical +
- I-Chemical +
( I-Chemical +
substituted I-Chemical +
benzyl I-Chemical +
) I-Chemical +
] I-Chemical +
pyrimidines I-Chemical +
were O +
synthesized O +
in O +
which O +
the O +
substituent O +
at O +
the O +
5 O -
' O +
- O +
position O +
was O +
a O +
carboxyphenyl B-Chemical +
group B-Chemical +
linked O +
to O +
the O +
benzyl B-Chemical +
moiety B-Chemical +
by O +
a O +
bridge O +
of O +
two O +
or O +
four O +
atoms O +
in O +
length O +
. O +

The O +
new O +
analogues O +
were O +
all O +
obtained O +
from O +
2,4 B-Chemical +
- I-Chemical +
diamino I-Chemical +
- I-Chemical +
5 I-Chemical +
- I-Chemical +
( I-Chemical +
5 I-Chemical -
' I-Chemical +
- I-Chemical +
iodo I-Chemical +
- I-Chemical +
2 I-Chemical -
' I-Chemical +
- I-Chemical +
methoxybenzyl I-Chemical +
) I-Chemical +
pyrimidine I-Chemical +
via O +
a O +
Sonogashira O +
reaction O +
, O +
followed O +
, O +
where O +
appropriate O +
, O +
by O +
catalytic O +
hydrogenation O +
. O +

The O +
new O +
analogues O +
were O +
tested O +
as O +
inhibitors O +
of O +
DHFR O +
from O +
Pneumocystis O +
carinii O +
( O +
Pc O +
) O +
, O +
Toxoplasma O +
gondii O +
( O +
Tg O +
) O +
, O +
and O +
Mycobacterium O +
avium O +
( O +
Ma O +
) O +
, O +
three O +
life O +
- O +
threatening O +
pathogens O +
often O +
found O +
in O +
AIDS O +
patients O +
and O +
individuals O +
whose O +
immune O +
system O +
is O +
impaired O +
as O +
a O +
result O +
of O +
treatment O +
with O +
immunosuppressive O +
chemotherapy O +
or O +
radiation O +
. O +

The O +
selectivity O +
index O +
( O +
SI O +
) O +
of O +
each O +
compound O +
was O +
obtained O +
by O +
dividing O +
its O +
inhibitory O +
concentration O +
( O +
IC O +
( O +
) O +
) O +
against O +
Pc O +
, O +
Tg O +
, O +
or O +
Ma O +
DHFR O +
by O +
its O +
IC O +
( O +
) O +
against O +
rat O +
DHFR O +
. O +

2,4 B-Chemical +
- I-Chemical +
Diamino I-Chemical +
- I-Chemical +
[ I-Chemical +
2 I-Chemical -
' I-Chemical +
- I-Chemical +
methoxy I-Chemical +
- I-Chemical +
5 I-Chemical -
' I-Chemical +
- I-Chemical +
( I-Chemical +
3 I-Chemical +
- I-Chemical +
carboxyphenyl I-Chemical +
) I-Chemical +
ethynylbenzyl I-Chemical +
] I-Chemical +
pyrimidine I-Chemical +
( O +
28 O +
) O +
, O +
with O +
an O +
IC O +
( O +
) O +
of O +
23 O +
nM O +
and O +
an O +
SI O +
of O +
28 O +
in O +
the O +
Pc O +
DHFR O +
assay O +
, O +
had O +
about O +
the O +
same O +
potency O +
as O +
PTX B-Chemical +
and O +
was O +
times O +
more O +
potent O +
than O +
TMP B-Chemical +
. O +

As O +
an O +
inhibitor O +
of O +
Tg O +
DHFR O +
, O +
28 O +
had O +
an O +
IC O +
( O +
) O +
of O +
5.5 O +
nM O +
( O +
- O +
fold O +
lower O +
than O +
that O +
of O +
TMP B-Chemical +
and O +
similar O +
to O +
that O +
of O +
PTX B-Chemical +
) O +
and O +
an O +
SI O +
value O +
of O +
( O +
2 O +
- O +
fold O +
better O +
than O +
TMP B-Chemical +
and O +
vastly O +
superior O +
to O +
PTX B-Chemical +
) O +
. O +

Against O +
Ma O +
DHFR O +
, O +
28 O +
had O +
IC O +
( O +
) O +
and O +
SI O +
values O +
of O +
1.5 O +
nM O +
and O +
, O +
respectively O +
, O +
compared O +
with O +
nM O +
and O +
for O +
TMP B-Chemical +
. O +

Although O +
it O +
had O +
2.5 O +
- O +
fold O +
lower O +
potency O +
than O +
28 O +
against O +
Ma O +
DHFR O +
( O +
IC O +
( O +
) O +
= O +
3.7 O +
nM O +
) O +
and O +
was O +
substantially O +
weaker O +
against O +
Pc O +
and O +
Tg O +
DHFR O +
, O +
2,4 B-Chemical +
- I-Chemical +
diamino I-Chemical +
- I-Chemical +
[ I-Chemical +
2 I-Chemical -
' I-Chemical +
- I-Chemical +
methoxy I-Chemical +
- I-Chemical +
5 I-Chemical -
' I-Chemical +
- I-Chemical +
( I-Chemical +
4 I-Chemical +
- I-Chemical +
carboxyphenyl I-Chemical +
) I-Chemical +
ethynylbenzyl I-Chemical +
] I-Chemical +
pyrimidine I-Chemical +
( O +
29 O +
) O +
, O +
with O +
the O +
carboxy B-Chemical +
group B-Chemical +
at O +
the O +
para O +
rather O +
than O +
the O +
meta O +
position O +
, O +
displayed O +
- O +
fold O +
selectivity O +
against O +
the O +
Ma O +
enzyme O +
and O +
was O +
the O +
most O +
selective O +
2,4 B-Chemical +
- I-Chemical +
diamino I-Chemical +
- I-Chemical +
5 I-Chemical +
- I-Chemical +
( I-Chemical +
5 I-Chemical -
' I-Chemical +
- I-Chemical +
substituted I-Chemical +
benzyl I-Chemical +
) I-Chemical +
pyrimidine I-Chemical +
inhibitor O +
of O +
this O +
enzyme O +
we O +
have O +
encountered O +
to O +
date O +
. O +

Additional O +
bioassay O +
data O +
for O +
these O +
compounds O +
are O +
also O +
reported O +
. O +

The O +
design O +
, O +
synthesis O +
, O +
and O +
biological O +
evaluation O +
of O +
several O +
unsaturated B-Chemical +
acyclonucleosides I-Chemical +
related O +
to O +
augustmycin B-Chemical +
A I-Chemical +
are O +
described O +
. O +

The O +
( B-Chemical +
propargyloxy I-Chemical +
) I-Chemical +
methyl I-Chemical +
acyclonucleoside I-Chemical +
analogues B-Chemical +
of O +
6 B-Chemical +
- I-Chemical +
chloropurine I-Chemical +
, O +
adenine B-Chemical +
, O +
6 B-Chemical +
- I-Chemical +
methoxypurine I-Chemical +
, O +
hypoxanthine B-Chemical +
, O +
6 B-Chemical +
- I-Chemical +
mercaptopurine I-Chemical +
, O +
and O +
azathioprine B-Chemical +
have O +
been O +
prepared O +
. O +

The O +
9 B-Chemical +
- I-Chemical +
[ I-Chemical +
( I-Chemical +
propargyloxy I-Chemical +
) I-Chemical +
methyl I-Chemical +
] I-Chemical +
adenine I-Chemical +
( O +
5 O +
) O +
and O +
9 B-Chemical +
- I-Chemical +
[ I-Chemical +
( I-Chemical +
propargyloxy I-Chemical +
) I-Chemical +
methyl I-Chemical +
] I-Chemical +
hypoxanthine I-Chemical +
( O +
12 O +
) O +
analogues B-Chemical +
were O +
converted O +
to O +
the O +
corresponding O +
5 B-Chemical -
' I-Chemical +
- I-Chemical +
tributylstannyl I-Chemical +
intermediates B-Chemical +
( O +
9 O +
and O +
13 O +
) O +
, O +
respectively O +
, O +
which O +
gave O +
9 B-Chemical +
- I-Chemical +
[ I-Chemical +
[ I-Chemical +
[ I-Chemical +
( I-Chemical +
Z I-Chemical +
) I-Chemical +
- I-Chemical +
5 I-Chemical +
- I-Chemical +
iodo I-Chemical +
- I-Chemical +
5 I-Chemical +
- I-Chemical +
propenyl I-Chemical +
] I-Chemical +
oxy I-Chemical +
] I-Chemical +
methyl I-Chemical +
] I-Chemical +
adenine I-Chemical +
( O +
) O +
and O +
9 B-Chemical +
- I-Chemical +
[ I-Chemical +
[ I-Chemical +
[ I-Chemical +
( I-Chemical +
Z I-Chemical +
) I-Chemical +
- I-Chemical +
5 I-Chemical +
- I-Chemical +
iodo I-Chemical +
- I-Chemical +
5 I-Chemical +
- I-Chemical +
propenyl I-Chemical +
] I-Chemical +
oxy I-Chemical +
] I-Chemical +
methyl I-Chemical +
] I-Chemical +
hypoxanthine I-Chemical +
( O +
14 O +
) O +
, O +
respectively O +
, O +
after O +
iododestannylation O +
. O +

The O +
[ O +
125I O +
] O +
- O +
radiolabeled O +
congeners O +
of O +
and O +
14 O +
were O +
prepared O +
as O +
potential O +
metabolic O +
markers O +
. O +

Among O +
the O +
unsaturated B-Chemical +
acyclonucleosides I-Chemical +
tested O +
, O +
9 B-Chemical +
- I-Chemical +
[ I-Chemical +
( I-Chemical +
propargyloxy I-Chemical +
) I-Chemical +
methyl I-Chemical +
] I-Chemical +
- I-Chemical +
6 I-Chemical +
- I-Chemical +
chloropurine I-Chemical +
( O +
3 O +
) O +
, O +
9 B-Chemical +
- I-Chemical +
[ I-Chemical +
( I-Chemical +
propargyloxy I-Chemical +
) I-Chemical +
methyl I-Chemical +
] I-Chemical +
- I-Chemical +
6 I-Chemical +
- I-Chemical +
mercaptopurine I-Chemical +
( O +
15 O +
) O +
, O +
9 B-Chemical +
- I-Chemical +
[ I-Chemical +
( I-Chemical +
propargyloxy I-Chemical +
) I-Chemical +
methyl I-Chemical +
] I-Chemical +
azathioprine I-Chemical +
( O +
17 O +
) O +
, O +
and O +
angustmycin B-Chemical +
A I-Chemical +
analogue O +
showed O +
inhibition O +
of O +
cancer O +
cell O +
growth O +
, O +
but O +
only O +
at O +
a O +
minimal O +
level O +
, O +
and O +
17 O +
also O +
showed O +
14 O -
% O +
cancer O +
cell O +
death O +
in O +
vitro O +
. O +

Compound O +
provided O +
approximately O +
protection O +
against O +
HIV O +
at O +
( O +
- O +
4 O +
) O +
M O +
concentrations O +
. O +

Biodistribution O +
results O +
of O +
[ O +
125I O +
] O +
- O +
in O +
mice O +
indicate O +
that O +
compound O +
is O +
readily O +
metabolized O +
via O +
deiodination O +
in O +
vivo O +
, O +
possibly O +
by O +
serving O +
as O +
a O +
substrate O +
for O +
the O +
enzyme O +
S O +
- O +
adenosyl O +
- O +
L O +
- O +
homocysteine O +
hydrolase O +
. O +

Degarelix O +
( O +
FE200486 B-Chemical +
, O +
Ac O +
- O +
d O +
- O +
2Nal O +
( O +
1 O +
) O +
- O +
d O +
- O +
4Cpa O +
( O +
2 O +
) O +
- O +
d O +
- O +
3Pal O +
( O +
3 O +
) O +
- O +
Ser O +
( O +
4 O +
) O +
- O +
4Aph O +
( O +
l O +
- O +
Hor O +
) O +
( O +
5 O +
) O +
- O +
d O +
- O +
4Aph O +
( O +
Cbm O +
) O +
( O +
6 O +
) O +
- O +
Leu O +
( O +
7 O +
) O +
- O +
ILys O +
( O +
8 O +
) O +
- O +
Pro O +
( O +
9 O +
) O +
- O +
d O +
- O +
Ala O +
( O +
) O +
- O +
NH O +
( O +
2 O +
) O +
) O +
is O +
a O +
potent O +
and O +
very O +
long O +
acting O +
antagonist O +
of O +
gonadotropin O +
- O +
releasing O +
hormone O +
( O +
GnRH O +
) O +
after O +
subcutaneous O +
administration O +
in O +
mammals O +
including O +
humans O +
. O +

Analogues O +
of O +
degarelix B-Chemical +
were O +
synthesized O +
, O +
characterized O +
, O +
and O +
screened O +
for O +
the O +
antagonism O +
of O +
GnRH O +
- O +
induced O +
response O +
in O +
a O +
reporter O +
gene O +
assay O +
in O +
HEK O +
- O +
293 O +
cells O +
expressing O +
the O +
human O +
GnRH O +
receptor O +
. O +

The O +
duration O +
of O +
action O +
was O +
also O +
determined O +
in O +
the O +
castrated O +
male O +
rat O +
assay O +
to O +
measure O +
the O +
extent O +
( O +
efficacy O +
and O +
duration O +
of O +
action O +
) O +
of O +
inhibition O +
of O +
luteinizing O +
hormone O +
( O +
LH O +
) O +
release O +
. O +

Structurally O +
, O +
this O +
series O +
of O +
analogues O +
has O +
novel O +
substitutions O +
at O +
positions O +
3 O +
, O +
7 O +
, O +
and O +
8 O +
and O +
N O +
( O +
alpha O +
) O +
- O +
methylation O +
at O +
positions O +
6 O +
, O +
7 O +
, O +
and O +
8 O +
in O +
the O +
structure O +
of O +
degarelix B-Chemical +
. O +

These O +
substitutions O +
were O +
designed O +
to O +
probe O +
the O +
spatial O +
limitations O +
of O +
the O +
receptor O +
's O +
cavity O +
and O +
to O +
map O +
the O +
steric O +
and O +
ionic O +
boundaries O +
. O +

Some O +
functional O +
groups O +
were O +
introduced O +
that O +
were O +
hypothesized O +
to O +
influence O +
the O +
phamacokinetic O +
properties O +
of O +
the O +
analogues O +
such O +
as O +
bioavailability O +
, O +
solubility O +
, O +
intra O +
- O +
or O +
intermolecular O +
hydrogen O +
bond O +
forming O +
capacity O +
, O +
and O +
ability O +
to O +
bind O +
carrier O +
proteins O +
. O +

Substitutions O +
at O +
positions O +
3 O +
( O +
[ B-Chemical +
N I-Chemical +
( I-Chemical +
beta I-Chemical +
) I-Chemical +
- I-Chemical +
( I-Chemical +
2 I-Chemical +
- I-Chemical +
pyridyl I-Chemical +
- I-Chemical +
methyl I-Chemical +
) I-Chemical +
d I-Chemical +
- I-Chemical +
Dap I-Chemical +
( I-Chemical +
3 I-Chemical +
) I-Chemical +
] I-Chemical +
degarelix I-Chemical +
, O +
IC O +
( O +
) O +
= O +
2.71 O +
nM O +
) O +
( O +
5 O +
) O +
, O +
7 O +
( O +
[ B-Chemical +
Pra I-Chemical +
( I-Chemical +
7 I-Chemical +
) I-Chemical +
] I-Chemical +
degarelix I-Chemical +
, O +
IC O +
( O +
) O +
= O +
2.11 O +
nM O +
) O +
( O +
16 O +
) O +
, O +
and O +
8 O +
( O +
[ B-Chemical +
N I-Chemical +
( I-Chemical +
delta I-Chemical +
) I-Chemical +
- I-Chemical +
( I-Chemical +
IGly I-Chemical +
) I-Chemical +
Orn I-Chemical +
( I-Chemical +
8 I-Chemical +
) I-Chemical +
] I-Chemical +
degarelix I-Chemical +
, O +
IC O +
( O +
) O +
= O +
1.38 O +
nM O +
) O +
( O +
) O +
and O +
N O +
- O +
methylation O +
( O +
[ B-Chemical +
N I-Chemical +
( I-Chemical +
alpha I-Chemical +
) I-Chemical +
- I-Chemical +
methyl I-Chemical +
- I-Chemical +
Leu I-Chemical +
( I-Chemical +
7 I-Chemical +
) I-Chemical +
] I-Chemical +
degarelix I-Chemical +
, O +
IC O +
( O +
) O +
= O +
1.47 O +
nM O +
) O +
( O +
32 O +
) O +
yielded O +
analogues O +
that O +
were O +
equipotent O +
to O +
degarelix B-Chemical +
( O +
2 O +
) O +
in O +
vitro O +
( O +
IC O +
( O +
) O +
= O +
1.64 O +
nM O +
) O +
but O +
shorter O +
acting O +
in O +
vivo O +
. O +

Out O +
of O +
the O +
33 O +
novel O +
analogues O +
tested O +
for O +
the O +
duration O +
of O +
action O +
in O +
this O +
series O +
, O +
two O +
analogues O +
( O +
[ B-Chemical +
N I-Chemical +
( I-Chemical +
epsilon I-Chemical +
) I-Chemical +
- I-Chemical +
cyclohexyl I-Chemical +
- I-Chemical +
Lys I-Chemical +
( I-Chemical +
8 I-Chemical +
) I-Chemical +
] I-Chemical +
degarelix I-Chemical +
, O +
IC O +
( O +
) O +
= O +
1.50 O +
nM O +
) O +
( O +
23 O +
) O +
and O +
( O +
[ B-Chemical +
N I-Chemical +
( I-Chemical +
beta I-Chemical +
) I-Chemical +
- I-Chemical +
( I-Chemical +
IbetaAla I-Chemical +
) I-Chemical +
Dap I-Chemical +
( I-Chemical +
8 I-Chemical +
) I-Chemical +
] I-Chemical +
degarelix I-Chemical +
, O +
IC O +
( O +
) O +
= O +
1.98 O +
nM O +
) O +
( O +
26 O +
) O +
had O +
antagonist O +
potencies O +
and O +
duration O +
of O +
action O +
similar O +
to O +
that O +
of O +
azaline B-Chemical +
B I-Chemical +
{ O +
inhibited O +
LH O +
( O +
& O +
gt O +
; O +
) O +
release O +
for O +
& O +
gt O +
; O +
72 O +
h O +
after O +
sc O +
injection O +
to O +
castrated O +
male O +
rats O +
at O +
a O +
standard O +
dose O +
of O +
mug O +
/ O +
rat O +
in O +
5 O -
% O +
mannitol O +
} O +
. O +

Under O +
similar O +
conditions O +
analogues O +
( O +
[ B-Chemical +
N I-Chemical +
( I-Chemical +
gamma I-Chemical +
) I-Chemical +
- I-Chemical +
( I-Chemical +
IGly I-Chemical +
) I-Chemical +
Dab I-Chemical +
( I-Chemical +
8 I-Chemical +
) I-Chemical +
] I-Chemical +
degarelix I-Chemical +
, O +
IC O +
( O +
) O +
= O +
1.56 O +
nM O +
) O +
( O +
21 O +
) O +
and O +
( O +
[ B-Chemical +
IOrn I-Chemical +
( I-Chemical +
8 I-Chemical +
) I-Chemical +
] I-Chemical +
degarelix I-Chemical +
, O +
IC O +
( O +
) O +
= O +
1.72 O +
nM O +
) O +
( O +
18 O +
) O +
had O +
a O +
longer O +
duration O +
of O +
action O +
{ O +
inhibited O +
LH O +
( O +
& O +
gt O +
; O +
96 O +
h O +
) O +
release O +
} O +
than O +
azaline B-Chemical +
B I-Chemical +
; O +
however O +
they O +
were O +
shorter O +
acting O +
than O +
degarelix B-Chemical +
. O +

Hydrophilicity O +
of O +
these O +
analogues O +
, O +
a O +
potential O +
measure O +
of O +
their O +
ability O +
to O +
be O +
formulated O +
for O +
sustained O +
release O +
, O +
was O +
determined O +
using O +
RP O +
- O +
HPLC O +
at O +
neutral O +
pH O +
yielding O +
analogues O +
with O +
shorter O +
as O +
well O +
as O +
longer O +
retention O +
times O +
. O +

No O +
correlation O +
was O +
found O +
between O +
retention O +
times O +
and O +
antagonist O +
potency O +
or O +
duration O +
of O +
action O +
. O +

16946562 O +
Novel O +
genetic O +
variations O +
and O +
haplotypes O +
of O +
hepatocyte O +
nuclear O +
factor O +
4alpha O +
( O +
HNF4A O +
) O +
found O +
in O +
Japanese O +
type O +
II O +
diabetic O +
patients O +
. O +

Thirty O +
- O +
nine O +
single O +
nucleotide O +
variations O +
, O +
including O +
16 O +
novel O +
ones O +
, O +
were O +
found O +
in O +
the O +
5 O -
' O +
promoter O +
region O +
, O +
all O +
of O +
the O +
exons O +
and O +
their O +
surrounding O +
introns O +
of O +
HNF4A O +
in O +
74 O +
Japanese O +
type O +
II O +
diabetic O +
patients O +
. O +

The O +
following O +
novel O +
variations O +
were O +
identified O +
( O +
based O +
on O +
the O +
amino O +
acid O +
numbering O +
of O +
splicing O +
variant O +
2 O +
) O +
: O +
- O +
> O +
C O +
in O +
the O +
5 O -
' O +
promoter O +
region O +
; O +
1154C O +
> O +
T O +
( O +
A385V O +
) O +
and O +
1193 O -
T O +
> O +
C O +
( O +
M398 O -
T O +
) O +
in O +
the O +
coding O +
exons O +
; O +
> O +
A O +
, O +
1852 O -
G O +
> O +
T O +
, O +
> O +
T O +
, O +
> O +
A O +
, O +
and O +
2362 O +
_ O -
2380 O +
delAAGAATGGTGTGGGAGAGG O +
in O +
the O +
3 O -
' O +
- O +
untranslated O +
region O +
, O +
and O +
IVS1 O -
+ O +
231 O -
G O +
> O +
A O +
, O +
IVS2 O +
- O +
83C O +
> O +
T O +
, O +
IVS3 O -
+ O +
> O +
T O +
, O +
IVS3 O +
- O +
54delC O +
, O +
IVS5 O -
+ O +
173 O +
_ O -
176 O +
delTTAG O +
, O +
IVS5 O +
- O +
181 O +
_ O +
- O +
, O +
IVS8 O +
- O +
> O +
G O +
, O +
and O +
IVS9 O +
- O +
151A O +
> O +
C O +
in O +
the O +
introns O +
. O +

The O +
allele O +
frequencies O +
were O +
0.311 O +
for O +
2362 O +
_ O -
2380 O +
delAAGAATGGTGTGGGAGAGG O +
, O +
0.054 O +
for O +
> O +
A O +
, O +
0.047 O +
for O +
1852 O -
G O +
> O +
T O +
, O +
0.020 O +
for O +
IVS1 O -
+ O +
231 O -
G O +
> O +
A O +
, O +
0.014 O +
for O +
IVS9 O +
- O +
151A O +
> O +
C O +
, O +
and O +
0.007 O +
for O +
the O +
other O +
11 O +
variations O +
. O +

In O +
addition O +
, O +
one O +
known O +
nonsynonymous O +
single O +
nucleotide O +
polymorphism O +
, O +
416C O +
> O +
T O +
( O +
T139I O +
) O +
, O +
was O +
detected O +
at O +
a O +
0.007 O +
frequency O +
. O +

Based O +
on O +
the O +
linkage O +
disequilibrium O +
profiles O +
, O +
the O +
region O +
analyzed O +
was O +
divided O +
into O +
three O +
blocks O +
. O +

Haplotype O +
analysis O +
determined O +
/ O +
inferred O +
, O +
16 O +
, O +
and O +
12 O +
haplotypes O +
for O +
block O +
1 O +
, O +
2 O +
, O +
and O +
3 O +
, O +
respectively O +
. O +

Our O +
results O +
on O +
HNF4A O +
variations O +
and O +
haplotypes O +
would O +
be O +
useful O +
for O +
pharmacogenetic O +
studies O +
in O +
Japanese O +
. O +

A O +
series O +
of O +
8 B-Chemical +
- I-Chemical +
( I-Chemical +
trifluoromethyl I-Chemical +
) I-Chemical +
- I-Chemical +
substituted I-Chemical +
quinolones I-Chemical +
has O +
been O +
prepared O +
and O +
evaluated O +
for O +
in O +
vitro O +
and O +
in O +
vivo O +
antibacterial O +
activity O +
, O +
and O +
phototolerance O +
in O +
a O +
mouse O +
phototolerance O +
assay O +
. O +

These O +
analogues O +
were O +
compared O +
to O +
the O +
corresponding O +
series O +
of O +
6,8 B-Chemical +
- I-Chemical +
difluoro I-Chemical +
- I-Chemical +
and O +
6 B-Chemical +
- I-Chemical +
fluoro I-Chemical +
- I-Chemical +
8H I-Chemical +
- I-Chemical +
quinolones I-Chemical +
( O +
ciprofloxacin B-Chemical +
type O +
) O +
. O +

Although O +
their O +
in O +
vitro O +
antibacterial O +
activities O +
are O +
less O +
than O +
the O +
6,8 B-Chemical +
- I-Chemical +
difluoro I-Chemical +
analogues B-Chemical +
, O +
the O +
8 B-Chemical +
- I-Chemical +
( I-Chemical +
trifluoromethyl I-Chemical +
) I-Chemical +
quinolones I-Chemical +
are O +
generally O +
equivalent O +
to O +
their O +
8H B-Chemical +
analogues B-Chemical +
. O +

In O +
vivo O +
, O +
they O +
are O +
comparable O +
to O +
the O +
6,8 B-Chemical +
- I-Chemical +
difluoro I-Chemical +
series B-Chemical +
and O +
show O +
up O +
to O +
- O +
fold O +
improvement O +
in O +
efficacy O +
when O +
compared O +
to O +
their O +
ciprofloxacin B-Chemical +
counterparts O +
vs O +
Streptococcus O +
pyogenes O +
and O +
Streptococcus O +
pneumonia O +
. O +

In O +
the O +
phototolerance O +
model O +
, O +
the O +
8 B-Chemical +
- I-Chemical +
( I-Chemical +
trifluoromethyl I-Chemical +
) I-Chemical +
quinolones I-Chemical +
are O +
comparable O +
to O +
the O +
8H B-Chemical +
- I-Chemical +
quinolones I-Chemical +
. O +

Both O +
of O +
these O +
series O +
display O +
much O +
higher O +
no O +
effect O +
doses O +
( O +
greater O +
tolerance O +
) O +
than O +
the O +
corresponding O +
6,8 B-Chemical +
- I-Chemical +
difluoroquinolones I-Chemical +
. O +

17368496 O +
Tissue O +
and O +
serum O +
levels O +
of O +
principal O +
androgens B-Chemical +
in O +
benign O +
prostatic O +
hyperplasia O +
and O +
prostate O +
cancer O +
. O +

Androgens B-Chemical +
are O +
considered O +
to O +
play O +
a O +
substantial O +
role O +
in O +
pathogenesis O +
of O +
both O +
benign O +
prostatic O +
hyperplasia O +
( O +
BPH O +
) O +
and O +
prostate O +
cancer O +
. O +

The O +
importance O +
of O +
determination O +
of O +
androgen B-Chemical +
levels O +
in O +
tissue O +
and O +
serum O +
for O +
cancer O +
progression O +
and O +
prognosis O +
has O +
been O +
poorly O +
understood O +
. O +

The O +
aim O +
of O +
study O +
was O +
to O +
find O +
out O +
hormonal O +
differences O +
in O +
both O +
diseases O +
, O +
their O +
correlations O +
between O +
intraprostatic O +
and O +
serum O +
levels O +
and O +
predicted O +
value O +
of O +
their O +
investigation O +
. O +

Testosterone B-Chemical +
, O +
dihydrotestosterone B-Chemical +
, O +
androstenedione B-Chemical +
and O +
also O +
epitestosterone B-Chemical +
were O +
determined O +
in O +
prostate O +
tissue O +
from O +
57 O +
patients O +
who O +
underwent O +
transvesical O +
prostatectomy O +
for O +
BPH O +
and O +
121 O +
patients O +
after O +
radical O +
prostatectomy O +
for O +
prostate O +
cancer O +
. O +

In O +
75 O +
subjects O +
with O +
cancer O +
and O +
51 O +
with O +
BPH O +
the O +
serum O +
samples O +
were O +
analyzed O +
for O +
testosterone B-Chemical +
, O +
dihydrotestosterone B-Chemical +
and O +
SHBG O +
. O +

Significantly O +
higher O +
intraprostatic O +
androgen B-Chemical +
concentrations O +
, O +
i.e. O +
8.85 O +
+ O +
/ O +
- O +
6.77 O +
versus O +
6.44 O +
+ O +
/ O +
- O +
6.43 O +
pmol O +
/ O +
g O +
, O +
p O +
< O +
0.01 O +
for O +
dihydrotestosterone B-Chemical +
, O +
and O +
4.61 O +
+ O +
/ O +
- O +
7.02 O +
versus O +
3.44 O +
+ O +
/ O +
- O +
4.53 O +
pmol O +
/ O +
g O +
, O +
p O +
< O +
0.05 O +
for O +
testosterone B-Chemical +
, O +
respectively O +
, O +
were O +
found O +
in O +
patients O +
with O +
prostate O +
cancer O +
than O +
in O +
BPH O +
. O +

Higher O +
levels O +
in O +
cancer O +
tissue O +
were O +
found O +
also O +
for O +
epitestosterone B-Chemical +
. O +

However O +
, O +
no O +
differences O +
were O +
found O +
in O +
serum O +
levels O +
. O +

Highly O +
significant O +
correlations O +
occurred O +
between O +
all O +
pairs O +
of O +
intraprostatic O +
androgens B-Chemical +
and O +
also O +
epitestosterone B-Chemical +
as O +
well O +
as O +
between O +
serum O +
testosterone B-Chemical +
and O +
dihydrotestosterone B-Chemical +
( O +
p O +
< O +
0.001 O +
) O +
in O +
both O +
BPH O +
and O +
cancer O +
groups O +
. O +

Correlation O +
was O +
not O +
found O +
between O +
corresponding O +
tissue O +
and O +
serum O +
testosterone B-Chemical +
and O +
dihydrotestosterone B-Chemical +
, O +
either O +
in O +
benign O +
or O +
cancer O +
samples O +
. O +

The O +
results O +
point O +
to O +
importance O +
of O +
intraprostatic O +
hormone O +
levels O +
for O +
evaluation O +
of O +
androgen O +
status O +
of O +
patients O +
, O +
contrasting O +
to O +
a O +
low O +
value O +
of O +
serum O +
hormone O +
measurement O +
. O +

Structure O +
- O +
activity O +
relationships O +
have O +
been O +
investigated O +
for O +
inhibition O +
of O +
DNA O +
- O +
dependent O +
protein O +
kinase O +
( O +
DNA O +
- O +
PK O +
) O +
and O +
ATM O +
kinase O +
by O +
a O +
series O +
of O +
pyran B-Chemical +
- I-Chemical +
2 I-Chemical +
- I-Chemical +
ones I-Chemical +
, O +
pyran B-Chemical +
- I-Chemical +
4 I-Chemical +
- I-Chemical +
ones I-Chemical +
, O +
thiopyran B-Chemical +
- I-Chemical +
4 I-Chemical +
- I-Chemical +
ones I-Chemical +
, O +
and O +
pyridin B-Chemical +
- I-Chemical +
4 I-Chemical +
- I-Chemical +
ones I-Chemical +
. O +

A O +
wide O +
range O +
of O +
IC50 O +
values O +
were O +
observed O +
for O +
pyranones B-Chemical +
and O +
thiopyranones B-Chemical +
substituted O +
at O +
the O +
6 O +
- O +
position O +
, O +
with O +
the O +
3 O +
- O +
and O +
5 O +
- O +
positions O +
proving O +
intolerant O +
to O +
substitution O +
. O +

Related O +
pyran B-Chemical +
- I-Chemical +
2 I-Chemical +
- I-Chemical +
ones I-Chemical +
, O +
pyran B-Chemical +
- I-Chemical +
4 I-Chemical +
- I-Chemical +
ones I-Chemical +
, O +
and O +
thiopyran B-Chemical +
- I-Chemical +
4 I-Chemical +
- I-Chemical +
ones I-Chemical +
showed O +
similar O +
IC50 O +
values O +
against O +
DNA O +
- O +
PK O +
, O +
whereas O +
the O +
pyridin B-Chemical +
- I-Chemical +
4 I-Chemical +
- I-Chemical +
one I-Chemical +
system O +
proved O +
, O +
in O +
general O +
, O +
ineffective O +
at O +
inhibiting O +
DNA O +
- O +
PK O +
. O +

Extended O +
libraries O +
exploring O +
the O +
6 O +
- O +
position O +
of O +
2 B-Chemical +
- I-Chemical +
morpholino I-Chemical +
- I-Chemical +
pyran I-Chemical +
- I-Chemical +
4 I-Chemical +
- I-Chemical +
ones I-Chemical +
and O +
2 B-Chemical +
- I-Chemical +
morpholino I-Chemical +
- I-Chemical +
thiopyrano I-Chemical +
- I-Chemical +
4 I-Chemical +
- I-Chemical +
ones I-Chemical +
identified O +
the O +
first O +
highly O +
potent O +
and O +
selective O +
ATM O +
inhibitor O +
2 B-Chemical +
- I-Chemical +
morpholin I-Chemical +
- I-Chemical +
4 I-Chemical +
- I-Chemical +
yl I-Chemical +
- I-Chemical +
6 I-Chemical +
- I-Chemical +
thianthren I-Chemical +
- I-Chemical +
1 I-Chemical +
- I-Chemical +
yl I-Chemical +
- I-Chemical +
pyran I-Chemical +
- I-Chemical +
4 I-Chemical +
- I-Chemical +
one I-Chemical +
( O +
151C O +
; O +
ATM O +
; O +
IC50 O +
= O +
13 O +
nM O +
) O +
and O +
revealed O +
constrained O +
SARs O +
for O +
ATM O +
inhibition O +
compared O +
with O +
DNA O +
- O +
PK O +
. O +

One O +
of O +
the O +
most O +
potent O +
DNA O +
- O +
PK O +
inhibitors O +
identified O +
, O +
2 B-Chemical +
- I-Chemical +
( I-Chemical +
4 I-Chemical +
- I-Chemical +
methoxyphenyl I-Chemical +
) I-Chemical +
- I-Chemical +
6 I-Chemical +
- I-Chemical +
( I-Chemical +
morpholin I-Chemical +
- I-Chemical +
4 I-Chemical +
- I-Chemical +
yl I-Chemical +
) I-Chemical +
pyran I-Chemical +
- I-Chemical +
4 I-Chemical +
- I-Chemical +
one I-Chemical +
( O +
16 O +
; O +
DNA O +
- O +
PK O +
; O +
IC50 O +
= O +
nM O +
) O +
effectively O +
sensitized O +
HeLa O +
cells O +
to O +
the O +
topoisomerase O +
II O +
inhibitor O +
etoposide B-Chemical +
in O +
vitro O +
. O +

Selective O +
protection O +
of O +
( B-Chemical +
9R I-Chemical +
) I-Chemical +
- I-Chemical +
9 I-Chemical +
- I-Chemical +
amino I-Chemical +
- I-Chemical +
9 I-Chemical +
- I-Chemical +
deoxoerythromycin I-Chemical +
A I-Chemical +
allowed O +
for O +
elimination O +
of O +
the O +
12 B-Chemical +
- I-Chemical +
hydroxyl I-Chemical +
group B-Chemical +
to O +
afford O +
a O +
versatile O +
12,21 B-Chemical +
- I-Chemical +
olefin I-Chemical +
intermediate B-Chemical +
. O +

Further O +
modifications O +
of O +
the O +
intermediate O +
led O +
to O +
the O +
syntheses O +
of O +
( B-Chemical +
9R I-Chemical +
) I-Chemical +
- I-Chemical +
9 I-Chemical +
- I-Chemical +
deoxo I-Chemical +
- I-Chemical +
9 I-Chemical +
- I-Chemical +
( I-Chemical +
N I-Chemical +
, I-Chemical +
N I-Chemical +
- I-Chemical +
dimethylamino I-Chemical +
) I-Chemical +
- I-Chemical +
12,21 I-Chemical +
- I-Chemical +
epoxyerythromycin I-Chemical +
B I-Chemical +
, O +
( B-Chemical +
9R I-Chemical +
) I-Chemical +
- I-Chemical +
9 I-Chemical +
- I-Chemical +
deoxo I-Chemical +
- I-Chemical +
9 I-Chemical +
- I-Chemical +
( I-Chemical +
N I-Chemical +
, I-Chemical +
N I-Chemical +
- I-Chemical +
dimethylamino I-Chemical +
) I-Chemical +
- I-Chemical +
21 I-Chemical +
- I-Chemical +
hydroxyerythromycin I-Chemical +
A I-Chemical +
, O +
and O +
( B-Chemical +
9R I-Chemical +
) I-Chemical +
- I-Chemical +
9 I-Chemical +
- I-Chemical +
deoxo I-Chemical +
- I-Chemical +
9 I-Chemical +
- I-Chemical +
( I-Chemical +
N I-Chemical +
, I-Chemical +
N I-Chemical +
- I-Chemical +
dimethylamino I-Chemical +
) I-Chemical +
- I-Chemical +
21 I-Chemical +
- I-Chemical +
hydroxyerythromycin I-Chemical +
B I-Chemical +
. O +

All O +
three O +
compounds O +
retained O +
antibacterial O +
activity O +
against O +
several O +
organisms O +
normally O +
susceptible O +
to O +
( B-Chemical +
9R I-Chemical +
) I-Chemical +
- I-Chemical +
9 I-Chemical +
- I-Chemical +
deoxo I-Chemical +
- I-Chemical +
9 I-Chemical +
- I-Chemical +
( I-Chemical +
N I-Chemical +
, I-Chemical +
N I-Chemical +
- I-Chemical +
dimethylamino I-Chemical +
) I-Chemical +
erythromycin I-Chemical +
A I-Chemical +
. O +

However O +
, O +
the O +
21 B-Chemical +
- I-Chemical +
hydroxylated I-Chemical +
erythromycin I-Chemical +
A I-Chemical +
analogue B-Chemical +
was O +
weaker O +
in O +
potency O +
than O +
the O +
corresponding O +
erythromycin B-Chemical +
B I-Chemical +
congener I-Chemical +
and O +
much O +
weaker O +
than O +
the O +
epoxy B-Chemical +
derivative B-Chemical +
. O +

This O +
suggests O +
that O +
while O +
substitution O +
of O +
a O +
polar O +
functionality O +
at O +
C O +
- O +
21 O +
does O +
not O +
abolish O +
antibacterial O +
activity O +
, O +
introduction O +
of O +
vicinal O +
polar O +
groups O +
at O +
both O +
C O +
- O +
12 O +
and O +
C O +
- O +
21 O +
may O +
lead O +
to O +
reduction O +
in O +
potency O +
. O +

Nevertheless O +
, O +
these O +
21 O +
- O +
functionalized O +
derivatives O +
of O +
( B-Chemical +
9R I-Chemical +
) I-Chemical +
- I-Chemical +
erythromycylamine I-Chemical +
provide O +
an O +
entry O +
into O +
novel O +
analogues O +
of O +
the O +
important O +
macrolide O +
antibiotic O +
erythromycin B-Chemical +
. O +

Thalamic O +
atrophy O +
and O +
cognition O +
in O +
unilateral O +
temporal O +
lobe O +
epilepsy O +
. O +

This O +
study O +
examined O +
quantitative O +
magnetic O +
resonance O +
volumes O +
of O +
the O +
thalamus O +
and O +
hippocampus O +
and O +
determined O +
their O +
relationship O +
with O +
cognitive O +
function O +
and O +
clinical O +
seizure O +
characteristics O +
in O +
a O +
sample O +
of O +
46 O +
unilateral O +
temporal O +
lobe O +
epilepsy O +
( O +
TLE O +
) O +
subjects O +
( O +
left O +
and O +
26 O +
right O +
) O +
and O +
29 O +
controls O +
. O +

The O +
hippocampus O +
and O +
thalamus O +
exhibited O +
different O +
patterns O +
of O +
volume O +
abnormality O +
, O +
different O +
associations O +
with O +
clinical O +
seizure O +
characteristics O +
, O +
and O +
different O +
patterns O +
of O +
relationship O +
with O +
cognitive O +
measures O +
. O +

Hippocampal O +
volume O +
reduction O +
was O +
primarily O +
ipsilateral O +
to O +
the O +
seizure O +
focus O +
, O +
and O +
thalamic O +
volume O +
reduction O +
was O +
bilateral O +
. O +

Ipsilateral O +
hippocampal O +
volume O +
was O +
significantly O +
correlated O +
with O +
both O +
early O +
neurodevelopmental O +
features O +
( O +
age O +
of O +
seizure O +
onset O +
) O +
and O +
disease O +
characteristics O +
( O +
duration O +
of O +
epilepsy O +
) O +
, O +
whereas O +
thalamus O +
integrity O +
was O +
related O +
only O +
to O +
disease O +
variables O +
. O +

Hippocampal O +
volume O +
showed O +
a O +
selective O +
association O +
with O +
verbal O +
memory O +
performance O +
. O +

In O +
contrast O +
, O +
both O +
left O +
and O +
right O +
thalamic O +
volumes O +
were O +
significantly O +
correlated O +
with O +
performance O +
on O +
both O +
memory O +
and O +
nonmemory O +
cognitive O +
domains O +
. O +

These O +
findings O +
underscore O +
the O +
importance O +
of O +
thalamic O +
atrophy O +
in O +
chronic O +
TLE O +
and O +
its O +
potential O +
implications O +
for O +
cognition O +
. O +

Quantitative O +
magnetic O +
resonance O +
image O +
analysis O +
of O +
the O +
cerebellum O +
in O +
macrocephalic O +
and O +
normocephalic O +
children O +
and O +
adults O +
with O +
autism O +
. O +

A O +
detailed O +
morphometric O +
analysis O +
of O +
the O +
cerebellum O +
in O +
autism O +
with O +
and O +
without O +
macrocephaly O +
. O +

Four O +
subject O +
groups O +
( O +
N O +
= O +
65 O +
; O +
male O +
; O +
IQs O +
> O +
or O +
= O +
65 O +
; O +
age O +
7 O +
to O +
26 O +
years O +
) O +
were O +
studied O +
with O +
quantitative O +
MRI O +
; O +
normocephalic O +
and O +
macrocephalic O +
individuals O +
with O +
autism O +
without O +
mental O +
retardation O +
were O +
compared O +
to O +
normocephalic O +
and O +
benign O +
macrocephalic O +
typically O +
developing O +
individuals O +
. O +

Total O +
cerebellum O +
volumes O +
and O +
surface O +
areas O +
of O +
four O +
lobular O +
midsagittal O +
groups O +
were O +
measured O +
. O +

Independent O +
t O +
- O +
tests O +
between O +
autism O +
and O +
control O +
subjects O +
matched O +
for O +
head O +
size O +
revealed O +
no O +
significant O +
differences O +
. O +

Multivariate O +
analyses O +
of O +
variance O +
were O +
also O +
performed O +
, O +
using O +
the O +
diagnostic O +
group O +
as O +
the O +
fixed O +
factor O +
, O +
cerebellar O +
measures O +
as O +
the O +
dependent O +
variables O +
and O +
total O +
intracranial O +
volume O +
, O +
total O +
brain O +
volume O +
, O +
age O +
, O +
verbal O +
IQ O +
, O +
and O +
performance O +
IQ O +
as O +
covariates O +
. O +

No O +
significant O +
differences O +
were O +
found O +
; O +
however O +
, O +
a O +
trend O +
was O +
noted O +
in O +
which O +
macrocephalic O +
individuals O +
with O +
autism O +
consistently O +
exhibited O +
slightly O +
smaller O +
cerebellar O +
volume O +
or O +
surface O +
area O +
when O +
compared O +
to O +
individuals O +
with O +
benign O +
macrocephaly O +
. O +

In O +
autism O +
, O +
with O +
and O +
without O +
macrocephaly O +
, O +
cerebellar O +
structures O +
were O +
found O +
to O +
be O +
proportional O +
to O +
head O +
size O +
and O +
did O +
not O +
differ O +
from O +
typically O +
developing O +
subjects O +
. O +

Visual O +
perception O +
in O +
prediagnostic O +
and O +
early O +
stage O +
Huntington O +
's O +
disease O +
. O +

Disturbances O +
of O +
visual O +
perception O +
frequently O +
accompany O +
neurodegenerative O +
disorders O +
but O +
have O +
been O +
little O +
studied O +
in O +
Huntington O +
's O +
disease O +
( O +
HD O +
) O +
gene O +
carriers O +
. O +

We O +
used O +
psychophysical O +
tests O +
to O +
assess O +
visual O +
perception O +
among O +
individuals O +
in O +
the O +
prediagnostic O +
and O +
early O +
stages O +
of O +
HD O +
. O +

The O +
sample O +
comprised O +
four O +
groups O +
, O +
which O +
included O +
nongene O +
carriers O +
( O +
NG O +
) O +
, O +
32 O +
prediagnostic O +
gene O +
carriers O +
with O +
minimal O +
neurological O +
abnormalities O +
( O +
PD1 O +
) O +
; O +
prediagnostic O +
gene O +
carriers O +
with O +
moderate O +
neurological O +
abnormalities O +
( O +
PD2 O +
) O +
, O +
and O +
36 O +
gene O +
carriers O +
with O +
diagnosed O +
HD O +
. O +

Contrast O +
sensitivity O +
for O +
stationary O +
and O +
moving O +
sinusoidal O +
gratings O +
, O +
and O +
tests O +
of O +
form O +
and O +
motion O +
discrimination O +
, O +
were O +
used O +
to O +
probe O +
different O +
visual O +
pathways O +
. O +

Patients O +
with O +
HD O +
showed O +
impaired O +
contrast O +
sensitivity O +
for O +
moving O +
gratings O +
. O +

For O +
one O +
of O +
the O +
three O +
contrast O +
sensitivity O +
tests O +
, O +
the O +
prediagnostic O +
gene O +
carriers O +
with O +
greater O +
neurological O +
abnormality O +
( O +
PD2 O +
) O +
also O +
had O +
impaired O +
performance O +
as O +
compared O +
with O +
NG O +
. O +

These O +
findings O +
suggest O +
that O +
early O +
stage O +
HD O +
disrupts O +
visual O +
functions O +
associated O +
with O +
the O +
magnocellular O +
pathway O +
. O +

However O +
, O +
these O +
changes O +
are O +
only O +
observed O +
in O +
individuals O +
diagnosed O +
with O +
HD O +
or O +
who O +
are O +
in O +
the O +
more O +
symptomatic O +
stages O +
of O +
prediagnostic O +
HD O +
. O +

Worker O +
size O +
in O +
the O +
formosan O +
subterranean O +
termite O +
in O +
relation O +
to O +
colony O +
breeding O +
structure O +
as O +
inferred O +
from O +
molecular O +
markers O +
. O +

The O +
Formosan O +
subterranean O +
termite O +
, O +
Coptotermes O +
formosanus O +
Shiraki O +
, O +
is O +
an O +
invasive O +
species O +
that O +
originated O +
in O +
China O +
and O +
has O +
been O +
introduced O +
to O +
Hawaii O +
and O +
the O +
U O +
. O +

S O +
. O +
mainland O +
. O +

Colonies O +
are O +
headed O +
either O +
by O +
a O +
pair O +
of O +
reproductives O +
( O +
simple O +
families O +
) O +
or O +
by O +
varying O +
numbers O +
of O +
inbreeding O +
reproductives O +
( O +
extended O +
families O +
) O +
, O +
and O +
therefore O +
have O +
variable O +
degrees O +
of O +
inbreeding O +
. O +

Worker O +
size O +
also O +
varies O +
among O +
colonies O +
of O +
Formosan O +
termites O +
. O +

We O +
tested O +
whether O +
variation O +
in O +
worker O +
size O +
can O +
be O +
explained O +
by O +
the O +
breeding O +
system O +
. O +

Workers O +
were O +
collected O +
from O +
colonies O +
from O +
three O +
geographically O +
separated O +
populations O +
( O +
China O +
, O +
Hawaii O +
, O +
and O +
Louisiana O +
) O +
, O +
and O +
body O +
weight O +
and O +
head O +
size O +
were O +
measured O +
. O +

Microsatellite O +
genotyping O +
was O +
used O +
to O +
establish O +
whether O +
colonies O +
were O +
simple O +
or O +
extended O +
families O +
and O +
to O +
determine O +
the O +
heterozygosity O +
of O +
workers O +
and O +
their O +
degree O +
of O +
inbreeding O +
relative O +
to O +
their O +
colony O +
( O +
F O +
( O +
IC O +
) O +
, O +
sensitive O +
to O +
the O +
number O +
of O +
reproductives O +
) O +
. O +

All O +
Chinese O +
colonies O +
contained O +
multiple O +
inbreeding O +
neotenics O +
. O +

In O +
Hawaii O +
, O +
37 O -
% O +
of O +
the O +
colonies O +
were O +
simple O +
families O +
and O +
63 O -
% O +
were O +
extended O +
families O +
, O +
both O +
having O +
considerable O +
degrees O +
of O +
inbreeding O +
. O +

In O +
Louisiana O +
, O +
57 O -
% O +
of O +
the O +
colonies O +
were O +
simple O +
families O +
, O +
which O +
were O +
mostly O +
headed O +
by O +
unrelated O +
pairs O +
, O +
and O +
43 O -
% O +
were O +
extended O +
families O +
. O +

In O +
simple O +
families O +
, O +
size O +
and O +
body O +
weight O +
of O +
workers O +
were O +
not O +
associated O +
with O +
F O +
( O +
IC O +
) O +
or O +
heterozygosity O +
. O +

In O +
extended O +
families O +
of O +
two O +
populations O +
, O +
both O +
size O +
parameters O +
were O +
negatively O +
correlated O +
with O +
F O +
( O +
IC O +
) O +
; O +
however O +
, O +
heterozygosity O +
was O +
not O +
associated O +
with O +
worker O +
size O +
in O +
any O +
of O +
the O +
populations O +
. O +

This O +
suggests O +
that O +
the O +
number O +
of O +
reproductives O +
within O +
colonies O +
has O +
a O +
stronger O +
influence O +
on O +
worker O +
size O +
than O +
the O +
individuals O +
' O +
genetic O +
diversity O +
in O +
Formosan O +
subterranean O +
termite O +
colonies O +
. O +

Photodynamic O +
diagnostics O +
of O +
bladder O +
tumors O +
. O +

Approximately O +
18,000 O +
new O +
cases O +
of O +
urothelial O +
cancer O +
of O +
the O +
bladder O +
occur O +
annually O +
, O +
making O +
it O +
the O +
most O +
frequent O +
urogenital O +
neoplasia O +
representing O +
nearly O +
4 O -
% O +
of O +
all O +
malignomas O +
. O +

Tumor O +
stage O +
defines O +
two O +
subgroups O +
requiring O +
specific O +
therapeutic O +
approaches O +
and O +
implying O +
distinct O +
prognoses O +
. O +

Non O +
- O +
muscle O +
- O +
invasive O +
urothelial O +
cancer O +
recurs O +
frequently O +
and O +
occasionally O +
progresses O +
to O +
muscle O +
- O +
invasive O +
stages O +
. O +

Remnant O +
tumor O +
after O +
initial O +
resection O +
is O +
seen O +
as O +
one O +
major O +
factor O +
in O +
high O +
recurrence O +
rates O +
. O +

Although O +
photodynamic O +
diagnostics O +
improving O +
detection O +
and O +
increasing O +
recurrence O +
- O +
free O +
survival O +
has O +
been O +
introduced O +
to O +
broad O +
application O +
, O +
it O +
has O +
yet O +
not O +
been O +
established O +
as O +
standard O +
procedure O +
. O +

This O +
article O +
reviews O +
the O +
current O +
literature O +
and O +
discusses O +
controversial O +
aspects O +
. O +

X O +
- O +
ray O +
beam O +
stabilization O +
at O +
BL O +
- O +
17A O +
, O +
the O +
protein O +
microcrystallography O +
beamline O +
of O +
the O +
Photon O +
Factory O +
. O +

BL O +
- O +
17A O +
is O +
a O +
new O +
structural O +
biology O +
beamline O +
at O +
the O +
Photon O +
Factory O +
, O +
Japan O +
. O +

The O +
high O +
- O +
brilliance O +
beam O +
, O +
derived O +
from O +
the O +
new O +
short O +
- O +
gap O +
undulator O +
( O +
SGU O +
# O +
17 O +
) O +
, O +
allows O +
for O +
unique O +
protein O +
crystallographic O +
experiments O +
such O +
as O +
data O +
collection O +
from O +
microcrystals O +
and O +
structural O +
determination O +
using O +
softer O +
X O +
- O +
rays O +
. O +

However O +
, O +
microcrystal O +
experiments O +
require O +
robust O +
beam O +
stability O +
during O +
data O +
collection O +
and O +
minor O +
fluctuations O +
could O +
not O +
be O +
ignored O +
. O +

Initially O +
, O +
significant O +
beam O +
instability O +
was O +
observed O +
at O +
BL O +
- O +
17A O +
. O +

The O +
causes O +
of O +
the O +
beam O +
instability O +
were O +
investigated O +
and O +
its O +
various O +
sources O +
identified O +
. O +

Subsequently O +
, O +
several O +
effective O +
countermeasures O +
have O +
been O +
implemented O +
, O +
and O +
the O +
fluctuation O +
of O +
the O +
beam O +
intensity O +
successfully O +
suppressed O +
to O +
within O +
1 O -
% O +
. O +

Here O +
the O +
instability O +
reduction O +
techniques O +
used O +
at O +
BL O +
- O +
17A O +
are O +
presented O +
. O +

Implementation O +
of O +
remote O +
monitoring O +
and O +
diffraction O +
evaluation O +
systems O +
at O +
the O +
Photon O +
Factory O +
macromolecular O +
crystallography O +
beamlines O +
. O +

Owing O +
to O +
recent O +
advances O +
in O +
high O +
- O +
throughput O +
technology O +
in O +
macromolecular O +
crystallography O +
beamlines O +
, O +
such O +
as O +
high O +
- O +
brilliant O +
X O +
- O +
ray O +
sources O +
, O +
high O +
- O +
speed O +
readout O +
detectors O +
and O +
robotics O +
, O +
the O +
number O +
of O +
samples O +
that O +
can O +
be O +
examined O +
in O +
a O +
single O +
visit O +
to O +
the O +
beamline O +
has O +
increased O +
dramatically O +
. O +

In O +
order O +
to O +
make O +
these O +
experiments O +
more O +
efficient O +
, O +
two O +
functions O +
, O +
remote O +
monitoring O +
and O +
diffraction O +
image O +
evaluation O +
, O +
have O +
been O +
implemented O +
in O +
the O +
macromolecular O +
crystallography O +
beamlines O +
at O +
the O +
Photon O +
Factory O +
( O +
PF O +
) O +
. O +

Remote O +
monitoring O +
allows O +
scientists O +
to O +
participate O +
in O +
the O +
experiment O +
by O +
watching O +
from O +
their O +
laboratories O +
, O +
without O +
having O +
to O +
come O +
to O +
the O +
beamline O +
. O +

Diffraction O +
image O +
evaluation O +
makes O +
experiments O +
easier O +
, O +
especially O +
when O +
using O +
the O +
sample O +
exchange O +
robot O +
. O +

To O +
implement O +
these O +
two O +
functions O +
, O +
two O +
independent O +
clients O +
have O +
been O +
developed O +
that O +
work O +
specifically O +
for O +
remote O +
monitoring O +
and O +
diffraction O +
image O +
evaluation O +
. O +

In O +
the O +
macromolecular O +
crystallography O +
beamlines O +
at O +
PF O +
, O +
beamline O +
control O +
is O +
performed O +
using O +
STARS O +
( O +
simple O +
transmission O +
and O +
retrieval O +
system O +
) O +
. O +

The O +
system O +
adopts O +
a O +
client O +
- O +
server O +
style O +
in O +
which O +
client O +
programs O +
communicate O +
with O +
each O +
other O +
through O +
a O +
server O +
process O +
using O +
the O +
STARS O +
protocol O +
. O +

This O +
is O +
an O +
advantage O +
of O +
the O +
extension O +
of O +
the O +
system O +
; O +
implementation O +
of O +
these O +
new O +
functions O +
required O +
few O +
modifications O +
of O +
the O +
existing O +
system O +
. O +

Inhomogeneity O +
of O +
Fecal O +
Flora O +
in O +
Separately O +
Reared O +
Laboratory O +
Mice O +
, O +
as O +
Detected O +
by O +
Denaturing O +
Gradient O +
Gel O +
Electrophoresis O +
( O +
DGGE O +
) O +
. O +

Laboratory O +
mice O +
were O +
divided O +
into O +
2 O +
groups O +
and O +
introduced O +
to O +
different O +
rooms O +
immediately O +
after O +
being O +
transferred O +
from O +
a O +
mouse O +
farm O +
. O +

Polymerase O +
chain O +
reaction O +
followed O +
by O +
denaturing O +
gradient O +
gel O +
electrophoresis O +
were O +
performed O +
on O +
the O +
V6 O +
- O +
V8 O +
regions O +
of O +
bacterial O +
16S O +
rDNA O +
obtained O +
from O +
fecal O +
samples O +
at O +
0 O +
, O +
1 O +
, O +
2 O +
, O +
3 O +
, O +
4 O +
and O +
8 O +
weeks O +
after O +
the O +
introduction O +
. O +

Binary O +
data O +
were O +
obtained O +
from O +
banding O +
patterns O +
, O +
and O +
Euclidean O +
distances O +
for O +
each O +
week O +
were O +
calculated O +
and O +
analyzed O +
by O +
cluster O +
analysis O +
and O +
non O +
- O +
metric O +
multidimensional O +
scaling O +
. O +

Euclidean O +
distances O +
were O +
significantly O +
higher O +
at O +
weeks O +
1 O +
and O +
2 O +
than O +
at O +
week O +
0 O +
in O +
both O +
groups O +
, O +
although O +
the O +
distances O +
between O +
the O +
2 O +
groups O +
were O +
significantly O +
higher O +
after O +
week O +
1 O +
than O +
week O +
0 O +
. O +

The O +
distances O +
between O +
the O +
2 O +
groups O +
were O +
significantly O +
higher O +
than O +
those O +
within O +
each O +
group O +
at O +
weeks O +
4 O +
and O +
8 O +
. O +

Mice O +
in O +
the O +
2 O +
groups O +
formed O +
clusters O +
at O +
weeks O +
2 O +
and O +
3 O +
respectively O +
, O +
and O +
mice O +
were O +
divided O +
into O +
2 O +
clusters O +
by O +
their O +
respective O +
groups O +
at O +
weeks O +
4 O +
and O +
8 O +
. O +

Mice O +
in O +
the O +
2 O +
groups O +
were O +
distributed O +
on O +
opposite O +
sides O +
of O +
the O +
origin O +
on O +
the O +
2 O +
- O +
dimensional O +
plane O +
after O +
week O +
2 O +
. O +

These O +
results O +
suggest O +
that O +
mouse O +
fecal O +
flora O +
changed O +
characteristically O +
, O +
according O +
to O +
the O +
local O +
environment O +
after O +
introduction O +
. O +

An O +
OLETF O +
Allele O +
of O +
Hyperglycemic O +
QTL O +
Nidd3 O +
/ O +
of O +
Is O +
Dominant O +
. O +

The O +
OLETF O +
rat O +
is O +
a O +
well O +
- O +
established O +
model O +
for O +
the O +
study O +
of O +
type O +
2 O +
diabetes O +
associated O +
with O +
obesity O +
and O +
has O +
been O +
shown O +
to O +
possess O +
multiple O +
hyperglycemic O +
alleles O +
in O +
its O +
genome O +
. O +

Here O +
we O +
focused O +
on O +
and O +
carefully O +
characterized O +
one O +
of O +
the O +
previously O +
reported O +
congenic O +
strains O +
, O +
F O +
. O +

O O +
- O +
Nidd3 O +
/ O +
of O +
that O +
carries O +
the O +
OLETF O +
allele O +
of O +
the O +
Nidd3 O +
/ O +
of O +
locus O +
( O +
also O +
known O +
as O +
Niddm21 O +
in O +
the O +
Rat O +
Genome O +
Database O +
) O +
in O +
the O +
normoglycemic O +
F344 O +
genetic O +
background O +
. O +

A O +
prominent O +
finding O +
was O +
that O +
the O +
F1 O +
progeny O +
between O +
the O +
congenic O +
and O +
the O +
F344 O +
stain O +
, O +
whose O +
genotype O +
is O +
heterozygote O +
at O +
the O +
Nidd3 O +
/ O +
of O +
locus O +
, O +
showed O +
mild O +
hyperglycemia O +
equal O +
to O +
the O +
parental O +
congenic O +
rat O +
, O +
suggesting O +
that O +
the O +
OLETF O +
allele O +
is O +
dominant O +
. O +

To O +
our O +
knowledge O +
, O +
this O +
is O +
the O +
first O +
study O +
in O +
which O +
a O +
diabetic O +
QTL O +
has O +
been O +
directly O +
demonstrated O +
to O +
be O +
dominant O +
by O +
using O +
congenic O +
strains O +
. O +

Protease O +
production O +
by O +
different O +
thermophilic O +
fungi O +
. O +

A O +
comparative O +
study O +
was O +
carried O +
out O +
to O +
evaluate O +
protease O +
production O +
in O +
solid O +
- O +
state O +
fermentation O +
( O +
SSF O +
) O +
and O +
submerged O +
fermentation O +
( O +
SmF O +
) O +
by O +
nine O +
different O +
thermophilic O +
fungi O +
- O +
Thermoascus O +
aurantiacus O +
Miehe O +
, O +
Thermomyces O +
lanuginosus O +
, O +
T O +
. O +

lanuginosus O +
TO O +
.03 O +
, O +
Aspergillus O +
flavus O +
1.2 O +
, O +
Aspergillus O +
sp O +
. O +

13.33 O +
, O +
Aspergillus O +
sp O +
. O +

13.34 O +
, O +
Aspergillus O +
sp O +
. O +

13.35 O +
, O +
Rhizomucor O +
pusillus O +
13.36 O +
and O +
Rhizomucor O +
sp O +
. O +

13.37 O +
- O +
using O +
substrates O +
containing O +
proteins O +
to O +
induce O +
enzyme O +
secretion O +
. O +

Soybean O +
extract O +
( O +
soybean O +
milk O +
) O +
, O +
soybean O +
flour O +
, O +
milk O +
powder O +
, O +
rice O +
, O +
and O +
wheat O +
bran O +
were O +
tested O +
. O +

The O +
most O +
satisfactory O +
results O +
were O +
obtained O +
when O +
using O +
wheat O +
bran O +
in O +
SSF O +
. O +

The O +
fungi O +
that O +
stood O +
out O +
in O +
SSF O +
were O +
T O +
. O +

lanuginosus O +
, O +
T O +
. O +

lanuginosus O +
TO O +
.03 O +
, O +
Aspergillus O +
sp O +
. O +

13.34 O +
, O +
Aspergillus O +
sp O +
. O +

13.35 O +
, O +
and O +
Rhizomucor O +
sp O +
. O +

13.37 O +
, O +
and O +
those O +
in O +
SmF O +
were O +
T O +
. O +

aurantiacus O +
, O +
T O +
. O +

lanuginosus O +
TO O +
.03 O +
, O +
and O +
13.37 O +
. O +

In O +
both O +
fermentation O +
systems O +
, O +
A O +
. O +

flavus O +
1.2 O +
and O +
R O +
. O +

pusillus O +
13.36 O +
presented O +
the O +
lowest O +
levels O +
of O +
proteolytic O +
activity O +
. O +

Involvement O +
of O +
the O +
incudostapedial O +
joint O +
anomaly O +
in O +
conductive O +
deafness O +
. O +

Conclusion O +
. O +

The O +
outcome O +
of O +
surgery O +
depends O +
on O +
complexities O +
of O +
middle O +
ear O +
anomalies O +
and O +
definite O +
diagnosis O +
can O +
only O +
be O +
achieved O +
during O +
exploratory O +
tympanotomy O +
. O +

We O +
must O +
be O +
aware O +
that O +
the O +
pathology O +
of O +
the O +
congenital O +
ossicular O +
anomalies O +
is O +
variable O +
and O +
careful O +
surgery O +
is O +
needed O +
for O +
hearing O +
improvement O +
. O +

Objective O +
. O +

This O +
study O +
aimed O +
to O +
investigate O +
congenital O +
ossicular O +
malformation O +
. O +

Subjects O +
and O +
methods O +
. O +

Fifteen O +
cases O +
of O +
ossicular O +
anomalies O +
without O +
external O +
ear O +
malformation O +
were O +
studied O +
. O +

The O +
anomaly O +
of O +
the O +
incus O +
- O +
stapes O +
complex O +
was O +
the O +
most O +
frequent O +
. O +

There O +
were O +
two O +
cases O +
of O +
fused O +
incudostapedial O +
( O +
IS O +
) O +
joint O +
, O +
which O +
is O +
an O +
extremely O +
rare O +
occurrence O +
. O +

Case O +
1 O +
was O +
a O +
33 O +
- O +
year O +
- O +
old O +
man O +
, O +
in O +
whom O +
otosclerosis O +
was O +
suspected O +
and O +
exploratory O +
tympanotomy O +
was O +
performed O +
. O +

The O +
IS O +
joint O +
was O +
fused O +
, O +
and O +
the O +
stapes O +
was O +
immobile O +
. O +

Small O +
fenestra O +
stapedectomy O +
was O +
performed O +
. O +

In O +
case O +
2 O +
, O +
a O +
52 O +
- O +
year O +
- O +
old O +
woman O +
, O +
otosclerosis O +
was O +
also O +
suspected O +
and O +
exploratory O +
tympanotomy O +
was O +
performed O +
. O +

The O +
IS O +
joint O +
was O +
fused O +
and O +
the O +
incus O +
was O +
fixed O +
. O +

After O +
the O +
long O +
process O +
of O +
the O +
incus O +
was O +
cut O +
, O +
the O +
stapes O +
became O +
mobile O +
. O +

However O +
, O +
since O +
the O +
incus O +
remained O +
immobile O +
, O +
it O +
was O +
removed O +
and O +
was O +
placed O +
on O +
the O +
stapes O +
. O +

In O +
both O +
cases O +
, O +
the O +
hearing O +
improved O +
after O +
surgery O +
. O +

The O +
averaged O +
hearing O +
gain O +
of O +
15 O +
cases O +
was O +
28.8 O +
dB O +
. O +

Tinnitus O +
and O +
brain O +
MRI O +
findings O +
in O +
Japanese O +
elderly O +
. O +

Conclusion O +
. O +

There O +
is O +
evidence O +
of O +
an O +
inverse O +
association O +
between O +
cerebral O +
infarction O +
and O +
tinnitus O +
in O +
this O +
study O +
. O +

The O +
effects O +
of O +
cerebral O +
infarction O +
on O +
tinnitus O +
could O +
be O +
explained O +
by O +
a O +
neurophysiological O +
model O +
of O +
tinnitus O +
. O +

Objectives O +
. O +

We O +
examined O +
the O +
relationship O +
between O +
tinnitus O +
and O +
brain O +
MRI O +
findings O +
including O +
cerebral O +
infarction O +
, O +
brain O +
atrophy O +
, O +
ventricular O +
dilatation O +
, O +
and O +
white O +
matter O +
lesions O +
. O +

Subjects O +
and O +
methods O +
. O +

This O +
was O +
a O +
cross O +
- O +
sectional O +
population O +
- O +
based O +
study O +
of O +
2193 O +
subjects O +
aged O +
41 O -
- O -
82 O +
years O +
living O +
in O +
Aichi O +
prefecture O +
, O +
Japan O +
. O +

Detailed O +
questionnaires O +
, O +
pure O +
tone O +
audiometry O +
, O +
and O +
brain O +
MRI O +
were O +
performed O +
. O +

Results O +
. O +

After O +
adjusting O +
for O +
potential O +
confounders O +
in O +
a O +
multiple O +
logistic O +
analysis O +
, O +
cerebral O +
infarction O +
was O +
inversely O +
associated O +
with O +
tinnitus O +
( O +
odds O +
ratio O +
( O +
OR O +
) O +
= O +
0.649 O +
, O +
95 O -
% O +
confidence O +
interval O +
( O +
CI O +
) O +
= O +
0.477 O -
- O -
0.884 O +
) O +
. O +

Cerebral O +
infarctions O +
of O +
the O +
basal O +
ganglia O +
( O +
OR O +
= O +
0.542 O +
) O +
, O +
thalamus O +
( O +
OR O +
= O +
0.441 O +
) O +
, O +
and O +
pons O +
( O +
OR O +
= O +
0.319 O +
) O +
were O +
especially O +
associated O +
with O +
tinnitus O +
. O +

Brain O +
atrophy O +
, O +
ventricular O +
dilatation O +
, O +
and O +
white O +
matter O +
lesions O +
had O +
no O +
significant O +
effects O +
on O +
the O +
prevalence O +
of O +
tinnitus O +
. O +

Combination O +
of O +
Bernouilli O +
effect O +
producing O +
maneuver O +
- O +
induced O +
pharyngeal O +
narrowing O +
rate O +
with O +
body O +
mass O +
index O +
as O +
predictive O +
tool O +
for O +
obstructive O +
sleep O +
apnea O +
syndrome O +
. O +

Conclusions O +
. O +

It O +
is O +
suggested O +
that O +
the O +
combination O +
of O +
the O +
pharyngeal O +
narrowing O +
rate O +
during O +
the O +
Bernouilli O +
effect O +
producing O +
maneuver O +
( O +
BEPM O +
) O +
with O +
the O +
body O +
mass O +
index O +
( O +
BMI O +
) O +
might O +
be O +
a O +
promising O +
predictive O +
method O +
for O +
obstructive O +
sleep O +
apnea O +
syndrome O +
( O +
OSAS O +
) O +
. O +

Objectives O +
. O +

An O +
attempt O +
was O +
made O +
to O +
clarify O +
the O +
possibility O +
that O +
the O +
dynamic O +
narrowing O +
of O +
the O +
pharynx O +
evaluated O +
by O +
nasopharyngoscopy O +
with O +
BEPM O +
, O +
a O +
forced O +
inspiration O +
through O +
the O +
nose O +
with O +
the O +
mouth O +
closed O +
, O +
might O +
be O +
a O +
reliable O +
clinical O +
daytime O +
predictor O +
for O +
identifying O +
patients O +
at O +
risk O +
of O +
developing O +
OSAS O +
. O +

Subjects O +
and O +
methods O +
. O +

Subjects O +
were O +
57 O +
patients O +
complaining O +
of O +
snoring O +
and O +
sleepiness O +
during O +
daytime O +
. O +

Endoscopic O +
images O +
of O +
the O +
retropalatal O +
pharynx O +
were O +
obtained O +
and O +
their O +
area O +
was O +
measured O +
by O +
NIH O +
imaging O +
. O +

The O +
pharyngeal O +
narrowing O +
rate O +
during O +
quiet O +
nasal O +
breathing O +
and O +
that O +
during O +
BEPM O +
were O +
compared O +
to O +
assess O +
pharyngeal O +
dynamics O +
. O +

To O +
increase O +
the O +
sensitivity O +
of O +
this O +
method O +
, O +
BMI O +
was O +
added O +
to O +
the O +
pharyngeal O +
narrowing O +
rate O +
during O +
BEPM O +
. O +

Results O +
. O +

The O +
criterion O +
of O +
BEPM O +
at O +
a O +
cut O +
- O +
off O +
value O +
of O +
with O +
BMI O +
at O +
a O +
cut O +
- O +
off O +
value O +
of O +
25 O +
kg O +
/ O +
m O +
( O +
2 O +
) O +
achieved O +
a O +
sensitivity O +
of O +
93 O -
% O +
, O +
while O +
the O +
specificity O +
was O +
67 O -
% O +
in O +
differentiating O +
simple O +
snorers O +
from O +
OSAS O +
patients O +
( O +
apnea O +
index O +
> O +
5 O +
) O +
. O +

In O +
addition O +
, O +
the O +
likelihood O +
ratio O +
of O +
the O +
method O +
was O +
found O +
to O +
be O +
2.81 O +
. O +

EEG O +
observations O +
in O +
a O +
case O +
with O +
thalamic O +
syndrome O +
. O +

A O +
case O +
of O +
thalamic O +
syndrome O +
of O +
the O +
D O +
 O +
 O +
jerine O +
- O +
Roussy O +
type O +
is O +
presented O +
. O +

EEG O +
studies O +
reveal O +
that O +
although O +
bilaterally O +
symmetrical O +
rhythmic O +
activity O +
may O +
be O +
present O +
when O +
the O +
patient O +
is O +
awake O +
, O +
during O +
drowsiness O +
and O +
deeper O +
sleep O +
a O +
marked O +
asymmetry O +
often O +
appears O +
with O +
early O +
disappearance O +
of O +
alpha O +
activity O +
and O +
reduction O +
or O +
abolition O +
of O +
spindles O +
on O +
the O +
side O +
involved O +
. O +

Thalamic O +
integration O +
in O +
the O +
sleep O +
mechanism O +
is O +
briefly O +
discussed O +
. O +

Two O +
2,3 B-Chemical +
- I-Chemical +
dihydrobenzofuran I-Chemical +
analogues B-Chemical +
of O +
hallucinogenic O +
amphetamines B-Chemical +
were O +
prepared O +
and O +
evaluated O +
for O +
activity O +
in O +
the O +
two O +
- O +
lever O +
drug O +
- O +
discrimination O +
paradigm O +
in O +
rats O +
trained O +
to O +
discriminate O +
saline O +
from O +
LSD B-Chemical +
tartrate I-Chemical +
( O +
0.08 O +
mg O +
/ O +
kg O +
) O +
and O +
for O +
the O +
ability O +
to O +
displace O +
[ B-Chemical +
125I I-Chemical +
] I-Chemical +
- I-Chemical +
( I-Chemical +
R I-Chemical +
) I-Chemical +
- I-Chemical +
DOI I-Chemical +
[ O +
( B-Chemical +
125I I-Chemical +
] I-Chemical +
- I-Chemical +
( I-Chemical +
R I-Chemical +
) I-Chemical +
- I-Chemical +
1 I-Chemical +
- I-Chemical +
( I-Chemical +
2,5 I-Chemical +
- I-Chemical +
dimethoxy I-Chemical +
- I-Chemical +
4 I-Chemical +
- I-Chemical +
iodophenyl I-Chemical +
) I-Chemical +
- I-Chemical +
2 I-Chemical +
- I-Chemical +
aminopropane I-Chemical +
) I-Chemical +
from O +
rat O +
cortical O +
homogenate O +
5 O +
- O +
HT2 O +
receptors O +
. O +

The O +
compounds O +
, O +
1 B-Chemical +
- I-Chemical +
( I-Chemical +
5 I-Chemical +
- I-Chemical +
methoxy I-Chemical +
- I-Chemical +
2,3 I-Chemical +
- I-Chemical +
dihydrobenzofuran I-Chemical +
- I-Chemical +
4 I-Chemical +
- I-Chemical +
yl I-Chemical +
) I-Chemical +
- I-Chemical +
2 I-Chemical +
- I-Chemical +
aminopropane I-Chemical +
( O +
6a O +
) O +
and O +
its O +
7 B-Chemical +
- I-Chemical +
brominated I-Chemical +
analogue B-Chemical +
6b O +
, O +
possessed O +
activity O +
comparable O +
to O +
their O +
conformationally O +
flexible O +
counterparts O +
1 B-Chemical +
- I-Chemical +
( I-Chemical +
2,5 I-Chemical +
- I-Chemical +
dimethoxyphenyl I-Chemical +
) I-Chemical +
- I-Chemical +
2 I-Chemical +
- I-Chemical +
aminopropane I-Chemical +
( O +
3 O +
) O +
and O +
its O +
4 B-Chemical +
- I-Chemical +
bromo I-Chemical +
derivative B-Chemical +
DOB B-Chemical +
( O +
5 O +
) O +
, O +
respectively O +
. O +

The O +
results O +
suggest O +
that O +
the O +
dihydrofuran B-Chemical +
ring O +
in O +
6a O +
and O +
6b O +
models O +
the O +
active O +
conformation O +
of O +
the O +
5 B-Chemical +
- I-Chemical +
methoxy I-Chemical +
groups B-Chemical +
in O +
3 O +
and O +
5 O +
. O +

Free O +
energy O +
of O +
binding O +
, O +
derived O +
from O +
radioligand O +
displacement O +
KA O +
values O +
, O +
indicated O +
that O +
addition O +
of O +
the O +
bromine B-Chemical +
in O +
either O +
series O +
contributes O +
2.4 O -
- O -
3.2 O +
kcal O +
/ O +
mol O +
of O +
binding O +
energy O +
. O +

On O +
the O +
basis O +
of O +
surface O +
area O +
of O +
the O +
bromine B-Chemical +
atom B-Chemical +
, O +
this O +
value O +
is O +
2 O -
- O -
3 O +
times O +
higher O +
than O +
would O +
be O +
expected O +
on O +
the O +
basis O +
of O +
hydrophobic O +
binding O +
. O +

Thus O +
, O +
hydrophobicity O +
of O +
the O +
para O +
substituent O +
alone O +
can O -
not O +
account O +
for O +
the O +
dramatic O +
enhancement O +
of O +
hallucinogenic O +
activity O +
. O +

Although O +
this O +
substituent O +
may O +
play O +
a O +
minor O +
role O +
in O +
orienting O +
the O +
conformation O +
of O +
the O +
5 B-Chemical +
- I-Chemical +
methoxy I-Chemical +
group B-Chemical +
in O +
derivatives O +
such O +
as O +
4 O +
and O +
5 O +
, O +
there O +
appears O +
to O +
be O +
some O +
other O +
, O +
as O +
yet O +
unknown O +
, O +
critical O +
receptor O +
interaction O +
. O +

A O +
series O +
of O +
substituted O +
1,4 B-Chemical +
- I-Chemical +
dihydronaphthoquinones I-Chemical +
, O +
hydroindoloquinones B-Chemical +
, O +
benzofuran B-Chemical +
- I-Chemical +
4,7 I-Chemical +
- I-Chemical +
dihydroquinones I-Chemical +
, O +
and O +
benzothiophene B-Chemical +
- I-Chemical +
4,7 I-Chemical +
- I-Chemical +
dihydroquinones I-Chemical +
were O +
synthesized O +
and O +
evaluated O +
for O +
inhibitory O +
activity O +
against O +
5 O +
- O +
lipoxygenase O +
. O +

These O +
compounds O +
were O +
found O +
to O +
be O +
active O +
in O +
vitro O +
for O +
LTC4 O +
/ O +
D4 O +
inhibition O +
with O +
the O +
potencies O +
( O +
IC50 O +
's O +
) O +
ranging O +
from O +
0.2 O +
to O +
85 O +
microM O +
. O +

Active O +
1,4 B-Chemical +
- I-Chemical +
dihydronaphthoquinone I-Chemical +
acetates I-Chemical +
( O +
IC50 O +
less O +
than O +
microM O +
) O +
were O +
evaluated O +
in O +
an O +
ex O +
vivo O +
LTB4 O +
inhibition O +
assay O +
. O +

The O +
acetates B-Chemical +
of O +
1,4 B-Chemical +
- I-Chemical +
dihydronaphthoquinones I-Chemical +
containing O +
the O +
alkyl B-Chemical +
substituent B-Chemical +
( I-Chemical +
s I-Chemical +
) I-Chemical +
( O +
2 B-Chemical +
- I-Chemical +
n I-Chemical +
- I-Chemical +
butyl I-Chemical +
, O +
11 O +
, O +
and O +
2,3 B-Chemical +
- I-Chemical +
diethyl I-Chemical +
, O +
15 O +
) O +
exhibited O +
the O +
best O +
activity O +
in O +
LTC4 O +
/ O +
D4 O +
inhibition O +
( O +
IC50 O +
= O +
0.2 O -
- O -
0.4 O +
microM O +
, O +
in O +
vitro O +
) O +
as O +
well O +
as O +
in O +
LTB4 O +
inhibition O +
( O +
inhibition O +
) O +
. O +

Thyrotropin O +
modulates O +
low O +
density O +
lipoprotein O +
binding O +
activity O +
in O +
FRTL O +
- O +
5 O +
thyroid O +
cells O +
. O +

FRTL O +
- O +
5 O +
cells O +
possess O +
high O +
affinity O +
low O +
density O +
lipoprotein O +
( O +
LDL O +
) O +
receptors O +
which O +
bind O +
, O +
internalize O +
, O +
and O +
degrade O +
LDL O +
. O +

When O +
FRTL O +
- O +
5 O +
cells O +
are O +
deprived O +
of O +
thyrotropin O +
( O +
TSH O +
) O +
the O +
binding O +
of O +
LDL O +
increases O +
more O +
than O +
2 O +
- O +
fold O +
. O +

Upon O +
addition O +
of O +
TSH O +
, O +
at O +
a O +
concentration O +
of O +
1 O +
x O +
( O +
- O +
) O +
M O +
or O +
greater O +
, O +
LDL O +
binding O +
decreases O +
rapidly O +
and O +
within O +
24 O +
h O +
reaches O +
the O +
level O +
which O +
is O +
typical O +
of O +
FRTL O +
- O +
5 O +
cells O +
chronically O +
stimulated O +
by O +
TSH O +
. O +

The O +
data O +
available O +
suggest O +
that O +
TSH O +
- O +
dependent O +
down O +
- O +
regulation O +
of O +
LDL O +
receptor O +
activity O +
is O +
exerted O +
through O +
a O +
reduction O +
of O +
the O +
number O +
of O +
active O +
LDL O +
receptors O +
, O +
with O +
no O +
change O +
in O +
affinity O +
. O +

It O +
is O +
unlikely O +
that O +
the O +
synthesis O +
of O +
LDL O +
receptors O +
is O +
impaired O +
, O +
since O +
LDL O +
receptor O +
messenger O +
RNA O +
is O +
not O +
decreased O +
by O +
TSH O +
. O +

The O +
effect O +
of O +
the O +
hormone O +
on O +
LDL O +
receptor O +
activity O +
can O +
be O +
mimicked O +
by O +
8 B-Chemical +
- I-Chemical +
Br I-Chemical +
- I-Chemical +
cAMP I-Chemical +
and O +
is O +
completely O +
abolished O +
by O +
the O +
protein O +
synthesis O +
inhibitor O +
cycloheximide B-Chemical +
but O +
not O +
by O +
actinomycin B-Chemical +
D I-Chemical +
. O +

TSH O +
regulation O +
of O +
LDL O +
receptor O +
activity O +
is O +
lost O +
in O +
v O +
- O +
ras O +
Ki O +
- O +
transformed O +
FRTL O +
- O +
5 O +
cells O +
( O +
Ki O +
Mol O +
) O +
which O +
also O +
have O +
lost O +
TSH O +
dependence O +
for O +
adenylate O +
cyclase O +
activation O +
and O +
growth O +
. O +

However O +
, O +
8 B-Chemical +
- I-Chemical +
Br I-Chemical +
- I-Chemical +
cAMP I-Chemical +
decreases O +
LDL O +
binding O +
in O +
Ki O +
Mol O +
FRTL O +
- O +
5 O +
cells O +
. O +

The O +
reduced O +
availability O +
of O +
LDL O +
receptor O +
in O +
TSH O +
- O +
stimulated O +
FRTL O +
- O +
5 O +
cells O +
may O +
be O +
related O +
to O +
the O +
increased O +
membrane O +
fluidity O +
( O +
Beguinot O +
, O +
F O +
. O +
, O +
Beguinot O +
, O +
L O +
. O +
, O +
Tramontano O +
, O +
D O +
. O +
, O +
Duilio O +
, O +
C O +
. O +
, O +
Formisano O +
, O +
S O +
. O +
, O +
Bifulco O +
, O +
M O +
. O +
, O +
Ambesi O +
- O +
Impiombato O +
, O +
F O +
. O +

S O +
. O +
, O +
and O +
Aloj O +
, O +
S O +
. O +

M O +
. O +
( O +
1987 O +
) O +
J O +
. O +

Biol O -
. O +

Chem O -
. O +
262 O +
, O +
1575 O -
- O -
1582 O +
) O +
or O +
may O +
reflect O +
increased O +
degradation O +
of O +
LDL O +
receptors O +
. O +

We O +
propose O +
that O +
a O +
lower O +
cholesterol O +
uptake O +
is O +
needed O +
in O +
an O +
actively O +
proliferating O +
cell O +
population O +
, O +
to O +
increase O +
the O +
production O +
of O +
isoprenoids B-Chemical +
whether O +
it O +
be O +
for O +
cholesterol B-Chemical +
biosynthesis O +
or O +
for O +
the O +
synthesis O +
of O +
other O +
compounds O +
requiring O +
isoprenoid O +
precursors O +
. O +

A O +
series O +
of O +
new O +
5 B-Chemical +
- I-Chemical +
( I-Chemical +
1 I-Chemical +
- I-Chemical +
hydroxy I-Chemical +
- I-Chemical +
2 I-Chemical +
- I-Chemical +
iodoethyl I-Chemical +
) I-Chemical +
- I-Chemical +
2 I-Chemical -
' I-Chemical +
- I-Chemical +
deoxyuridine I-Chemical +
and O +
uridine B-Chemical +
compounds B-Chemical +
( O +
11 O +
, O +
16 O +
) O +
was O +
synthesized O +
by O +
the O +
regiospecific O +
addition O +
of O +
HOI B-Chemical +
to O +
the O +
vinyl B-Chemical +
substituent B-Chemical +
of O +
5 B-Chemical +
- I-Chemical +
vinyl I-Chemical +
- I-Chemical +
2 I-Chemical -
' I-Chemical +
- I-Chemical +
deoxyuridine I-Chemical +
( O +
) O +
, O +
5 B-Chemical +
- I-Chemical +
vinyl I-Chemical +
- I-Chemical +
2 I-Chemical -
' I-Chemical +
- I-Chemical +
fluoro I-Chemical +
- I-Chemical +
2 I-Chemical -
' I-Chemical +
- I-Chemical +
deoxyuridine I-Chemical +
( O +
) O +
, O +
5 B-Chemical +
- I-Chemical +
vinyluridine I-Chemical +
( O +
) O +
, O +
and O +
( B-Chemical +
E I-Chemical +
) I-Chemical +
- I-Chemical +
5 I-Chemical +
- I-Chemical +
( I-Chemical +
2 I-Chemical +
- I-Chemical +
iodovinyl I-Chemical +
) I-Chemical +
- I-Chemical +
2 I-Chemical -
' I-Chemical +
- I-Chemical +
deoxyuridine I-Chemical +
( O +
4b O +
) O +
. O +

Treatment O +
of O +
the O +
iodohydrins B-Chemical +
11a O +
- O +
c O +
with O +
methanolic B-Chemical +
sulfuric I-Chemical +
acid I-Chemical +
afforded O +
the O +
corresponding O +
5 B-Chemical +
- I-Chemical +
( I-Chemical +
1 I-Chemical +
- I-Chemical +
methoxy I-Chemical +
- I-Chemical +
2 I-Chemical +
- I-Chemical +
iodoethyl I-Chemical +
) I-Chemical +
derivatives B-Chemical +
( O +
12a O +
- O +
c O +
) O +
. O +

In O +
contrast O +
, O +
reaction O +
of O +
5 B-Chemical +
- I-Chemical +
( I-Chemical +
1 I-Chemical +
- I-Chemical +
hydroxy I-Chemical +
- I-Chemical +
2 I-Chemical +
- I-Chemical +
iodoethyl I-Chemical +
) I-Chemical +
- I-Chemical +
2 I-Chemical -
' I-Chemical +
- I-Chemical +
deoxyuridine I-Chemical +
( O +
11a O +
) O +
with O +
sodium B-Chemical +
carbonate I-Chemical +
in O +
methanol B-Chemical +
afforded O +
a O +
mixture O +
of O +
5 B-Chemical +
- I-Chemical +
( I-Chemical +
1 I-Chemical +
- I-Chemical +
hydroxy I-Chemical +
- I-Chemical +
2 I-Chemical +
- I-Chemical +
methoxyethyl I-Chemical +
) I-Chemical +
- I-Chemical +
2 I-Chemical -
' I-Chemical +
- I-Chemical +
deoxyuridine I-Chemical +
( O +
13 O +
) O +
and O +
2,3 B-Chemical +
- I-Chemical +
dihydro I-Chemical +
- I-Chemical +
3 I-Chemical +
- I-Chemical +
hydroxy I-Chemical +
- I-Chemical +
5 I-Chemical +
- I-Chemical +
( I-Chemical +
2 I-Chemical -
' I-Chemical +
- I-Chemical +
deoxy I-Chemical +
- I-Chemical +
beta I-Chemical +
- I-Chemical +
D I-Chemical +
- I-Chemical +
ribofuranosyl I-Chemical +
) I-Chemical +
- I-Chemical +
furano I-Chemical +
[ I-Chemical +
2,3 I-Chemical +
- I-Chemical +
d I-Chemical +
] I-Chemical +
pyrimidin I-Chemical +
- I-Chemical +
6 I-Chemical +
( I-Chemical +
5H I-Chemical +
) I-Chemical +
- I-Chemical +
one I-Chemical +
( O +
14 O +
) O +
. O +

The O +
most O +
active O +
compound O +
, O +
5 B-Chemical +
- I-Chemical +
( I-Chemical +
1 I-Chemical +
- I-Chemical +
methoxy I-Chemical +
- I-Chemical +
2 I-Chemical +
- I-Chemical +
iodoethyl I-Chemical +
) I-Chemical +
- I-Chemical +
2 I-Chemical -
' I-Chemical +
- I-Chemical +
deoxyuridine I-Chemical +
( O +
12a O +
, O +
ID50 O +
= O +
0.1 O +
micrograms O +
/ O +
mL O +
) O +
, O +
which O +
exhibited O +
antiviral O +
activity O +
( O +
HSV O +
- O +
1 O +
) O +
- O +
fold O +
higher O +
than O +
that O +
of O +
the O +
5 B-Chemical +
- I-Chemical +
( I-Chemical +
1 I-Chemical +
- I-Chemical +
hydroxy I-Chemical +
- I-Chemical +
2 I-Chemical +
- I-Chemical +
iodoethyl I-Chemical +
) I-Chemical +
analogue B-Chemical +
( O +
11a O +
) O +
, O +
was O +
less O +
active O +
than O +
IVDU B-Chemical +
or O +
acyclovir B-Chemical +
( O +
ID50 O +
= O +
0.01 O -
- O -
0.1 O +
micrograms O +
/ O +
mL O +
range O +
) O +
. O +

The O +
C B-Chemical +
- I-Chemical +
5 I-Chemical +
substituent B-Chemical +
in O +
the O +
2 B-Chemical -
' I-Chemical +
- I-Chemical +
deoxyuridine I-Chemical +
series B-Chemical +
was O +
a O +
determinant O +
of O +
cytotoxic O +
activity O +
, O +
as O +
determined O +
in O +
the O +
in O +
vitro O +
L1210 O +
screen O +
, O +
where O +
the O +
relative O +
activity O +
order O +
was O +
CH B-Chemical +
( I-Chemical +
OH I-Chemical +
) I-Chemical +
CHI2 I-Chemical +
( O +
16 O +
) O +
greater O +
than O +
CH B-Chemical +
( I-Chemical +
OMe I-Chemical +
) I-Chemical +
CH2I I-Chemical +
( O +
12a O +
) O +
greater O +
than O +
CH B-Chemical +
( I-Chemical +
OH I-Chemical +
) I-Chemical +
CH2I I-Chemical +
( O +
11a O +
) O +
congruent O +
to O +
CH B-Chemical +
( I-Chemical +
OH I-Chemical +
) I-Chemical +
CH2OMe I-Chemical +
( O +
13 O +
) O +
. O +

The O +
2 B-Chemical -
' I-Chemical +
- I-Chemical +
substituent O +
was O +
also O +
a O +
determinant O +
of O +
cytotoxic O +
activity O +
in O +
the O +
5 B-Chemical +
- I-Chemical +
( I-Chemical +
1 I-Chemical +
- I-Chemical +
hydroxy I-Chemical +
- I-Chemical +
2 I-Chemical +
- I-Chemical +
iodoethyl I-Chemical +
) I-Chemical +
( O +
11a O +
- O +
c O +
) O +
and O +
5 B-Chemical +
- I-Chemical +
( I-Chemical +
1 I-Chemical +
- I-Chemical +
methoxy I-Chemical +
- I-Chemical +
2 I-Chemical +
- I-Chemical +
iodoethyl I-Chemical +
) I-Chemical +
series B-Chemical +
of O +
compounds O +
, O +
where O +
the O +
relative O +
activity O +
profile O +
was O +
2 B-Chemical -
' I-Chemical +
- I-Chemical +
deoxyuridine I-Chemical +
greater O +
than O +
2 B-Chemical -
' I-Chemical +
- I-Chemical +
fluoro I-Chemical +
- I-Chemical +
2 I-Chemical -
' I-Chemical +
- I-Chemical +
deoxyuridine I-Chemical +
greater O +
than O +
uridine B-Chemical +
( O +
11a O +
greater O +
than O +
11b O +
greater O +
than O +
or O +
equal O +
to O +
11c O +
; O +
12a O +
greater O +
than O +
12b O +
greater O +
than O +
12c O +
) O +
. O +

The O +
most O +
active O +
cytotoxic O +
agent O +
( O +
16 O +
) O +
, O +
possessing O +
a O +
5 B-Chemical +
- I-Chemical +
( I-Chemical +
1 I-Chemical +
- I-Chemical +
hydroxy I-Chemical +
- I-Chemical +
2,2 I-Chemical +
- I-Chemical +
diiodoethyl I-Chemical +
) I-Chemical +
substituent B-Chemical +
( O +
ED50 O +
= O +
0.77 O +
micrograms O +
/ O +
mL O +
) O +
, O +
exhibited O +
an O +
activity O +
approaching O +
that O +
of O +
melphalan B-Chemical +
( O +
ED50 O +
= O +
0.15 O +
micrograms O +
/ O +
mL O +
) O +
. O +

All O +
compounds O +
tested O +
, O +
except O +
for O +
13 O +
and O +
14 O +
, O +
exhibited O +
high O +
affinity O +
( O +
Ki O +
= O +
0.035 O -
- O -
0.22 O +
mM O +
range O +
relative O +
to O +
deoxyuridine B-Chemical +
, O +
Ki O +
= O +
0.125 O +
) O +
for O +
the O +
murine O +
NBMPR O +
- O +
sensitive O +
erythrocyte O +
nucleoside O +
transport O +
system O +
, O +
suggesting O +
that O +
these O +
iodohydrins B-Chemical +
are O +
good O +
permeants O +
of O +
cell O +
membranes O +
. O +

The O +
thermal O +
Fischer O +
indolization O +
of O +
hydrazones B-Chemical +
resulting O +
from O +
4 B-Chemical +
- I-Chemical +
hydrazino I-Chemical +
- I-Chemical +
5 I-Chemical +
- I-Chemical +
methyl I-Chemical +
- I-Chemical +
1H I-Chemical +
- I-Chemical +
pyridin I-Chemical +
- I-Chemical +
2 I-Chemical +
- I-Chemical +
one I-Chemical +
and O +
various O +
beta B-Chemical +
- I-Chemical +
and O +
alpha B-Chemical +
- I-Chemical +
tetralones I-Chemical +
led O +
to O +
4 B-Chemical +
- I-Chemical +
methyl I-Chemical +
- I-Chemical +
6,7 I-Chemical +
- I-Chemical +
dihydro I-Chemical +
- I-Chemical +
2H I-Chemical +
, I-Chemical +
5H I-Chemical +
- I-Chemical +
pyrido I-Chemical +
[ I-Chemical +
4,3 I-Chemical +
- I-Chemical +
b I-Chemical +
] I-Chemical +
benzo I-Chemical +
[ I-Chemical +
e I-Chemical +
] I-Chemical +
indol I-Chemical +
- I-Chemical +
1 I-Chemical +
- I-Chemical +
ones I-Chemical +
and O +
4 B-Chemical +
- I-Chemical +
methyl I-Chemical +
- I-Chemical +
11 I-Chemical +
- I-Chemical +
dihydro I-Chemical +
- I-Chemical +
2H I-Chemical +
, I-Chemical +
5H I-Chemical +
- I-Chemical +
pyrido I-Chemical +
[ I-Chemical +
4,3 I-Chemical +
- I-Chemical +
b I-Chemical +
] I-Chemical +
benzo I-Chemical +
[ I-Chemical +
g I-Chemical +
] I-Chemical +
indol I-Chemical +
- I-Chemical +
1 I-Chemical +
- I-Chemical +
ones I-Chemical +
, O +
respectively O +
. O +

After O +
aromatization O +
, O +
these O +
compounds O +
were O +
transformed O +
by O +
phosphorus B-Chemical +
oxychloride I-Chemical +
, O +
giving O +
1 B-Chemical +
- I-Chemical +
chloro I-Chemical +
- I-Chemical +
4 I-Chemical +
- I-Chemical +
methyl I-Chemical +
- I-Chemical +
5H I-Chemical +
- I-Chemical +
pyrido I-Chemical +
[ I-Chemical +
4,3 I-Chemical +
- I-Chemical +
b I-Chemical +
] I-Chemical +
benzo I-Chemical +
[ I-Chemical +
e I-Chemical +
] I-Chemical +
- I-Chemical +
and O +
- B-Chemical +
benzo I-Chemical +
[ I-Chemical +
g I-Chemical +
] I-Chemical +
indoles I-Chemical +
which O +
were O +
substituted O +
by O +
[ B-Chemical +
( I-Chemical +
dialkylamino I-Chemical +
) I-Chemical +
alkyl I-Chemical +
] I-Chemical +
amines I-Chemical +
. O +

The O +
resulting O +
1 B-Chemical +
- I-Chemical +
[ I-Chemical +
[ I-Chemical +
( I-Chemical +
dialkylamino I-Chemical +
) I-Chemical +
alkyl I-Chemical +
] I-Chemical +
amino I-Chemical +
] I-Chemical +
- I-Chemical +
4 I-Chemical +
- I-Chemical +
methyl I-Chemical +
- I-Chemical +
5H I-Chemical +
- I-Chemical +
pyrido I-Chemical +
- I-Chemical +
[ I-Chemical +
4,3 I-Chemical +
- I-Chemical +
b I-Chemical +
] I-Chemical +
benzo I-Chemical +
[ I-Chemical +
e I-Chemical +
] I-Chemical +
- I-Chemical +
and O +
- B-Chemical +
benzo I-Chemical +
[ I-Chemical +
g I-Chemical +
] I-Chemical +
indoles I-Chemical +
, O +
as O +
well O +
as O +
hydroxy B-Chemical +
derivatives B-Chemical +
obtained O +
by O +
demethylation O +
of O +
methoxylated O +
compounds O +
with O +
hydrobromic B-Chemical +
acid I-Chemical +
, O +
were O +
tested O +
for O +
antitumor O +
activity O +
in O +
vitro O +
( O +
leukemic O +
and O +
solid O +
tumor O +
cells O +
) O +
and O +
in O +
vivo O +
on O +
various O +
experimental O +
tumor O +
models O +
using O +
the O +
standard O +
NCI O +
protocols O +
. O +

1 B-Chemical +
- I-Chemical +
[ I-Chemical +
[ I-Chemical +
3 I-Chemical +
- I-Chemical +
( I-Chemical +
Dialkylamino I-Chemical +
) I-Chemical +
propyl I-Chemical +
] I-Chemical +
- I-Chemical +
amino I-Chemical +
] I-Chemical +
- I-Chemical +
4 I-Chemical +
- I-Chemical +
methyl I-Chemical +
- I-Chemical +
9 I-Chemical +
- I-Chemical +
hydroxy I-Chemical +
- I-Chemical +
5H I-Chemical +
- I-Chemical +
pyrido I-Chemical +
[ I-Chemical +
4,3 I-Chemical +
- I-Chemical +
b I-Chemical +
] I-Chemical +
benzo I-Chemical +
[ I-Chemical +
e I-Chemical +
] I-Chemical +
indoles I-Chemical +
appeared O +
as O +
a O +
promising O +
new O +
class O +
of O +
antineoplastic O +
agents O +
. O +

2944474 O +
Effect O +
of O +
recombinant O +
human O +
fibroblast O +
interferon O +
and O +
mezerein B-Chemical +
on O +
growth O +
, O +
differentiation O +
, O +
immune O +
interferon O +
binding O +
and O +
tumor O +
associated O +
antigen O +
expression O +
in O +
human O +
melanoma O +
cells O +
. O +

The O +
combination O +
of O +
recombinant O +
human O +
fibroblast O +
interferon O +
( O +
INF O +
- O +
delta O +
) O +
and O +
the O +
antileukemic O +
compound O +
mezerein B-Chemical +
( O +
MEZ B-Chemical +
) O +
results O +
in O +
a O +
synergistic O +
suppression O +
in O +
the O +
growth O +
of O +
human O +
melanoma O +
cells O +
and O +
a O +
concomitant O +
increase O +
in O +
melanin B-Chemical +
synthesis O +
. O +

In O +
the O +
present O +
study O +
we O +
have O +
further O +
analyzed O +
this O +
synergistic O +
interaction O +
and O +
have O +
also O +
evaluated O +
the O +
effect O +
of O +
IFN O +
- O +
delta O +
and O +
MEZ B-Chemical +
, O +
alone O +
and O +
in O +
combination O +
, O +
on O +
recombinant O +
human O +
gamma O +
interferon O +
( O +
IFN O +
- O +
gamma O +
) O +
binding O +
and O +
Class O +
I O +
HLA O +
and O +
melanoma O +
associated O +
antigen O +
( O +
MAA O +
) O +
expression O +
in O +
the O +
HO O +
- O +
1 O +
human O +
melanoma O +
cell O +
line O +
. O +

Single O +
cell O +
clones O +
isolated O +
from O +
the O +
HO O +
- O +
1 O +
cell O +
line O +
varied O +
in O +
their O +
sensitivity O +
to O +
the O +
antiproliferative O +
effects O +
of O +
IFN O +
- O +
delta O +
and O +
MEZ B-Chemical +
. O +

With O +
all O +
twelve O +
clones O +
, O +
however O +
, O +
the O +
combination O +
of O +
IFN O +
- O +
delta O +
plus O +
MEZ B-Chemical +
was O +
more O +
growth O +
inhibitory O +
than O +
either O +
agent O +
used O +
alone O +
, O +
even O +
in O +
HO O +
- O +
1 O +
subclones O +
displaying O +
relative O +
resistance O +
to O +
IFN O +
- O +
delta O +
. O +

By O +
continuous O +
growth O +
in O +
gradually O +
increasing O +
concentrations O +
of O +
IFN O +
- O +
delta O +
, O +
a O +
variant O +
population O +
of O +
HO O +
- O +
1 O +
cells O +
, O +
HO O +
- O +
1 O +
delta O +
R O +
- O +
D O +
, O +
was O +
generated O +
which O +
was O +
more O +
resistant O +
to O +
the O +
antigrowth O +
effects O +
of O +
IFN O +
- O +
delta O +
than O +
the O +
original O +
HO O +
- O +
1 O +
parental O +
cell O +
line O +
. O +

In O +
the O +
IFN O +
delta O +
R O +
- O +
D O +
cell O +
line O +
the O +
combination O +
of O +
IFN O +
- O +
delta O +
plus O +
MEZ B-Chemical +
synergistically O +
suppressed O +
growth O +
. O +

Exposure O +
of O +
HO O +
- O +
1 O +
cells O +
to O +
units O +
/ O +
ml O +
IFN O +
- O +
delta O +
or O +
ng O +
/ O +
ml O +
MEZ B-Chemical +
for O +
96 O +
hr O +
resulted O +
in O +
no O +
change O +
or O +
an O +
increase O +
in O +
the O +
binding O +
of O +
labelled O +
IFN O +
- O +
gamma O +
to O +
surface O +
receptors O +
, O +
whereas O +
the O +
combination O +
of O +
IFN O +
- O +
delta O +
plus O +
MEZ B-Chemical +
increased O +
IFN O +
- O +
gamma O +
binding O +
2 O +
- O +
to O +
- O +
4 O +
- O +
fold O +
in O +
HO O +
- O +
1 O +
cells O +
. O +

This O +
increase O +
was O +
the O +
result O +
of O +
an O +
increase O +
in O +
the O +
number O +
of O +
receptors O +
on O +
treated O +
cells O +
coupled O +
with O +
a O +
protection O +
against O +
a O +
decrease O +
in O +
receptors O +
observed O +
for O +
confluent O +
untreated O +
cells O +
. O +

Changes O +
in O +
IFN O +
- O +
gamma O +
binding O +
resulting O +
from O +
treatment O +
with O +
IFN O +
- O +
delta O +
plus O +
MEZ B-Chemical +
were O +
not O +
associated O +
with O +
alterations O +
in O +
the O +
binding O +
affinity O +
of O +
INF O +
- O +
gamma O +
to O +
its O +
receptor O +
. O +

Changes O +
were O +
also O +
observed O +
in O +
the O +
expression O +
of O +
HLA O +
Class O +
I O +
antigens O +
and O +
MAAs O +
following O +
treatment O +
of O +
HO O +
- O +
1 O +
cells O +
with O +
IFN O +
- O +
delta O +
, O +
MEZ B-Chemical +
or O +
IFN O +
- O +
delta O +
plus O +
MEZ B-Chemical +
. O +

IFN O +
- O +
delta O +
and O +
MEZ B-Chemical +
increased O +
the O +
expression O +
of O +
HLA O +
Class O +
I O +
antigens O +
a O +
96 O +
kd O +
MAA O +
defined O +
by O +
MoAb O +
CL203 O +
, O +
a O +
kd O +
MAA O +
defined O +
by O +
MoAb O +
376.96 O +
and O +
a O +
115 O +
kd O +
MAA O +
defined O +
by O +
MoAb O +
345.134 O +
but O +
decreased O +
the O +
expression O +
of O +
a O +
high O +
molecular O +
weight O +
- O +
melanoma O +
associated O +
antigen O +
( O +
HMW O +
- O +
MAA O +
) O +
defined O +
by O +
MoAb O +
325.28 O +
S O +
. O +

( O +
ABSTRACT O +
TRUNCATED O +
AT O +
WORDS O +
) O +

Conversion O +
of O +
the O +
8 B-Chemical +
- I-Chemical +
phenolic I-Chemical +
1,2,3,4,5,6 I-Chemical +
- I-Chemical +
hexahydro I-Chemical +
- I-Chemical +
2,6 I-Chemical +
- I-Chemical +
methano I-Chemical +
- I-Chemical +
3 I-Chemical +
- I-Chemical +
benzazocines I-Chemical +
to O +
the O +
corresponding O +
8 B-Chemical +
- I-Chemical +
thiophenolic I-Chemical +
analogues B-Chemical +
was O +
achieved O +
by O +
three O +
different O +
routes O +
. O +

Diazotization O +
of O +
8 B-Chemical +
- I-Chemical +
amino I-Chemical +
- I-Chemical +
2,6 I-Chemical +
- I-Chemical +
methano I-Chemical +
- I-Chemical +
3 I-Chemical +
- I-Chemical +
benzazocine I-Chemical +
( O +
2 O +
) O +
followed O +
by O +
the O +
reaction O +
with O +
CH3SNa B-Chemical +
afforded O +
8 B-Chemical +
- I-Chemical +
( I-Chemical +
methylthio I-Chemical +
) I-Chemical +
- I-Chemical +
1,2,3,4,5,6 I-Chemical +
- I-Chemical +
hexahydro I-Chemical +
- I-Chemical +
2,6 I-Chemical +
- I-Chemical +
methano I-Chemical +
- I-Chemical +
3 I-Chemical +
- I-Chemical +
benzazocine I-Chemical +
( O +
3 O +
) O +
. O +

Another O +
route O +
using O +
Grewe O +
cyclization O +
was O +
also O +
examined O +
for O +
the O +
synthesis O +
of O +
3 O +
. O +

As O +
the O +
most O +
effective O +
route O +
, O +
Newman O +
- O +
Kwart O +
rearrangement O +
of O +
benzazocines O +
was O +
selected O +
and O +
closely O +
investigated O +
. O +

8 B-Chemical +
- I-Chemical +
( I-Chemical +
N I-Chemical +
, I-Chemical +
N I-Chemical +
- I-Chemical +
Dimethylthiocarbamoyl I-Chemical +
) I-Chemical +
oxy I-Chemical +
derivatives B-Chemical +
( O +
6a O +
- O +
e O +
) O +
rearranged O +
to O +
8 B-Chemical +
- I-Chemical +
( I-Chemical +
N I-Chemical +
, I-Chemical +
N I-Chemical +
- I-Chemical +
dimethylcarbamoyl I-Chemical +
) I-Chemical +
thio I-Chemical +
derivatives B-Chemical +
( O +
7a O +
- O +
e O +
) O +
in O +
good O +
yields O +
. O +

Reductive O +
cleavage O +
of O +
7a O +
- O +
e O +
and O +
subsequent O +
methylation O +
or O +
acylations O +
gave O +
the O +
title O +
compounds O +
( O +
3 O +
, O +
8 O -
- O -
24 O +
) O +
. O +

Although O +
analgesic O +
activities O +
of O +
sulfur O +
- O +
containing O +
benzazocines B-Chemical +
decreased O +
compared O +
to O +
the O +
corresponding O +
hydroxy B-Chemical +
compounds B-Chemical +
, O +
the O +
N B-Chemical +
- I-Chemical +
methyl I-Chemical +
derivative B-Chemical +
( O +
S B-Chemical +
- I-Chemical +
metazocine I-Chemical +
, O +
8 O +
) O +
showed O +
potent O +
analgesic O +
activity O +
. O +

A O +
series O +
of O +
analogues O +
of O +
the O +
analgesic O +
dipeptide O +
derivative O +
H O +
- O +
Lys O +
- O +
Trp O +
( O +
NPS O +
) O +
- O +
OMe O +
has O +
been O +
designed O +
to O +
determine O +
the O +
influence O +
of O +
the O +
( B-Chemical +
2 I-Chemical +
- I-Chemical +
nitrophenyl I-Chemical +
) I-Chemical +
sulfenyl I-Chemical +
( O +
NPS B-Chemical +
) O +
moiety B-Chemical +
on O +
the O +
activity O +
. O +

The O +
syntheses O +
and O +
antinociceptive O +
effects O +
of O +
these O +
analogues O +
of O +
general O +
formula O +
H O +
- O +
Lys O +
- O +
Trp O +
( O +
R O +
) O +
- O +
OMe O +
[ O +
R O +
= O +
phenylsulfenyl B-Chemical +
( O +
PS B-Chemical +
) O +
( O +
9 O +
) O +
; O +
R O +
= O +
( O +
2 B-Chemical +
- I-Chemical +
carbomethyoxyphenyl I-Chemical +
) I-Chemical +
sulfenyl I-Chemical +
( O +
CmPS B-Chemical +
) O +
( O +
) O +
; O +
R O +
= O +
( O +
4 B-Chemical +
- I-Chemical +
nitrophenyl I-Chemical +
) I-Chemical +
sulfenyl I-Chemical +
( O +
pNPS B-Chemical +
) O +
( O +
11 O +
) O +
; O +
R O +
= O +
( O +
2,4 B-Chemical +
- I-Chemical +
dinitrophenyl I-Chemical +
) I-Chemical +
sulfenyl I-Chemical +
( O +
DNPS B-Chemical +
) O +
( O +
12 O +
) O +
; O +
R O +
= O +
[ B-Chemical +
2 I-Chemical +
- I-Chemical +
( I-Chemical +
acetylamino I-Chemical +
) I-Chemical +
- I-Chemical +
2 I-Chemical +
- I-Chemical +
carbomethoxyethyl I-Chemical +
] I-Chemical +
sulfenyl I-Chemical +
( O +
AacCmES B-Chemical +
) O +
( O +
13 O +
) O +
; O +
R O +
= O +
[ B-Chemical +
2 I-Chemical +
- I-Chemical +
( I-Chemical +
acetylamino I-Chemical +
) I-Chemical +
phenyl I-Chemical +
] I-Chemical +
sulfenyl I-Chemical +
( O +
AacPS B-Chemical +
) O +
( O +
17 O +
) O +
; O +
R O +
= O +
tert B-Chemical +
- I-Chemical +
butylsulfenyl I-Chemical +
( O +
t B-Chemical +
- I-Chemical +
BuS I-Chemical +
) O +
( O +
23 O +
) O +
; O +
R O +
= O +
( B-Chemical +
2 I-Chemical +
- I-Chemical +
carbomethoxyethyl I-Chemical +
) I-Chemical +
sulfenyl I-Chemical +
( O +
CmES B-Chemical +
) O +
( O +
24 O +
) O +
] O +
are O +
described O +
. O +

Reaction O +
of O +
Z O +
- O +
Lys O +
( O +
Z O +
) O +
- O +
Trp O +
- O +
OMe O +
( O +
3 O +
) O +
with O +
PS B-Chemical +
- O +
, O +
CmPS B-Chemical +
- O +
, O +
pNPS B-Chemical +
- O +
, O +
DNPS B-Chemical +
- O +
, O +
and O +
AacCmES B-Chemical +
- I-Chemical +
Cl I-Chemical +
afforded O +
the O +
corresponding O +
2 B-Chemical +
- I-Chemical +
( I-Chemical +
sulfenyl I-Chemical +
) I-Chemical +
tryptophan I-Chemical +
derivatives B-Chemical +
, O +
which O +
on O +
treatment O +
with O +
boron B-Chemical +
- I-Chemical +
tris I-Chemical +
( I-Chemical +
trifluoroacetate I-Chemical +
) I-Chemical +
/ O +
trifluoroacetic B-Chemical +
acid I-Chemical +
or O +
trimethylsilyl B-Chemical +
iodide I-Chemical +
in O +
acetonitrile B-Chemical +
( O +
Me3SiI B-Chemical +
/ O +
CH3CN B-Chemical +
) O +
provided O +
9 O -
- O -
13 O +
, O +
respectively O +
. O +

Sulfenylation O +
of O +
3 O +
with O +
NPS B-Chemical +
- I-Chemical +
Cl I-Chemical +
gave O +
Z O +
- O +
Lys O +
( O +
Z O +
) O +
- O +
Trp O +
( O +
NPS O +
) O +
- O +
OMe O +
, O +
which O +
, O +
on O +
catalytic O +
hydrogenation O +
of O +
the O +
nitro O +
group O +
using O +
Pd O +
/ O +
C O +
followed O +
by O +
acetylation O +
of O +
the O +
resulting O +
amino O +
function O +
and O +
removal O +
of O +
the O +
protecting O +
Z O +
groups O +
, O +
gave O +
17 O +
. O +

Condensation O +
of O +
2 B-Chemical +
- I-Chemical +
( I-Chemical +
tert I-Chemical +
- I-Chemical +
butylsulfenyl I-Chemical +
) I-Chemical +
- I-Chemical +
and O +
2 B-Chemical +
- I-Chemical +
[ I-Chemical +
( I-Chemical +
2 I-Chemical +
- I-Chemical +
carbomethoxyethyl I-Chemical +
) I-Chemical +
sulfenyl I-Chemical +
] I-Chemical +
tryptophan I-Chemical +
methyl I-Chemical +
ester I-Chemical +
, O +
obtained O +
by O +
reaction O +
of O +
methyl B-Chemical +
3a I-Chemical +
- I-Chemical +
hydroxy I-Chemical +
- I-Chemical +
1,2,3,3 I-Chemical +
a I-Chemical +
, I-Chemical +
8,8 I-Chemical +
a I-Chemical +
- I-Chemical +
hexahydropyrrolo I-Chemical +
[ I-Chemical +
2,3 I-Chemical +
- I-Chemical +
b I-Chemical +
] I-Chemical +
indole I-Chemical +
- I-Chemical +
2 I-Chemical +
- I-Chemical +
carboxyla I-Chemical +
te I-Chemical +
with O +
the O +
corresponding O +
thiol O +
, O +
with O +
Z O +
- O +
Lys O +
( O +
Z O +
) O +
- O +
OSu O +
afforded O +
Z O +
- O +
Lys O +
( O +
Z O +
) O +
- O +
Trp O +
( O +
t O +
- O +
BuS O +
) O +
- O +
OMe O +
and O +
Z O +
- O +
Lys O +
( O +
Z O +
) O +
- O +
Trp O +
( O +
CmES O +
) O +
- O +
OMe O +
, O +
which O +
on O +
treatment O +
with O +
Me3SiI B-Chemical +
/ O +
CH3CN B-Chemical +
provided O +
23 O +
and O +
24 O +
, O +
respectively O +
. O +

Intracerebroventricular O +
administration O +
of O +
elicited O +
a O +
naloxone B-Chemical +
- O +
reversible O +
antinociceptive O +
effect O +
in O +
mice O +
similar O +
to O +
that O +
of O +
H O +
- O +
Lys O +
- O +
Trp O +
( O +
NPS O +
) O +
- O +
OMe O +
. O +

No O +
analgesia O +
was O +
however O +
found O +
with O +
the O +
phenylsulfenyl B-Chemical +
or O +
acyclic B-Chemical +
sulfenyl I-Chemical +
substituted I-Chemical +
dipeptides I-Chemical +
9 O +
, O +
11 O +
, O +
and O +
17 O +
or O +
13 O +
, O +
23 O +
, O +
and O +
24 O +
. O +

The O +
Trp B-Chemical +
( I-Chemical +
DNPS I-Chemical +
) I-Chemical +
- O +
containing O +
analogue O +
was O +
neurotoxic O +
. O +

Structure O +
- O +
activity O +
studies O +
indicate O +
that O +
the O +
role O +
of O +
the O +
NPS B-Chemical +
and O +
CmPS B-Chemical +
moieties B-Chemical +
could O +
be O +
related O +
to O +
the O +
adoption O +
of O +
a O +
preferential O +
active O +
conformation O +
. O +

A O +
series O +
of O +
22 B-Chemical +
- I-Chemical +
hydroxycholesterol I-Chemical +
derivatives B-Chemical +
with O +
a O +
modified O +
side O +
chain O +
terminus O +
was O +
prepared O +
. O +

These O +
agents O +
were O +
evaluated O +
in O +
vitro O +
and O +
in O +
vivo O +
for O +
their O +
ability O +
to O +
suppress O +
HMG O +
CoA O +
reductase O +
, O +
the O +
rate O +
- O +
limiting O +
enzyme O +
of O +
cholesterol B-Chemical +
biosynthesis O +
. O +

In O +
tissue O +
culture O +
assays O +
, O +
22 B-Chemical +
- I-Chemical +
hydroxycholesterol I-Chemical +
as O +
well O +
as O +
the O +
side O +
chain O +
modified O +
analogues O +
were O +
potent O +
inhibitors O +
of O +
HMG O +
CoA O +
reductase O +
. O +

However O +
, O +
only O +
those O +
sterols O +
with O +
a O +
modified O +
side O +
chain O +
terminus O +
were O +
effective O +
suppressors O +
of O +
liver O +
reductase O +
when O +
administered O +
ig O +
to O +
rats O +
. O +

22 B-Chemical +
- I-Chemical +
Hydroxy I-Chemical +
- I-Chemical +
25 I-Chemical +
- I-Chemical +
methylcholesterol I-Chemical +
( O +
4a O +
) O +
and O +
25 B-Chemical +
- I-Chemical +
fluoro I-Chemical +
- I-Chemical +
22 I-Chemical +
- I-Chemical +
hydroxycholesterol I-Chemical +
( O +
15a O +
) O +
significantly O +
lowered O +
serum O +
cholesterol O +
levels O +
when O +
administered O +
ig O +
to O +
primates O +
; O +
25 B-Chemical +
- I-Chemical +
chloro I-Chemical +
- I-Chemical +
22 I-Chemical +
- I-Chemical +
hydroxycholesterol I-Chemical +
( O +
15b O +
) O +
and O +
the O +
analogue O +
with O +
a O +
cyclopropyl B-Chemical +
terminus O +
, O +
, O +
were O +
ineffective O +
. O +

The O +
cholesterol B-Chemical +
- O +
lowering O +
sterols B-Chemical +
did O +
not O +
significantly O +
alter O +
lipoprotein O +
levels O +
; O +
however O +
, O +
the O +
two O +
compounds O +
have O +
been O +
shown O +
to O +
inhibit O +
acyl O +
- O +
coenzyme O +
A O +
: O +
cholesterol O +
acyl O +
- O +
transferase O +
( O +
ACAT O +
) O +
in O +
tissue O +
culture O +
studies O +
. O +

Metabolism O +
of O +
D B-Chemical +
- I-Chemical +
and O +
L B-Chemical +
- I-Chemical +
glyceraldehyde I-Chemical +
in O +
adipose O +
tissue O +
: O +
a O +
stereochemical O +
probe O +
for O +
glycerokinase O +
activity O +
. O +

Distributions O +
of O +
( B-Chemical +
14 I-Chemical +
) I-Chemical +
C I-Chemical +
have O +
been O +
determined O +
in O +
free O +
glycerol B-Chemical +
, O +
in O +
glycerol B-Chemical +
from O +
triglycerides B-Chemical +
, O +
in O +
glucose B-Chemical +
from O +
glycogen B-Chemical +
, O +
and O +
in O +
lactate O +
after O +
incubation O +
of O +
d B-Chemical +
- I-Chemical +
glyceraldehyde I-Chemical +
- I-Chemical +
3 I-Chemical +
- I-Chemical +
( I-Chemical +
14 I-Chemical +
) I-Chemical +
C I-Chemical +
and O +
l B-Chemical +
- I-Chemical +
glyceraldehyde I-Chemical +
- I-Chemical +
3 I-Chemical +
- I-Chemical +
( I-Chemical +
14 I-Chemical +
) I-Chemical +
C I-Chemical +
with O +
rat O +
adipose O +
tissue O +
. O +

The O +
distributions O +
are O +
interpreted O +
in O +
terms O +
of O +
presently O +
accepted O +
possible O +
reactions O +
for O +
the O +
initial O +
metabolism O +
of O +
glyceraldehyde B-Chemical +
. O +

Formation O +
of O +
glycerol B-Chemical +
- I-Chemical +
1 I-Chemical +
- I-Chemical +
( I-Chemical +
14 I-Chemical +
) I-Chemical +
C I-Chemical +
from O +
d B-Chemical +
- I-Chemical +
glyceraldehyde I-Chemical +
- I-Chemical +
3 I-Chemical +
- I-Chemical +
( I-Chemical +
14 I-Chemical +
) I-Chemical +
C I-Chemical +
indicates O +
that O +
in O +
adipose O +
tissue O +
glyceraldehyde B-Chemical +
is O +
reduced O +
to O +
glycerol B-Chemical +
. O +

Incorporation O +
of O +
( B-Chemical +
14 I-Chemical +
) I-Chemical +
C I-Chemical +
from O +
d B-Chemical +
- I-Chemical +
glyceraldehyde I-Chemical +
- I-Chemical +
3 I-Chemical +
- I-Chemical +
( I-Chemical +
14 I-Chemical +
) I-Chemical +
C I-Chemical +
into O +
carbon B-Chemical +
3 O +
of O +
the O +
glycerol B-Chemical +
of O +
triglyceride B-Chemical +
indicates O +
that O +
d B-Chemical +
- I-Chemical +
glyceraldehyde I-Chemical +
is O +
either O +
phosphorylated O +
or O +
oxidized O +
to O +
d B-Chemical +
- I-Chemical +
glyceric I-Chemical +
acid I-Chemical +
, O +
or O +
both O +
, O +
in O +
its O +
initial O +
metabolism O +
. O +

Incorporation O +
of O +
( B-Chemical +
14 I-Chemical +
) I-Chemical +
C I-Chemical +
from O +
l B-Chemical +
- I-Chemical +
glyceraldehyde I-Chemical +
- I-Chemical +
3 I-Chemical +
- I-Chemical +
( I-Chemical +
14 I-Chemical +
) I-Chemical +
C I-Chemical +
into O +
carbon B-Chemical +
3 O +
of O +
glycerol B-Chemical +
indicates O +
that O +
l B-Chemical +
- I-Chemical +
glyceraldehyde I-Chemical +
is O +
reduced O +
to O +
glycerol B-Chemical +
, O +
which O +
is O +
phosphorylated O +
and O +
( O +
or O +
) O +
converted O +
to O +
d B-Chemical +
- I-Chemical +
glyceric I-Chemical +
acid I-Chemical +
via O +
l B-Chemical +
- I-Chemical +
glyceric I-Chemical +
acid I-Chemical +
. O +

Some O +
( B-Chemical +
14 I-Chemical +
) I-Chemical +
C I-Chemical +
from O +
l B-Chemical +
- I-Chemical +
glyceraldehyde I-Chemical +
- I-Chemical +
3 I-Chemical +
- I-Chemical +
( I-Chemical +
14 I-Chemical +
) I-Chemical +
C I-Chemical +
is O +
incorporated O +
into O +
carbon B-Chemical +
1 O +
of O +
glycerol B-Chemical +
of O +
triglycerides B-Chemical +
and O +
carbon B-Chemical +
4 O +
of O +
glycogen B-Chemical +
; O +
the O +
explanation O +
for O +
this O +
incorporation O +
is O +
uncertain O +
. O +

596853 O +
[ O +
Synthesis O +
and O +
properties O +
of O +
carminomycinone B-Chemical +
derivatives B-Chemical +
] O +

The O +
possibility O +
of O +
chemical O +
modification O +
of O +
carminomycinone B-Chemical +
- I-Chemical +
aglycone I-Chemical +
( O +
II O +
) O +
of O +
carminomicin B-Chemical +
, O +
a O +
side O +
product O +
in O +
the O +
antibiotic O +
production O +
was O +
studied O +
. O +

The O +
methyl B-Chemical +
group B-Chemical +
C B-Chemical +
- I-Chemical +
14 I-Chemical +
was O +
functionilized O +
by O +
introducing O +
the O +
bromine B-Chemical +
atom B-Chemical +
and O +
performing O +
a O +
number O +
of O +
exchange O +
reactions O +
with O +
the O +
bromine B-Chemical +
atom B-Chemical +
. O +

It O +
was O +
found O +
that O +
under O +
definite O +
conditions O +
( O +
1 O +
. O +
1 O +
equiv O +
. O +

Br2 B-Chemical +
in O +
dioxane B-Chemical +
, O +
degrees O +
, O +
24 O +
hours O +
) O +
carminomycinone B-Chemical +
( O +
II O +
) O +
was O +
subjected O +
to O +
selective O +
bromination O +
into O +
the O +
side O +
acetyl B-Chemical +
group B-Chemical +
with O +
formation O +
of O +
14 B-Chemical +
- I-Chemical +
bromcarminomycinone I-Chemical +
( O +
III O +
) O +
. O +

On O +
interaction O +
with O +
anhydrous O +
potassium B-Chemical +
acetate I-Chemical +
14 I-Chemical +
- I-Chemical +
bromcarminomycinone I-Chemical +
( O +
III O +
) O +
yield O +
14 B-Chemical +
- I-Chemical +
acetoxycarminomycinone I-Chemical +
( O +
IV O +
) O +
. O +

In O +
its O +
turn O +
the O +
latter O +
compound O +
( O +
IV O +
) O +
easily O +
hydrolized O +
to O +
14 B-Chemical +
- I-Chemical +
oxycarminomycinone I-Chemical +
( O +
V O +
) O +
in O +
treatment O +
with O +
aqueous O +
alkali O +
or O +
acid O +
. O +

14 B-Chemical +
- I-Chemical +
oxycarminomycinone I-Chemical +
( O +
V O +
) O +
was O +
also O +
prepared O +
with O +
a O +
high O +
yield O +
( O +
per O +
cent O +
) O +
by O +
direct O +
alkaline O +
hydrolysis O +
of O +
14 B-Chemical +
- I-Chemical +
bromcarminomycinone I-Chemical +
( O +
III O +
) O +
in O +
treatment O +
with O +
0.1 O +
N O +
solution O +
of O +
sodium B-Chemical +
carbonate I-Chemical +
in O +
a O +
mixture O +
of O +
dioxane B-Chemical +
and O +
water O +
. O +

The O +
structure O +
of O +
14 O +
- O +
substituted O +
derivatives B-Chemical +
of O +
carminomycinone B-Chemical +
was O +
proved O +
by O +
analytical O +
and O +
spectral O +
data O +
and O +
confirmed O +
by O +
their O +
transformation O +
. O +

Thus O +
, O +
according O +
to O +
the O +
data O +
of O +
mass O +
- O +
spectrometry O +
14 B-Chemical +
- I-Chemical +
oxycarminomycinone I-Chemical +
( O +
V O +
) O +
had O +
a O +
molecular O +
weight O +
of O +
c O +
. O +

u O +
. O +

In O +
treatment O +
with O +
an O +
excess O +
of O +
acetic B-Chemical +
anhydride I-Chemical +
in O +
pyridine B-Chemical +
it O +
formed O +
a O +
hexa B-Chemical +
- I-Chemical +
acetyl I-Chemical +
derivative B-Chemical +
, O +
i.e. O +
4 B-Chemical +
, I-Chemical +
6 I-Chemical +
, I-Chemical +
7 I-Chemical +
, I-Chemical +
9 I-Chemical +
, I-Chemical +
11 I-Chemical +
, I-Chemical +
14 I-Chemical +
- I-Chemical +
hexa I-Chemical +
- I-Chemical +
acetyl I-Chemical +
- I-Chemical +
14 I-Chemical +
- I-Chemical +
oxycarminomycinone I-Chemical +
( O +
VI O +
) O +
. O +

The O +
aglycones B-Chemical +
( O +
III O +
- O +
V O +
) O +
prepared O +
by O +
us O +
may O +
serve O +
a O +
starting O +
material O +
in O +
chemical O +
synthesis O +
, O +
as O +
well O +
as O +
biosynthesis O +
of O +
semi O +
- O +
synthetic O +
preparations O +
of O +
the O +
carminomycin B-Chemical +
series B-Chemical +
. O +

6264792 O +
Inhibition O +
of O +
renin O +
secretion O +
by O +
intrarenal O +
alpha O +
- O +
adrenoceptor O +
blockade O +
. O +

This O +
study O +
was O +
designed O +
to O +
determine O +
whether O +
renal O +
alpha O +
- O +
adrenoceptors O +
can O +
mediate O +
tonic O +
neural O +
stimulation O +
of O +
renin O +
secretion O +
. O +

The O +
effect O +
of O +
alpha O +
- O +
adrenoceptor O +
blockade O +
by O +
phenoxybenzamine B-Chemical +
( O +
POB B-Chemical +
) O +
or O +
prazosin B-Chemical +
on O +
renin O +
secretion O +
rate O +
( O +
RSR O +
) O +
was O +
studied O +
in O +
pentobarbital B-Chemical +
- O +
anesthetized O +
dogs O +
in O +
which O +
renal O +
perfusion O +
pressure O +
was O +
held O +
constant O +
with O +
an O +
adjustable O +
aortic O +
clamp O +
. O +

POB B-Chemical +
alone O +
( O +
micrograms O +
. O +

kg O +
- O +
1 O +
. O +
min O +
- O +
1 O +
iv O +
) O +
did O +
not O +
change O +
arterial O +
plasma O +
renin O +
activity O +
( O +
PRA O +
) O +
. O +

However O +
, O +
when O +
beta O +
- O +
adrenoceptors O +
were O +
blocked O +
by O +
intravenous O +
propranolol B-Chemical +
, O +
intravenous O +
POB B-Chemical +
infusion O +
( O +
micrograms O +
. O +

kg O +
- O +
1 O +
. O +
min O +
- O +
1 O +
) O +
decreased O +
PRA O +
and O +
RSR O +
to O +
48 O +
+ O +
/ O +
- O +
8 O +
and O +
21 O +
+ O +
/ O +
- O +
9 O -
% O +
of O +
previous O +
levels O +
within O +
min O +
. O +

This O +
effect O +
was O +
abolished O +
by O +
acute O +
bilateral O +
renal O +
denervation O +
. O +

Direct O +
intrarenal O +
POB B-Chemical +
infusion O +
( O +
or O +
3.3 O +
micrograms O +
. O +

kg O +
- O +
1 O +
. O +
min O +
- O +
1 O +
) O +
decreased O +
RSR O +
, O +
whereas O +
intravenous O +
POB B-Chemical +
( O +
3.3 O +
micrograms O +
. O +

kg O +
- O +
1 O +
. O +
min O +
- O +
1 O +
) O +
had O +
no O +
effect O +
on O +
either O +
RSR O +
or O +
PRA O +
in O +
propranolol B-Chemical +
- O +
pretreated O +
dogs O +
. O +

Prazosin B-Chemical +
( O +
1 O +
microgram O +
. O +

kg O +
- O +
1 O +
. O +
min O +
- O +
1 O +
iv O +
) O +
also O +
significantly O +
decreased O +
PRA O +
. O +

These O +
data O +
indicate O +
that O +
when O +
beta O +
- O +
adrenoceptors O +
are O +
blocked O +
by O +
propranolol B-Chemical +
, O +
tonic O +
neural O +
stimulation O +
of O +
renin O +
secretion O +
is O +
mediated O +
by O +
renal O +
alpha O +
- O +
adrenoceptors O +
. O +

Adenosine O +
5 O -
' O +
- O +
triphosphate O +
( O +
ATP B-Chemical +
) O +
derivatives B-Chemical +
of O +
the O +
types O +
N6 B-Chemical +
- I-Chemical +
R I-Chemical +
- I-Chemical +
ATP I-Chemical +
[ O +
R O +
= O +
( B-Chemical +
CH2 I-Chemical +
) I-Chemical +
nNHCOCH2I I-Chemical +
, O +
( B-Chemical +
CH2 I-Chemical +
) I-Chemical +
nNHCO I-Chemical +
- I-Chemical +
( I-Chemical +
CH2 I-Chemical +
) I-Chemical +
mNHCOCH2I I-Chemical +
, O +
or O +
( B-Chemical +
CH2 I-Chemical +
) I-Chemical +
nCON I-Chemical +
( I-Chemical +
Me I-Chemical +
) I-Chemical +
( I-Chemical +
CH2 I-Chemical +
) I-Chemical +
mN I-Chemical +
( I-Chemical +
Me I-Chemical +
) I-Chemical +
CO I-Chemical +
( I-Chemical +
CH2 I-Chemical +
) I-Chemical +
nNHCOCH2I I-Chemical +
] O +
, O +
N6 B-Chemical +
- I-Chemical +
Me I-Chemical +
- I-Chemical +
N6 I-Chemical +
- I-Chemical +
R I-Chemical +
- I-Chemical +
ATP I-Chemical +
[ O +
R O +
= O +
( B-Chemical +
CH2 I-Chemical +
) I-Chemical +
nN I-Chemical +
- I-Chemical +
( I-Chemical +
Me I-Chemical +
) I-Chemical +
CO I-Chemical +
( I-Chemical +
CH2 I-Chemical +
) I-Chemical +
mNHCOCH2I I-Chemical +
] O +
, O +
and O +
8 B-Chemical +
- I-Chemical +
R I-Chemical +
- I-Chemical +
ATP I-Chemical +
[ O +
R O +
= O +
NM B-Chemical +
( I-Chemical +
CH2 I-Chemical +
) I-Chemical +
nNHCOCH2I I-Chemical +
] O +
with O +
5 O +
- O +
- O +
19 O +
spacer O +
atoms O +
between O +
N6 O +
or O +
C O +
- O +
8 O +
and O +
iodine B-Chemical +
have O +
been O +
evaluated O +
as O +
potential O +
exo O +
- O +
ATP B-Chemical +
- O +
site O +
- O +
directed O +
reagents O +
for O +
phosphokinases O +
. O +

Substrate O +
and O +
inhibitor O +
properties O +
indicated O +
that O +
the O +
compounds O +
possessed O +
affinity O +
for O +
the O +
ATP B-Chemical +
sites O +
of O +
the O +
muscle O +
( O +
M O +
) O +
, O +
kidney O +
( O +
K O +
) O +
, O +
and O +
liver O +
( O +
L O +
) O +
isozymes O +
of O +
rat O +
pyruvate O +
kinase O +
( O +
PK O +
) O +
, O +
of O +
E O +
. O +

coli O +
thymidine O +
kinase O +
( O +
TK O +
) O +
, O +
and O +
of O +
yeast O +
hexokinase O +
( O +
HK O +
) O +
and O +
rat O +
KH O +
I O +
, O +
II O +
, O +
and O +
III O +
isozymes O +
. O +

Tests O +
for O +
time O +
- O +
dependent O +
loss O +
of O +
enzyme O +
activity O +
( O +
inactivation O +
) O +
were O +
performed O +
under O +
conditions O +
in O +
which O +
a O +
large O +
proportion O +
of O +
each O +
phosphokinase O +
was O +
present O +
as O +
an O +
enzyme O +
- O +
inhibitor O +
complex O +
. O +

No O +
ATP B-Chemical +
- O +
site O +
- O +
directed O +
inactivations O +
resulted O +
when O +
the O +
M O +
, O +
L O +
, O +
or O +
K O +
isozymes O +
of O +
PK O +
were O +
exposed O +
for O +
8 O +
h O +
, O +
22 O +
degrees O +
C O +
, O +
to O +
5 O +
mM O +
levels O +
of O +
18 O +
ATP B-Chemical +
derivatives B-Chemical +
or O +
6 O +
analogous O +
ADP B-Chemical +
derivatives B-Chemical +
or O +
when O +
yeast O +
HK O +
or O +
rat O +
KH O +
I O +
, O +
II O +
, O +
or O +
III O +
was O +
exposed O +
for O +
6 O +
h O +
, O +
22 O +
degrees O +
C O +
, O +
to O +
5 O +
mM O +
levels O +
of O +
28 O +
ATP B-Chemical +
derivatives B-Chemical +
. O +

Escherichia O +
coli O +
TK O +
was O +
inactivated O +
by O +
6 O +
of O +
25 O +
ATP O +
derivatives O +
tested O +
at O +
mM O +
, O +
6 O +
h O +
, O +
0 O +
degrees O +
C O +
; O +
inactivation O +
was O +
slowed O +
by O +
MgATP B-Chemical +
in O +
the O +
case O +
of O +
N6 B-Chemical +
- I-Chemical +
CH3 I-Chemical +
- I-Chemical +
N6 I-Chemical +
- I-Chemical +
R I-Chemical +
- I-Chemical +
ATP I-Chemical +
[ O +
R O +
= O +
( B-Chemical +
CH2 I-Chemical +
) I-Chemical +
4N I-Chemical +
( I-Chemical +
CH3 I-Chemical +
) I-Chemical +
CO I-Chemical +
( I-Chemical +
CH2 I-Chemical +
) I-Chemical +
5NHCOCH2I I-Chemical +
] O +
. O +

Only O +
1 O -
% O +
of O +
298 O +
enzyme O +
- O +
inhibitor O +
combinations O +
exhibited O +
ATP B-Chemical +
- O +
site O +
- O +
directed O +
inactivation O +
, O +
signifying O +
that O +
few O +
suitably O +
positioned O +
and O +
sufficiently O +
reactive O +
nucleophilic O +
groups O +
were O +
present O +
near O +
the O +
enzymic O +
ATP B-Chemical +
sites O +
. O +

Studies O +
have O +
now O +
shown O +
that O +
exo O +
- O +
active O +
- O +
site O +
- O +
directed O +
reagents O +
can O +
act O +
as O +
isozyme O +
- O +
or O +
species O +
- O +
selective O +
enzyme O +
inhibitors O +
. O +

The O +
present O +
survey O +
indicates O +
that O +
in O +
many O +
cases O +
such O +
reagents O +
may O +
be O +
difficult O +
of O +
access O +
when O +
data O +
are O +
not O +
available O +
regarding O +
structural O +
or O +
physicochemical O +
features O +
of O +
the O +
target O +
enzyme O +
adjacent O +
to O +
its O +
catalytic O +
site O +
. O +

The O +
synthesis O +
of O +
aminoaceto B-Chemical +
- I-Chemical +
2 I-Chemical -
' I-Chemical +
, I-Chemical +
6 I-Chemical -
' I-Chemical +
- I-Chemical +
xylidides I-Chemical +
substituted B-Chemical +
on O +
the O +
amide B-Chemical +
nitrogen B-Chemical +
with O +
2 B-Chemical +
- I-Chemical +
( I-Chemical +
diethylamino I-Chemical +
) I-Chemical +
ethyl I-Chemical +
, O +
2 B-Chemical +
- I-Chemical +
aminoethyl I-Chemical +
, O +
2 B-Chemical +
- I-Chemical +
hydroxyethyl I-Chemical +
, O +
and O +
2 B-Chemical +
- I-Chemical +
ethoxyethyl I-Chemical +
groups B-Chemical +
is O +
described O +
. O +

The O +
2 B-Chemical +
- I-Chemical +
aminoethyl I-Chemical +
derivatives B-Chemical +
were O +
prepared O +
by O +
treatment O +
of O +
N B-Chemical +
- I-Chemical +
( I-Chemical +
2 I-Chemical +
- I-Chemical +
phthalimidoethyl I-Chemical +
) I-Chemical +
- I-Chemical +
2 I-Chemical -
' I-Chemical +
, I-Chemical +
6 I-Chemical -
' I-Chemical +
- I-Chemical +
xylidine I-Chemical +
with O +
chloroacetyl B-Chemical +
chloride I-Chemical +
, O +
followed O +
by O +
treatment O +
with O +
either O +
potassium B-Chemical +
phthalmide I-Chemical +
or O +
diethylamine B-Chemical +
. O +

Hydrazinolysis O +
of O +
the O +
phthalimides B-Chemical +
liberated O +
the O +
free O +
amines B-Chemical +
. O +

The O +
remaining O +
target O +
compounds O +
were O +
produced O +
by O +
alkylation O +
of O +
lidocaine B-Chemical +
or O +
of O +
2 B-Chemical +
- I-Chemical +
phthalimidoaceto I-Chemical +
- I-Chemical +
2 I-Chemical -
' I-Chemical +
, I-Chemical +
6 I-Chemical -
' I-Chemical +
- I-Chemical +
xylidide I-Chemical +
with O +
the O +
appropriate O +
halide B-Chemical +
and O +
sodium B-Chemical +
hydride I-Chemical +
, O +
followed O +
by O +
hydrazinolysis O +
where O +
necessary O +
. O +

All O +
target O +
compounds O +
were O +
evaluated O +
for O +
antiarrhythmic O +
efficacy O +
against O +
chloroform B-Chemical +
- O +
induced O +
ventricular O +
tachycardia O +
, O +
as O +
well O +
as O +
for O +
acute O +
CNS O +
toxicity O +
in O +
mice O +
. O +

Most O +
of O +
the O +
target O +
compounds O +
were O +
more O +
potent O +
than O +
the O +
corresponding O +
secondary O +
amides O +
and O +
had O +
improved O +
therapeutic O +
margins O +
toward O +
CNS O +
toxicity O +
. O +

The O +
diamines O +
N B-Chemical +
- I-Chemical +
( I-Chemical +
2 I-Chemical +
- I-Chemical +
aminoethyl I-Chemical +
) I-Chemical +
- I-Chemical +
2 I-Chemical +
- I-Chemical +
aminoaceto I-Chemical +
- I-Chemical +
2 I-Chemical -
' I-Chemical +
, I-Chemical +
6 I-Chemical -
' I-Chemical +
- I-Chemical +
xylidide I-Chemical +
( O +
13 O +
) O +
and O +
N B-Chemical +
- I-Chemical +
( I-Chemical +
2 I-Chemical +
- I-Chemical +
aminoethyl I-Chemical +
) I-Chemical +
- I-Chemical +
- I-Chemical +
2 I-Chemical +
- I-Chemical +
( I-Chemical +
diethylamino I-Chemical +
) I-Chemical +
aceto I-Chemical +
- I-Chemical +
2 I-Chemical -
' I-Chemical +
, I-Chemical +
6 I-Chemical -
' I-Chemical +
- I-Chemical +
xylidide I-Chemical +
( O +
29 O +
) O +
are O +
especially O +
promising O +
in O +
this O +
respect O +
. O +

Several O +
compounds O +
were O +
tested O +
as O +
spinal O +
anesthetics O +
. O +

Evidence O +
for O +
messenger O +
ribonucleic O +
acid O +
of O +
an O +
ammonium O +
- O +
inducible O +
glutamate O +
dehydrogenase O +
and O +
synthesis O +
, O +
covalent O +
modification O +
, O +
and O +
degradation O +
of O +
enzyme O +
subunits O +
in O +
uninduced O +
Chlorella O +
sorokiniana O +
cells O +
. O +

The O +
cells O +
of O +
Chlorella O +
sorokiniana O +
cultured O +
in O +
nitrate B-Chemical +
medium O +
contain O +
no O +
detectable O +
catalytic O +
activity O +
of O +
an O +
ammonium O +
- O +
inducible O +
nicotinamide O +
adenine O +
dinucleotide O +
phosphate O +
- O +
specific O +
glutamate O +
dehydrogenase O +
( O +
NADP O +
- O +
GDH O +
) O +
. O +

However O +
, O +
several O +
lines O +
of O +
experimental O +
evidence O +
indicated O +
that O +
the O +
NADP O +
- O +
GDH O +
messenger O +
ribonucleic O +
acid O +
was O +
present O +
at O +
high O +
levels O +
and O +
was O +
being O +
translated O +
in O +
uninduced O +
cells O +
. O +

First O +
, O +
binding O +
studies O +
with O +
125I O +
- O +
labeled O +
anti O +
- O +
NADP O +
- O +
GDH O +
immunoglobulin O +
G O +
and O +
total O +
polysomes O +
isolated O +
from O +
uninduced O +
and O +
induced O +
cells O +
showed O +
that O +
NADP O +
- O +
GDH O +
subunits O +
were O +
being O +
synthesized O +
on O +
polysomes O +
from O +
both O +
types O +
of O +
cells O +
. O +

Second O +
, O +
when O +
polyadenylic B-Chemical +
acid I-Chemical +
- O +
containing O +
ribonucleic O +
acid O +
was O +
extracted O +
from O +
polysomes O +
from O +
uninduced O +
and O +
induced O +
cells O +
and O +
placed O +
into O +
a O +
messenger O +
ribonucleic O +
acid O +
- O +
dependent O +
in O +
vitro O +
translation O +
system O +
, O +
NADP O +
- O +
GDH O +
subunits O +
were O +
synthesized O +
from O +
the O +
ribonucleic O +
acid O +
from O +
both O +
sources O +
. O +

Third O +
, O +
when O +
ammonia B-Chemical +
was O +
added O +
to O +
uninduced O +
cells O +
, O +
NADP O +
- O +
GDH O +
antigen O +
accumulated O +
without O +
an O +
apparent O +
induction O +
lag O +
. O +

Fourth O +
, O +
by O +
use O +
of O +
a O +
specific O +
immunoprecipitation O +
procedure O +
coupled O +
to O +
pulse O +
- O +
chase O +
studies O +
with O +
[ B-Chemical +
35S I-Chemical +
] I-Chemical +
sulfate I-Chemical +
, O +
it O +
was O +
shown O +
that O +
the O +
NADP O +
- O +
GDH O +
subunits O +
are O +
rapidly O +
synthesized O +
, O +
covalently O +
modified O +
, O +
and O +
then O +
degraded O +
in O +
uninduced O +
cells O +
. O +

Hypoxic O +
cells O +
are O +
an O +
important O +
target O +
for O +
antitumor O +
therapy O +
because O +
tumors O +
are O +
typically O +
characterized O +
by O +
such O +
cells O +
. O +

Virtually O +
all O +
tumors O +
which O +
are O +
present O +
as O +
solid O +
masses O +
contain O +
hypoxic O +
cells O +
, O +
while O +
normal O +
cells O +
generally O +
have O +
an O +
adequate O +
supply O +
of O +
oxygen O +
. O +

Accordingly O +
, O +
antitumor O +
agents O +
can O +
be O +
made O +
selective O +
for O +
tumors O +
by O +
virtue O +
of O +
high O +
activity O +
under O +
hypoxic O +
conditions O +
. O +

The O +
initial O +
purpose O +
of O +
this O +
work O +
was O +
to O +
determine O +
the O +
influence O +
of O +
different O +
groups O +
in O +
position O +
3 O +
. O +

Thus O +
, O +
the O +
synthesis O +
of O +
some O +
3 B-Chemical +
- I-Chemical +
NH I-Chemical +
- I-Chemical +
substituted I-Chemical +
derivatives B-Chemical +
( O +
2a O +
, O +
3a O +
, O +
4a O +
) O +
starting O +
from O +
3 B-Chemical +
- I-Chemical +
amino I-Chemical +
- I-Chemical +
2 I-Chemical +
- I-Chemical +
quinoxalinecarbonitrile I-Chemical +
1,4 I-Chemical +
- I-Chemical +
di I-Chemical +
- I-Chemical +
N I-Chemical +
- I-Chemical +
oxide I-Chemical +
( O +
1a O +
) O +
is O +
described O +
. O +

Reductive O +
deamination O +
of O +
compounds O +
1a O +
- O +
k O +
provides O +
the O +
2 B-Chemical +
- I-Chemical +
quinoxalinecarbonitriles I-Chemical +
5a O +
- O +
k O +
, O +
which O +
are O +
more O +
potent O +
, O +
while O +
selectivity O +
is O +
maintained O +
or O +
increased O +
in O +
some O +
derivatives O +
. O +

The O +
compound O +
7 B-Chemical +
- I-Chemical +
( I-Chemical +
4 I-Chemical +
- I-Chemical +
nitrophenyl I-Chemical +
) I-Chemical +
- I-Chemical +
2 I-Chemical +
- I-Chemical +
quinoxalinecarbonitrile I-Chemical +
1,4 I-Chemical +
- I-Chemical +
di I-Chemical +
- I-Chemical +
N I-Chemical +
- I-Chemical +
oxide I-Chemical +
( O +
5k O +
) O +
is O +
- O +
fold O +
more O +
potent O +
than O +
tirapazamine B-Chemical +
( O +
3 B-Chemical +
- I-Chemical +
amino I-Chemical +
- I-Chemical +
1,2,4 I-Chemical +
- I-Chemical +
benzotriazine I-Chemical +
1,4 I-Chemical +
- I-Chemical +
di I-Chemical +
- I-Chemical +
N I-Chemical +
- I-Chemical +
oxide I-Chemical +
) O +
, O +
which O +
has O +
been O +
used O +
as O +
a O +
standard O +
. O +

Three O +
derivatives O +
( O +
5 O -
g O +
, O +
i O +
, O +
k O +
) O +
show O +
a O +
hypoxic O +
cytotoxicity O +
ratio O +
( O +
HCR O +
) O +
& O +
gt O +
; O +
or O +
= O +
, O +
better O +
than O +
that O +
of O +
tirapazamine B-Chemical +
( O +
HCR O +
= O +
75 O +
) O +
in O +
V79 O +
cells O +
. O +

Replacement O +
of O +
the O +
3 B-Chemical +
- I-Chemical +
amino I-Chemical +
group B-Chemical +
by O +
chlorine B-Chemical +
affords O +
the O +
potent O +
but O +
nonselective O +
3 B-Chemical +
- I-Chemical +
chloro I-Chemical +
derivatives B-Chemical +
6a O +
- O +
k O +
showing O +
similar O +
toxicities O +
under O +
both O +
aerobic O +
and O +
hypoxic O +
conditions O +
. O +

These O +
compounds O +
were O +
used O +
as O +
intermediates O +
for O +
the O +
synthesis O +
of O +
a O +
new O +
series O +
of O +
water O +
- O +
soluble O +
compounds O +
derived O +
from O +
3 B-Chemical +
- I-Chemical +
[ I-Chemical +
[ I-Chemical +
( I-Chemical +
N I-Chemical +
, I-Chemical +
N I-Chemical +
- I-Chemical +
dialkylamino I-Chemical +
) I-Chemical +
alkyl I-Chemical +
[ I-Chemical +
amino I-Chemical +
] I-Chemical +
- I-Chemical +
2 I-Chemical +
- I-Chemical +
quinoxalinecarbonitrile I-Chemical +
1,4 I-Chemical +
- I-Chemical +
di I-Chemical +
- I-Chemical +
N I-Chemical +
- I-Chemical +
oxides I-Chemical +
- O +
i O +
and O +
11a O +
- O +
i O +
. O +

The O +
7 B-Chemical +
- I-Chemical +
chloro I-Chemical +
and O +
the O +
7 B-Chemical +
- I-Chemical +
trifluoromethyl I-Chemical +
derivatives B-Chemical +
, O +
f O +
have O +
demonstrated O +
high O +
potency O +
( O +
0.4 O +
and O +
0.3 O +
microM O +
) O +
and O +
excellent O +
selectivity O +
( O +
HCR O +
= O +
and O +
) O +
. O +

Several O +
7 B-Chemical +
- I-Chemical +
chloro I-Chemical +
analogues B-Chemical +
, O +
12b O +
, O +
13b O +
.1 O +
, O +
b O +
.2 O +
, O +
and O +
14b O +
, O +
and O +
the O +
dimer O +
16b O +
have O +
been O +
prepared O +
and O +
evaluated O +
in O +
order O +
to O +
determine O +
the O +
optimum O +
lateral O +
chain O +
in O +
position O +
3 O +
, O +
which O +
appears O +
to O +
be O +
the O +
[ O +
( B-Chemical +
N I-Chemical +
, I-Chemical +
N I-Chemical +
- I-Chemical +
dimethylamino I-Chemical +
) I-Chemical +
propyl I-Chemical +
] I-Chemical +
amino I-Chemical +
moiety B-Chemical +
. O +

The O +
determination O +
of O +
the O +
structure O +
and O +
function O +
of O +
the O +
sigma O +
receptor O +
subtypes O +
and O +
their O +
physiological O +
role O +
( O +
s O +
) O +
has O +
been O +
impeded O +
by O +
the O +
unavailability O +
of O +
selective O +
ligands O +
. O +

We O +
have O +
developed O +
a O +
new O +
class O +
of O +
sigma O +
subtype O +
selective O +
receptor O +
ligands O +
that O +
are O +
( B-Chemical +
E I-Chemical +
) I-Chemical +
- I-Chemical +
8 I-Chemical +
- I-Chemical +
benzylidene I-Chemical +
derivatives B-Chemical +
of O +
the O +
synthetic O +
opioid O +
( B-Chemical +
+ I-Chemical +
/ I-Chemical +
- I-Chemical +
) I-Chemical +
- I-Chemical +
, O +
( B-Chemical +
+ I-Chemical +
) I-Chemical +
- I-Chemical +
, O +
and O +
( B-Chemical +
- I-Chemical +
) I-Chemical +
- I-Chemical +
2 I-Chemical +
- I-Chemical +
methyl I-Chemical +
- I-Chemical +
5 I-Chemical +
- I-Chemical +
( I-Chemical +
3 I-Chemical +
- I-Chemical +
hydroxyphenyl I-Chemical +
) I-Chemical +
morphan I-Chemical +
- I-Chemical +
7 I-Chemical +
- I-Chemical +
one I-Chemical +
( O +
1 O +
) O +
. O +

The O +
derivatives O +
can O +
be O +
prepared O +
by O +
reaction O +
of O +
1 O +
, O +
( O +
+ O +
) O +
- O +
1 O +
, O +
and O +
( O +
- O +
) O +
- O +
1 O +
with O +
the O +
appropriate O +
benzaldehyde B-Chemical +
under O +
Claisen O +
- O +
Schmidt O +
conditions O +
. O +

Incorporation O +
of O +
substituted O +
( B-Chemical +
E I-Chemical +
) I-Chemical +
- I-Chemical +
8 I-Chemical +
- I-Chemical +
benzylidene I-Chemical +
moieties B-Chemical +
onto O +
the O +
7 O +
- O +
keto O +
precursor O +
of O +
( B-Chemical +
+ I-Chemical +
) I-Chemical +
- I-Chemical +
2 I-Chemical +
- I-Chemical +
methyl I-Chemical +
- I-Chemical +
5 I-Chemical +
- I-Chemical +
( I-Chemical +
3 I-Chemical +
- I-Chemical +
hydroxyphenyl I-Chemical +
) I-Chemical +
morphan I-Chemical +
, O +
( O +
+ O +
) O +
- O +
1 O +
, O +
produces O +
compounds O +
( O +
- O +
) O +
- O +
2 O +
through O +
( O +
- O +
) O +
- O +
7 O +
( O +
5.8 O -
- O -
32.0 O +
nM O +
, O +
sigma O +
1 O +
) O +
, O +
which O +
have O +
between O +
a O +
25 O +
- O +
and O +
131 O +
- O +
fold O +
increase O +
in O +
affinity O +
for O +
the O +
sigma O +
1 O +
receptor O +
subtype O +
relative O +
to O +
the O +
keto O +
precursor O +
( O +
+ O +
) O +
- O +
1 O +
( O +
Ki O +
= O +
762 O +
nM O +
, O +
sigma O +
1 O +
) O +
. O +

Compound O +
( O +
- O +
) O +
- O +
2 O +
is O +
the O +
most O +
selective O +
of O +
this O +
group O +
( O +
16 O +
- O +
fold O +
) O +
for O +
the O +
sigma O +
1 O +
subtype O +
versus O +
sigma O +
2 O +
. O +

Substitution O +
of O +
an O +
( B-Chemical +
E I-Chemical +
) I-Chemical +
- I-Chemical +
8 I-Chemical +
- I-Chemical +
benzylidene I-Chemical +
moiety O +
onto O +
the O +
7 O +
- O +
keto O +
precursor O +
of O +
( O +
- O +
) O +
- O +
2 O +
- O +
methyl O +
- O +
5 O +
- O +
( O +
3 O +
- O +
hydroxyphenyl O +
) O +
morphan O +
, O +
( O +
- O +
) O +
- O +
1 O +
, O +
produces O +
compounds O +
( O +
+ O +
) O +
- O +
2 O +
- O +
( O +
+ O +
) O +
- O +
9 O +
( O +
6.4 O -
- O -
52.6 O +
nM O +
, O +
sigma O +
2 O +
) O +
, O +
which O +
have O +
at O +
least O +
a O +
475 O -
- O -
3906 O +
- O +
fold O +
increase O +
in O +
affinity O +
for O +
the O +
sigma O +
2 O +
receptor O +
subtype O +
relative O +
to O +
the O +
keto O +
precursor O +
( O +
- O +
) O +
- O +
1 O +
( O +
Ki O +
= O +
25 O +
x O +
( O +
3 O +
) O +
nM O +
) O +
. O +

This O +
enhancement O +
of O +
sigma O +
2 O +
receptor O +
affinity O +
is O +
accompanied O +
by O +
substantial O +
selectivity O +
of O +
all O +
of O +
these O +
dextrorotatory O +
products O +
for O +
the O +
sigma O +
2 O +
relative O +
to O +
the O +
sigma O +
1 O +
subtype O +
( O +
32 O -
- O -
238 O +
- O +
fold O +
) O +
, O +
and O +
thus O +
, O +
they O +
are O +
among O +
the O +
most O +
sigma O +
2 O +
selective O +
compounds O +
currently O +
known O +
. O +

Furthermore O +
, O +
the O +
sigma O +
1 O +
subtype O +
is O +
highly O +
enantioselective O +
for O +
the O +
levorotatory O +
isomers O +
, O +
( O +
- O +
) O +
- O +
2 O +
- O +
( O +
- O +
) O +
- O +
7 O +
( O +
41 O -
- O -
1034 O +
- O +
fold O +
) O +
, O +
whereas O +
the O +
sigma O +
2 O +
subtype O +
is O +
only O +
somewhat O +
enantioselective O +
for O +
the O +
dextrorotatory O +
isomers O +
, O +
( O +
+ O +
) O +
- O +
2 O +
- O +
( O +
+ O +
) O +
- O +
7 O +
( O +
2.6 O -
- O -
9.3 O +
- O +
fold O +
) O +
. O +

All O +
of O +
these O +
derivatives O +
retain O +
substantial O +
affinity O +
for O +
the O +
mu O +
opioid O +
receptor O +
. O +

Despite O +
the O +
high O +
affinity O +
of O +
the O +
dextrorotatory O +
derivatives O +
for O +
the O +
mu O +
opioid O +
receptor O +
, O +
the O +
high O +
affinity O +
and O +
selectivity O +
for O +
sigma O +
2 O +
over O +
sigma O +
1 O +
sites O +
will O +
surely O +
prove O +
beneficial O +
as O +
tools O +
for O +
the O +
delineation O +
of O +
the O +
function O +
and O +
physiological O +
role O +
of O +
sigma O +
2 O +
receptors O +
. O +

N O +
, O +
O O +
- O +
Dicarbethoxy O +
- O +
4 O +
- O +
chlorobenzenesulfohydroxamate O +
( O +
1c O +
) O +
and O +
O B-Chemical +
- I-Chemical +
carbethoxy I-Chemical +
- I-Chemical +
N I-Chemical +
- I-Chemical +
hydroxysaccharin I-Chemical +
( O +
6 O +
) O +
, O +
both O +
potential O +
carbethoxylating O +
agents O +
, O +
inhibited O +
yeast O +
aldehyde O +
dehydrogenase O +
( O +
AlDH O +
) O +
with O +
IC50 O +
's O +
of O +
24 O +
and O +
56 O +
microM O +
, O +
respectively O +
. O +

The O +
esterase O +
activity O +
of O +
the O +
enzyme O +
was O +
commensurably O +
inhibited O +
. O +

AlDH O +
activity O +
was O +
only O +
partially O +
restored O +
on O +
incubation O +
with O +
mercaptoethanol B-Chemical +
( O +
mM O +
) O +
for O +
1 O +
h O +
. O +

On O +
incubation O +
with O +
rat O +
plasma O +
, O +
1c O +
liberated O +
nitroxyl B-Chemical +
, O +
a O +
potent O +
inhibitor O +
of O +
AlDH O +
. O +

Under O +
the O +
same O +
conditions O +
, O +
nitroxyl B-Chemical +
generation O +
from O +
6 O +
was O +
minimal O +
, O +
a O +
result O +
compatible O +
with O +
a O +
previous O +
observation O +
that O +
nitroxyl B-Chemical +
generation O +
from O +
N B-Chemical +
- I-Chemical +
hydroxysaccharin I-Chemical +
( O +
7 O +
) O +
, O +
the O +
product O +
of O +
the O +
hydrolysis O +
of O +
the O +
carbethoxy B-Chemical +
group B-Chemical +
of O +
6 O +
, O +
was O +
minimal O +
at O +
physiological O +
pH O +
. O +

Since O +
chemical O +
carbethoxylating O +
agents O +
represented O +
by O +
the O +
O B-Chemical +
- I-Chemical +
carbethoxylated I-Chemical +
N I-Chemical +
- I-Chemical +
hydroxyphthalimide I-Chemical +
, O +
1 B-Chemical +
- I-Chemical +
hydroxybenzotriazole I-Chemical +
, O +
and O +
N B-Chemical +
- I-Chemical +
hydroxysuccinimide I-Chemical +
( O +
8 O +
, O +
9 O +
, O +
and O +
, O +
respectively O +
) O +
likewise O +
inhibited O +
yeast O +
AlDH O +
, O +
albeit O +
with O +
IC50 O +
's O +
1 O +
order O +
of O +
magnitude O +
higher O +
, O +
we O +
postulate O +
that O +
1c O +
and O +
6 O +
act O +
as O +
irreversible O +
inhibitors O +
of O +
AlDH O +
by O +
carbethoxylating O +
the O +
active O +
site O +
of O +
the O +
enzyme O +
. O +

8654448 O +
Activity O +
of O +
beta O +
- O +
lactamase O +
inhibitor O +
combinations O +
on O +
Escherichia O +
coli O +
isolates O +
exhibiting O +
various O +
patterns O +
of O +
resistance O +
to O +
beta B-Chemical +
- I-Chemical +
lactam I-Chemical +
agents O +
. O +

The O +
efficacy O +
of O +
the O +
clinically O +
available O +
beta O +
- O +
lactam O +
/ O +
beta O +
- O +
lactamase O +
inhibitor O +
combinations O +
( O +
amoxicillin B-Chemical +
/ O +
clavulanic B-Chemical +
acid I-Chemical +
( O +
CA B-Chemical +
) O +
, O +
ticarcillin B-Chemical +
/ O +
CA B-Chemical +
, O +
amoxicillin B-Chemical +
/ O +
sulbactam B-Chemical +
, O +
and O +
piperacillin B-Chemical +
/ O +
tazobactam B-Chemical +
) O +
was O +
evaluated O +
on O +
amoxicillin B-Chemical +
- O +
resistant O +
Escherichia O +
coli O +
isolates O +
having O +
the O +
main O +
patterns O +
of O +
beta B-Chemical +
- I-Chemical +
lactam I-Chemical +
resistance O +
. O +

The O +
patterns O +
, O +
which O +
reflect O +
the O +
production O +
of O +
various O +
beta O +
- O +
lactamase O +
enzymes O +
, O +
were O +
analyzed O +
by O +
a O +
principal O +
component O +
analysis O +
of O +
susceptibility O +
to O +
11 O +
beta B-Chemical +
- I-Chemical +
lactam I-Chemical +
antibiotics O +
or O +
beta B-Chemical +
- I-Chemical +
lactam I-Chemical +
/ O +
beta O +
- O +
lactamase O +
inhibitor O +
combinations O +
. O +

Sixty O +
- O +
two O +
percent O +
of O +
strains O +
were O +
not O +
very O +
susceptible O +
to O +
penicillins B-Chemical +
, O +
cephalothin B-Chemical +
, O +
or O +
any O +
beta B-Chemical +
- I-Chemical +
lactam I-Chemical +
/ O +
beta O +
- O +
lactamase O +
inhibitor O +
combinations O +
except O +
for O +
piperacillin B-Chemical +
/ O +
tazobactam B-Chemical +
; O +
these O +
strains O +
may O +
represent O +
high O +
- O +
level O +
broad O +
- O +
spectrum O +
beta O +
- O +
lactamase O +
( O +
so O +
- O +
called O +
penicillinase O +
) O +
production O +
phenotype O +
or O +
inhibitor O +
- O +
resistant O +
TEM O +
- O +
like O +
enzyme O +
production O +
phenotype O +
. O +

Of O +
the O +
strains O +
, O +
14.7 O -
% O +
were O +
resistant O +
to O +
amoxicillin B-Chemical +
and O +
ticarcillin B-Chemical +
compatible O +
with O +
low O +
- O +
level O +
broad O +
- O +
spectrum O +
beta O +
- O +
lactamase O +
production O +
phenotype O +
; O +
5.7 O -
% O +
were O +
cefoxitin B-Chemical +
resistant O +
and O +
were O +
postulated O +
to O +
present O +
a O +
high O +
- O +
level O +
cephalosporinase O +
production O +
phenotype O +
; O +
and O +
2.6 O -
% O +
were O +
resistant O +
to O +
cephalothin B-Chemical +
only O +
, O +
attributable O +
to O +
a O +
low O +
- O +
level O +
cephalosporinase O +
production O +
phenotype O +
. O +

Three O +
percent O +
of O +
strains O +
were O +
intermediate O +
or O +
resistant O +
to O +
cefotaxime B-Chemical +
and O +
may O +
produce O +
an O +
extended O +
- O +
spectrum O +
beta O +
- O +
lactamase O +
, O +
and O +
the O +
remaining O +
strains O +
( O +
12 O +
% O +
) O +
, O +
resistant O +
to O +
all O +
tested O +
antibiotics O +
except O +
for O +
cefotaxime B-Chemical +
and O +
piperacillin B-Chemical +
/ O +
tazobactam B-Chemical +
, O +
were O +
hypothesized O +
to O +
produce O +
both O +
broad O +
- O +
spectrum O +
beta O +
- O +
lactamase O +
plus O +
cephalosporinase O +
. O +

The O +
minimal O +
inhibitory O +
concentration O +
( O +
MIC O +
) O +
for O +
these O +
phenotype O +
patterns O +
indicated O +
that O +
combinations O +
of O +
CA B-Chemical +
plus O +
amoxicillin B-Chemical +
or O +
ticarcillin B-Chemical +
, O +
or O +
sulbactam B-Chemical +
plus O +
amoxicillin B-Chemical +
, O +
restored O +
the O +
activity O +
of O +
penicillins B-Chemical +
against O +
phenotype O +
1 O +
strains O +
, O +
whereas O +
these O +
combinations O +
remained O +
inactive O +
against O +
the O +
other O +
phenotype O +
strains O +
. O +

Piperacillin B-Chemical +
plus O +
tazobactam B-Chemical +
showed O +
the O +
best O +
in O +
vitro O +
effect O +
against O +
the O +
strains O +
of O +
all O +
resistance O +
phenotypes O +
. O +

In O +
the O +
present O +
investigation O +
, O +
the O +
last O +
two O +
possible O +
modes O +
of O +
generating O +
conformationally O +
semirigid O +
diacylglycerol B-Chemical +
( O +
DAG B-Chemical +
) O +
analogues B-Chemical +
embedded O +
into O +
five O +
- O +
membered O +
ring O +
lactones B-Chemical +
as O +
templates O +
III O +
and O +
IV O +
are O +
investigated O +
. O +

The O +
first O +
two O +
templates O +
studied O +
in O +
previous O +
investigations O +
corresponded O +
to O +
2 B-Chemical +
- I-Chemical +
deoxyribonolactone I-Chemical +
( O +
template O +
I O +
) O +
and O +
4,4 B-Chemical +
- I-Chemical +
disubstituted I-Chemical +
gamma I-Chemical +
- I-Chemical +
butyrolactone I-Chemical +
( O +
template O +
II O +
) O +
, O +
with O +
the O +
latter O +
producing O +
potent O +
protein O +
kinase O +
C O +
( O +
PK O +
- O +
C O +
) O +
ligands O +
with O +
low O +
nanomolar O +
binding O +
affinities O +
. O +

The O +
templates O +
reported O +
in O +
this O +
work O +
correspond O +
to O +
2,3 B-Chemical +
- I-Chemical +
dideoxy I-Chemical +
- I-Chemical +
L I-Chemical +
- I-Chemical +
erythro I-Chemical +
- I-Chemical +
or O +
- B-Chemical +
threo I-Chemical +
- I-Chemical +
hexono I-Chemical +
- I-Chemical +
1,4 I-Chemical +
- I-Chemical +
lactone I-Chemical +
( O +
template O +
III O +
) O +
and O +
2 B-Chemical +
- I-Chemical +
deoxyapiolactone I-Chemical +
( O +
template O +
IV O +
) O +
. O +

Compounds O +
constructed O +
with O +
the O +
dideoxy B-Chemical +
- I-Chemical +
L I-Chemical +
- I-Chemical +
erythro I-Chemical +
- I-Chemical +
or O +
- B-Chemical +
threo I-Chemical +
- I-Chemical +
hexono I-Chemical +
- I-Chemical +
1,4 I-Chemical +
- I-Chemical +
lactone I-Chemical +
template O +
were O +
synthesized O +
stereospecifically O +
from O +
tri B-Chemical +
- I-Chemical +
O I-Chemical +
- I-Chemical +
acetyl I-Chemical +
- I-Chemical +
L I-Chemical +
- I-Chemical +
glucal I-Chemical +
and O +
L B-Chemical +
- I-Chemical +
galactono I-Chemical +
- I-Chemical +
1,4 I-Chemical +
- I-Chemical +
lactone I-Chemical +
, O +
respectively O +
. O +

Compounds O +
constructed O +
with O +
the O +
2 B-Chemical +
- I-Chemical +
deoxyapiolactone I-Chemical +
template O +
were O +
synthesized O +
stereoselectively O +
from O +
di B-Chemical +
- I-Chemical +
O I-Chemical +
- I-Chemical +
isopropylidene I-Chemical +
- I-Chemical +
alpha I-Chemical +
- I-Chemical +
D I-Chemical +
- I-Chemical +
apiose I-Chemical +
. O +

Inhibition O +
of O +
the O +
binding O +
of O +
[ B-Chemical +
3H I-Chemical +
] I-Chemical +
phorbol I-Chemical +
- I-Chemical +
12,13 I-Chemical +
- I-Chemical +
dibutyrate I-Chemical +
to O +
PK O +
- O +
C O +
alpha O +
showed O +
that O +
only O +
the O +
threo B-Chemical +
- I-Chemical +
isomer I-Chemical +
, O +
5 B-Chemical +
- I-Chemical +
O I-Chemical +
- I-Chemical +
tetradecanoyl I-Chemical +
- I-Chemical +
2,3 I-Chemical +
- I-Chemical +
dideoxy I-Chemical +
- I-Chemical +
L I-Chemical +
- I-Chemical +
threo I-Chemical +
- I-Chemical +
hexono I-Chemical +
- I-Chemical +
1,4 I-Chemical +
- I-Chemical +
lactone I-Chemical +
( O +
2 O +
) O +
was O +
a O +
good O +
PK O +
- O +
C O +
ligand O +
( O +
Ki O +
= O +
1 O +
microM O +
) O +
. O +

The O +
rest O +
of O +
the O +
ligands O +
had O +
poorer O +
affinities O +
with O +
Ki O +
values O +
between O +
and O +
28 O +
microM O +
. O +

With O +
these O +
results O +
, O +
the O +
order O +
of O +
importance O +
of O +
five O +
- O +
membered O +
ring O +
lactones B-Chemical +
as O +
competent O +
templates O +
for O +
the O +
construction O +
of O +
semirigid O +
DAG B-Chemical +
surrogates O +
with O +
effective O +
PK O +
- O +
C O +
binding O +
affinity O +
can O +
be O +
established O +
as O +
II O +
& O +
gt O +
; O +
& O +
gt O +
; O +
I O +
approximately O +
III O +
& O +
gt O +
; O +
IV O +
. O +

XBMP O +
- O +
1B O +
( O +
Xtld O +
) O +
, O +
a O +
Xenopus O +
homolog O +
of O +
dorso O +
- O +
ventral O +
polarity O +
gene O +
in O +
Drosophila O +
, O +
modifies O +
tissue O +
phenotypes O +
of O +
ventral O +
explants O +
. O +

Previously O +
we O +
have O +
isolated O +
a O +
Xenopus O +
cDNA O +
homolog O +
of O +
bone O +
morphogenetic O +
protein O +
- O +
1 O +
( O +
XBMP O +
- O +
1A O +
) O +
. O +

In O +
the O +
present O +
report O +
we O +
describe O +
a O +
new O +
cDNA O +
clone O +
called O +
XBMP O +
- O +
1B O +
( O +
or O +
Xtld O +
) O +
from O +
a O +
Xenopus O +
embryonic O +
library O +
. O +

Sequence O +
analysis O +
indicates O +
that O +
these O +
two O +
clones O +
share O +
an O +
indentical O +
N O +
- O +
terminal O +
sequence O +
, O +
including O +
a O +
region O +
of O +
metalloprotease O +
domain O +
, O +
three O +
copies O +
of O +
a O +
repeat O +
first O +
found O +
in O +
complement O +
proteins O +
C1r O +
/ O +
s O +
and O +
an O +
epidermal O +
growth O +
factor O +
( O +
EGF O +
) O +
- O +
like O +
sequence O +
. O +

XBMP O +
- O +
1B O +
protein O +
has O +
an O +
additional O +
copy O +
of O +
an O +
EGF O +
- O +
like O +
sequence O +
followed O +
by O +
two O +
copies O +
of O +
complement O +
1 O +
r O +
/ O +
s O +
repeat O +
in O +
the O +
C O +
- O +
terminus O +
. O +

The O +
overall O +
protein O +
structure O +
predicted O +
from O +
the O +
XBMP O +
- O +
1B O +
sequence O +
reveals O +
that O +
it O +
encodes O +
a O +
protein O +
homologous O +
to O +
Drosophila O +
tolloid O +
. O +

Three O +
XBMP O +
- O +
1 O +
transcripts O +
( O +
2.9 O +
, O +
5.2 O +
and O +
6.6 O +
kb O +
) O +
were O +
detected O +
by O +
northern O +
blot O +
analysis O +
. O +

However O +
, O +
the O +
2.9 O +
kb O +
transcript O +
hybridized O +
specifically O +
with O +
XBMP O +
- O +
1A O +
and O +
the O +
5.2 O +
and O +
6.6 O +
kb O +
transcripts O +
hybridized O +
with O +
XBMP O +
- O +
1B O +
. O +

In O +
Drosophila O +
, O +
a O +
major O +
function O +
of O +
tolloid O +
is O +
to O +
augment O +
the O +
activity O +
of O +
the O +
decapentaplegic O +
gene O +
product O +
, O +
a O +
close O +
relative O +
of O +
tumor O +
growth O +
factor O +
( O +
TGF O +
) O +
- O +
beta O +
superfamily O +
members O +
, O +
BMP O +
- O +
2 O -
/ O -
4 O +
. O +

Although O +
XBMP O +
- O +
1 O +
and O +
XBMP O +
- O +
4 O +
are O +
detected O +
in O +
various O +
adult O +
tissues O +
of O +
Xenopus O +
, O +
the O +
expression O +
pattern O +
of O +
these O +
two O +
genes O +
was O +
not O +
tightly O +
correlated O +
. O +

In O +
the O +
embryo O +
, O +
the O +
expression O +
of O +
XBMP O +
- O +
1 O +
increased O +
gradually O +
from O +
the O +
morula O +
to O +
the O +
swimming O +
tadpole O +
stages O +
. O +

Injection O +
of O +
XBMP O +
- O +
1B O +
RNA O +
into O +
the O +
ventral O +
blastomeres O +
at O +
the O +
4 O +
- O +
cell O +
stage O +
caused O +
an O +
elongation O +
of O +
the O +
ventral O +
marginal O +
zone O +
explants O +
and O +
converted O +
globin O +
- O +
positive O +
blood O +
cells O +
to O +
mesenchymal O +
and O +
muscle O +
tissues O +
at O +
later O +
stages O +
. O +

It O +
was O +
shown O +
that O +
XBMP O +
- O +
1A O +
was O +
less O +
active O +
and O +
a O +
1A O +
mutant O +
lacking O +
the O +
signal O +
sequence O +
was O +
inactive O +
. O +

Further O +
studies O +
revealed O +
that O +
injection O +
of O +
XBMP O +
- O +
1B O +
RNA O +
into O +
the O +
ventral O +
marginal O +
zone O +
induced O +
up O +
- O +
regulation O +
of O +
dorsal O +
marginal O +
zone O +
markers O +
, O +
such O +
as O +
goosecoid O +
and O +
chordin O +
, O +
at O +
the O +
gastrulation O +
stage O +
. O +

These O +
data O +
indicate O +
that O +
XBMP O +
- O +
1 O +
may O +
have O +
a O +
role O +
in O +
determining O +
dorso O +
- O +
ventral O +
patterning O +
in O +
Xenopus O +
, O +
but O +
in O +
a O +
different O +
way O +
from O +
the O +
dpp O +
/ O +
tolloid O +
system O +
demonstrated O +
in O +
Drosophila O +
. O +

The O +
synthesis O +
of O +
a O +
range O +
of O +
3 B-Chemical +
- I-Chemical +
hydroxy I-Chemical +
- I-Chemical +
4 I-Chemical +
( I-Chemical +
1H I-Chemical +
) I-Chemical +
- I-Chemical +
pyridinones I-Chemical +
with O +
potential O +
for O +
the O +
chelation O +
of O +
iron B-Chemical +
( I-Chemical +
III I-Chemical +
) I-Chemical +
is O +
described O +
. O +

The O +
pKa O +
values O +
of O +
respective O +
ligands O +
and O +
the O +
stability O +
constants O +
of O +
their O +
iron B-Chemical +
( I-Chemical +
III I-Chemical +
) I-Chemical +
complexes B-Chemical +
are O +
presented O +
. O +

The O +
distribution O +
coefficient O +
values O +
of O +
a O +
range O +
of O +
48 O +
hydroxypyridinones B-Chemical +
and O +
their O +
corresponding O +
iron B-Chemical +
( I-Chemical +
III I-Chemical +
) I-Chemical +
complexes B-Chemical +
between O +
1 B-Chemical +
- I-Chemical +
octanol I-Chemical +
and O +
MOPS O +
buffer O +
( O +
pH O +
7.4 O +
) O +
are O +
reported O +
. O +

The O +
range O +
of O +
log O +
Dcomplex O +
values O +
covers O +
7 O +
orders O +
of O +
magnitude O +
. O +

The O +
results O +
suggest O +
the O +
existence O +
of O +
a O +
biphasic O +
relationship O +
between O +
the O +
distribution O +
coefficient O +
values O +
of O +
the O +
chelator O +
and O +
the O +
corresponding O +
iron B-Chemical +
( I-Chemical +
III I-Chemical +
) I-Chemical +
complexes B-Chemical +
. O +

For O +
ligands O +
with O +
a O +
log O +
Dligand O +
= O +
- O +
1 O +
, O +
a O +
linear O +
relationship O +
exists O +
with O +
a O +
value O +
of O +
the O +
slope O +
2.53 O +
, O +
whereas O +
with O +
ligands O +
with O +
a O +
log O +
Dligand O +
& O +
lt O +
; O +
- O +
1 O +
, O +
a O +
linear O +
relationship O +
exists O +
with O +
a O +
slope O +
of O +
0.49 O +
. O +

The O +
reduced O +
slope O +
for O +
the O +
more O +
hydrophilic O +
molecules O +
of O +
the O +
series O +
offers O +
some O +
advantage O +
for O +
this O +
type O +
of O +
hydroxypyridinone B-Chemical +
as O +
the O +
distribution O +
coefficients O +
for O +
such O +
complexes O +
do O +
not O +
change O +
so O +
rapidly O +
with O +
increasing O +
ligand O +
hydrophilicity O +
. O +

The O +
ability O +
of O +
selected O +
3 B-Chemical +
- I-Chemical +
hydroxypyridinones I-Chemical +
to O +
facilitate O +
the O +
excretion O +
of O +
iron O +
in O +
bile O +
was O +
investigated O +
in O +
non O +
- O +
iron O +
- O +
overloaded O +
, O +
bile O +
duct O +
- O +
cannulated O +
rats O +
and O +
in O +
a O +
[ B-Chemical +
59Fe I-Chemical +
] I-Chemical +
ferritin I-Chemical +
- O +
loaded O +
rat O +
model O +
. O +

Both O +
systems O +
compare O +
the O +
ability O +
of O +
chelators O +
to O +
remove O +
iron O +
from O +
the O +
liver O +
, O +
the O +
prime O +
target O +
organ O +
in O +
thalassemia O +
. O +

The O +
N B-Chemical +
- I-Chemical +
( I-Chemical +
hydroxyalkyl I-Chemical +
) I-Chemical +
- I-Chemical +
3 I-Chemical +
- I-Chemical +
hydroxypyridin I-Chemical +
- I-Chemical +
4 I-Chemical +
- I-Chemical +
ones I-Chemical +
are O +
demonstrated O +
to O +
be O +
orally O +
active O +
under O +
the O +
in O +
vivo O +
conditions O +
adopted O +
. O +

Thus O +
both O +
1 B-Chemical +
- I-Chemical +
( I-Chemical +
hydroxyalkyl I-Chemical +
) I-Chemical +
- I-Chemical +
and O +
1 B-Chemical +
- I-Chemical +
( I-Chemical +
carboxyalkyl I-Chemical +
) I-Chemical +
pyridinones I-Chemical +
are O +
able O +
to O +
remove O +
iron B-Chemical +
from O +
the O +
liver O +
. O +

Although O +
1 B-Chemical +
- I-Chemical +
( I-Chemical +
carboxyalkyl I-Chemical +
) I-Chemical +
hydroxypyridinones I-Chemical +
are O +
active O +
, O +
they O +
do O +
not O +
demonstrate O +
any O +
clear O +
advantage O +
over O +
Deferiprone B-Chemical +
( O +
1,2 B-Chemical +
- I-Chemical +
dimethyl I-Chemical +
- I-Chemical +
3 I-Chemical +
- I-Chemical +
hydroxypyridin I-Chemical +
- I-Chemical +
4 I-Chemical +
- I-Chemical +
one I-Chemical +
) O +
. O +

Indeed O +
1 B-Chemical +
- I-Chemical +
( I-Chemical +
hydroxyalkyl I-Chemical +
) I-Chemical +
hydroxypyridinones I-Chemical +
which O +
are O +
known O +
to O +
be O +
rapidly O +
converted O +
to O +
1 B-Chemical +
- I-Chemical +
( I-Chemical +
carboxyalkyl I-Chemical +
) I-Chemical +
hydroxypyridinones I-Chemical +
are O +
also O +
marginally O +
superior O +
to O +
Deferiprone B-Chemical +
. O +

In O +
contrast O +
, O +
2 B-Chemical +
- I-Chemical +
ethyl I-Chemical +
- I-Chemical +
1 I-Chemical +
- I-Chemical +
( I-Chemical +
2 I-Chemical -
' I-Chemical +
- I-Chemical +
hydroxyethyl I-Chemical +
) I-Chemical +
- I-Chemical +
3 I-Chemical +
- I-Chemical +
hydroxypyridin I-Chemical +
- I-Chemical +
4 I-Chemical +
- I-Chemical +
one I-Chemical +
, O +
which O +
is O +
not O +
metabolized O +
to O +
the O +
corresponding O +
( B-Chemical +
carboxyalkyl I-Chemical +
) I-Chemical +
hydroxypyridinone I-Chemical +
, O +
was O +
found O +
to O +
be O +
superior O +
to O +
Deferiprone B-Chemical +
and O +
therefore O +
deserves O +
further O +
consideration O +
as O +
an O +
orally O +
active O +
iron O +
chelator O +
with O +
potential O +
for O +
the O +
treatment O +
of O +
iron B-Chemical +
overload O +
associated O +
with O +
transfusion O +
- O +
dependent O +
thalassemia O +
. O +

